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2Abstract
In neuroendocrine cells, immature secretory granules (ISGs) bud from the trans Golgi 
network (TGN), and then undergo a maturation process that includes ISG-ISG 
homotypic fusion, removal o f excess membranes via clathrin-coated vesicles (CCVs) 
and acidification of the granules. These mature secretory granules (MSGs) can then fuse 
with the plasma membrane upon receiving an external signal, and finally release their 
content in the extracellular space.
In this thesis, I will present evidence that Synaptotagmin IV (Syt IV) is one of the 
components involved in the regulation of granule maturation in neuroendocrine cells.
Syt IV is a neuron and neuroendocrine cell-specific isoform, which belongs to the 
synaptotagmin family o f membrane trafficking proteins. After confirming that Syt IV is 
localised on ISGs and absent from MSGs in PCI2 cells, I investigated whether Syt IV is 
involved in ISG homotypic fusion by adding the purified Syt IV cytoplasmic domain 
into an in vitro assay, where it functions as a dominant negative. Addition of this 
domain, but not a similar domain from Syt I, resulted in a dose-dependent inhibition of 
ISG-ISG fusion. Furthermore, I found that Syt IV binds to the ISG-SNARE Syntaxin 6 
(Stx6), suggesting that the two proteins might be part of the same machinery that 
regulates ISG maturation.
In addition, I used an in vivo approach based on the processing o f secretogranin II 
(Sgll) into its degradation product p i8, which occurs during ISG maturation, to assay 
Syt IV function. I show that the Syt IV cytoplasmic domain, as well as siRNA-mediated 
knockdown of Syt IV inhibits Sgll processing by prohormone convertase 2 (PC2). 
Interestingly, PC2 is found mostly in the pro-form, suggesting that activation of PC2 is 
also inhibited. We conclude that Syt IV is an essential component for the process of  
secretory granule maturation.
Lastly, I found that Syt IV binds preferentially to membrane-bound clathrin adaptor 
protein-1 (AP-1). This suggests that Syt IV might be sorted from maturing SGs in a 
complex, possibly via an ISG-SNARE protein that interacts directly with AP-1.
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1 Chapter 1: Introduction
1.1 Vesicular transport along the secretory pathway
A eukaryotic cell is subdivided into functionally distinct, membrane-enclosed 
compartments or organelles. Each compartment contains its own characteristic set of 
proteins and unique functional properties. Proteins entering the secretory pathway start 
their route in the endoplasmic reticulum (ER), and move in an anterograde direction 
towards the Golgi complex, with a final destination in the plasma membrane, 
lysosomes, endosomes or the exterior o f the cell. Proteins are transported via vesicular 
transport from their site of synthesis to their specific residence (Palade, 1975). Indeed, 
the work of Palade et al has established that the transfer of cargo molecules between 
organelles of the secretory pathway is mediated by shuttling transport vesicles. Two 
highly controlled steps define the vesicular transport of cargo along the secretory 
pathway: budding and fusion. Vesicles bud from a “donor compartment” (vesicle 
budding), excluding resident proteins of the donor compartment (protein sorting). The 
budded vesicles are then targeted to a specific “acceptor compartment”, into which they 
unload their cargo upon fusion of their membranes (vesicle fusion). The budding of 
transport vesicles and the selective incorporation of cargo into the forming vesicles are 
both mediated by protein coats, whereas membrane fusion is mediated by SNAREs 
(soluble N-ethylmaleimide sensitive factor attachment protein receptor) and their 
regulatory proteins (Bonifacino and Glick, 2004).
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Proteins containing an ER-signal sequence are translocated across the ER membrane 
through an aqueous ER-translocon pore complex (Rapoport, 1992). In the ER, protein 
chaperones facilitate the correct folding and assembly o f protein complexes. In addition 
to the correct folding o f newly synthesised proteins, a series of post-translational 
modifications, such as N-glycosylation and the generation o f disulphide bonds, occur. 
Only correctly folded proteins can exit the ER and are transported to the Golgi complex. 
Transport from ER to the Golgi is mediated via vesicles that contain coatomer protein II 
(COP II) coats. After transport vesicles have budded from the ER, they fuse together 
forming vesicular tubular clusters (VTCs), also called the ER-Golgi intermediate 
compartment (ERGIC) (Duden, 2003). The ERGIC transports the proteins to the Golgi 
complex, where they fuse and deliver their contents. Proteins enter the Golgi on its cis 
side and exit from the trans side before export to their final destinations. Proteins that 
have escaped the quality control in the ER are returned from the cis Golgi in COP I- 
coated vesicles. During the transport o f proteins though the Golgi stacks, the majority of 
post-translational modifications, such as O-glycosylation, trimming of N-linked 
oligosaccharides, added in the ER, and sulphation, occur.
Once in the trans-Golgi network (TGN), proteins are sorted for delivery to distinct 
destinations (Farquhar and Palade, 1981). Indeed, various trafficking routes emanate 
from the TGN, including pathways to lysosomes, endosomes, and the plasma membrane 
via constitutive secretory vesicles or via secretory granules in the regulated secretory 
pathway, although the latter vesicles are found only in specialised cell types, such as 
endocrine, neuroendocrine and exocrine cells.
Two major sorting mechanisms occur in the TGN: sorting fo r  entry and/or sorting by 
retention. Sorting fo r  entry describes a mechanism by which sorting signals mediate the 
sorting o f proteins into the nascent vesicles. For example, sorting of lysosomal enzymes
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destined for delivery to lysosomes is mediated by mannose 6-phosphate (M6P) groups, 
recognised by the M6P-receptor (M6PR). The MPR contains motifs, such as tyrosine or 
dileucine-based motifs that will bind the adaptor protein 1 (AP-1) and GGAs (Golgi 
associated, y ear-containing, ADP-ribosylation factor (ARF) binding protein). These 
adaptor proteins recruit clathrin lattices to the budding site. This will mediate the 
inclusion o f the lysosomal hydrolases into clathrin-coated vesicles (CCVs) that are 
targeted specifically to lysosomes (Kornfeld and Mellman, 1989).
Sorting by retention is used for the retention of proteins in their correct compartments, 
for example, the one used by the TGN-resident proteins or immature secretory granules 
proteins (ISGs) (Kuliawat and Arvan, 1994).
The transport of cargo along the secretory pathway, described herein, is anterograde 
transport (towards the plasma membrane). However, to balance this directional 
movement o f cargo, organelle homeostasis requires the retrieval of transport machinery 
components back to the corresponding donor compartment for re-use (retrograde 
transport), a process that also occurs by vesicular transport (Figure 1 shows the 
intracellular transport between different organelles in the cell) (Bonifacino and Glick, 
2004).
For delivery of their content, the formed vesicles have to be targeted to the right 
compartment, where they undergo membrane fusion. In the cell, specific proteins such 
as tethering factors ensure that these carriers recognise and fuse with the specific 
organelle. These processes help maintain the identity of each compartment in the cell.
C0P1I
Figure 1: Intracellular transport pathways.
The scheme shows the vesicular transport between different compartments within 
the cell (indicated by arrows). Budding of vesicles uses coat proteins, COPII (blue), 
COPI (red), clathrin (orange) (Bonifacino, 2004).
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1.2 Membrane fusion and SNARE proteins
Membrane fusion is an important process and allows the passage of molecules 
from one compartment to another within the cell or their release to the extracellular 
space. This process must be carefully controlled and regulated to ensure specificity. 
Membrane fusion can occur between similar compartments, called homotypic fusion , 
such as fusion between early endosomes or between ISGs, or between two different 
compartments, called heterotypic fusion, such as of vesicles with the plasma membrane 
fusion. In all cases however, the multiple protein families that control membrane fusion 
events are conserved from yeast to human as well as being conserved throughout the 
cell from the ER to the plasma membrane. Each membrane fusion event involves 
different members of these families localised to distinct compartments.
One family of proteins found to be necessary for membrane fusion events are the 
SNARE (soluble N-ethylmaleimide sensitive factor attachment protein receptor) 
proteins. SNAREs are small proteins of around 100-300 amino acids in length. Around 
36 distinct SNAREs are found in mammalian cells and 24 in yeast (Bock et al., 2001). 
Syntaxin 1 (S tx l) (Bennett et al., 1992), SNAP-25 (25 kDa synaptosome-associated 
protein) (Oyler et al., 1989) and VAMP2 (vesicle-associated membrane protein) 
(Trimble et al., 1988), the first identified SNAREs, are abundantly expressed in 
neuronal cells and are involved in exocytosis. Since their identification, a multitude of 
other SNARE proteins, which localise to distinct subcellular compartments and 
contribute to the regulation of specific membrane fusion events, were identified (Chen 
and Scheller, 2001). SNAREs were originally classified as t-SNAREs, associated with 
the target compartment, such as Stxl and SNAP-25, and v-SNAREs, associated with
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the vesicular compartment, such as VAM P-2 (Sollner et al., 1993). To avoid confusion 
in the case of homotypic membrane fusion, where target and vesicular SNAREs are 
undistinguishable, SNAREs have been reclassified as R-SNARE or Q-SNARE, 
depending on the presence of an arginine (R) or glutamine (Q) in the SNARE motif 
(Fasshauer et al., 1998). The middle of the SNARE bundle is defined as the “0 ” layer, 
where there is interaction o f three Q residues, contributed by Stxl (termed Qa SNARE), 
the N-terminal domain of SNAP-25 (termed Qb-SNARE), and the C-terminal domain 
of SNAP-25 (termed Qc SNARE) and one R residue (contributed by VAM P-2) in the 
synaptic SNARE complex (Fasshauer et al., 1998). This classification is now more 
widely used than the previous one, and it is believed that one member of each family 
contribute a single SNARE motif, resulting in the Qa-Qb-Qc-R configuration of a 
SNARE complex (Figure 2 shows the subcellular localisation and classification of 
mammalian SNAREs) (Bock et al., 2001). Crystal structure analysis showed that 
SNARE proteins assemble into a four-helical bundle, with each helix contributed by the 
SNARE motif of S tx l, N-terminal SNARE motif of SNAP-25, C-terminal SNARE  
motif of SNAP-25 and VAM P-2, forming the SNARE complex, that is resistant to SDS 
denaturation (Hayashi et al., 1994) and heat stable up to 90 °C (Fasshauer et al., 1997) 
(Figure 3 represents SNARE complex organisation) (Sutton et al., 1998).
Although considerable advances in our understanding of the molecular mechanisms 
governing membrane fusion have been made, how membrane fusion occurs or how 
precisely SNAREs act is not fully understood.
VAMP2
VAMP3.8
VAMP4
SNAP
membrin
ykte soc22b betl
R-SNAREs(VAMPs) ■  Qb-SNAREs(SNAP N)
Qa-SNAREs(syntaxins) ■  Qc-SNAREs(SNAP C) 
■  SNAPs with Qb and Qc
Figure 2: Subcellular localisation and classification of mammalian 
SNAREs. The scheme represents the different subcelluar localisation of the 
identified mammalian SNAREs. Syntaxins (classified as QaSNAREs) are rep­
resented in red, N-terminal domain of SNAP-25 homologues (Qb-SNAREs) 
in black, C-terminal of SNAP-25 homologues (Qc-SNAREs) in light green. 
Proteins such as SNAP-25 have two SNARE domains (Qbc-SNAREs) are 
represented in dark green (Bock, 2001).
Figure 3: SNARE complex formation. Top: SNARE complex 
representation. The SNARE motifs of Vamp-2 (or also called 
Synaptobrevin-II, (Sb)) in blue, Stxl in red and SNAP-25 in 
green (Snl and Sn2) assemble into a four-helical bundle, which 
is the core of the SNARE complex. Middle: organisation of the 
backbone of the SNARE complex into layers, with the “0 layer” 
in the middle (red) and 15 hydrophobic layers (black). Bottom: 
‘0 layer’ of the SNARE complex. Q-SNAREs and R-SNAREs 
are characterised by by glutamine (Q) or arginine (R) residue, 
respectively, in the central layer of the SNARE complex, (Sutton, 
R et al, 1998).
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Membrane fusion occurs in successive steps. First, tethering factors ensure that vesicles 
are transported and linked to its cognate target membranes. After tethering, vesicles and 
target compartments are brought in close apposition, a process called docking. Finally, 
membrane fusion can occur after SNARE proteins from opposite membranes assemble 
into a trans-SNARE complex. After fusion, cis-SNARE complexes are disassembled by 
the action of the AAA ATPase, NSF (N-ethylmaleimide-sensitive factor) and its 
cofactor D-SNAP in an ATP-dependent manner (Sollner et al., 1993). This will allow 
SNARE proteins to enter into another round of fusion.
The discovery that SNARE proteins on opposite membranes assemble into a core 
complex led to the suggestion that formation of the trans-SNARE  complex is involved 
in the fusion step itself, i.e. bilayer mixing (Sutton et al., 1998). In support of this idea, 
purified SNAREs reconstituted into liposomes mediated their fusion, provided that Q 
and R-SNAREs are on different liposomes (Weber et al., 1998). In another study, cells 
were engineered to produce “flipped” SNAREs that faced the outside of the cell rather 
than the cytoplasm. When cells containing a “flipped” v-SNARE were mixed with cells 
containing the cognate “flipped” t-SNAREs, efficient cell-cell fusion occurred (Hu et 
al., 2003). A different study conducted in permeabilised PCI2 cells found that inhibition 
of exocytosis after treatment with botulinum neurotoxin E (BoNT/E), which cleaves 
SNAP-25, could be rescued by the addition of a soluble C-terminal “SNARE domain” 
of SNAP-25, but not with SNAP-25 carrying mutations in the hydrophobic residues 
along its carboxy-terminal coil domain (Chen et al., 1999). Moreover, the irreversible 
assembly of the SNARE core complex occurred only after the arrival of calcium (Chen 
et al., 1999). This confirms that the formation of the core complex, which occurs after 
calcium entry, is crucial for SNARE function. SNARE complex formation is believed to 
occur by “zippering” of the coiled-coil domains from their N-terminal membrane-distal
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to their C-terminal membrane-proximal ends (Mayer, 2001). Indeed, the replacement of 
the transmembrane domains of SNARE proteins with phospholipids that do not span the 
lipid bilayer prevent fusion of liposomes (McNew et al., 2000). It was therefore 
suggested that SNARE complex formation would bring the two opposite membranes in 
close proximity, and this will promote spontaneous fusion between lipid bilayers by 
excluding water from the membrane interface. This model places the role of SNARE 
proteins in the final step of fusion.
Another model, the fusion pore model, emerged following studies conducted mainly in 
yeast vacuole fusion. This hypothesis suggests that the close membrane apposition 
mediated by SNAREs brings multimeric protein complexes on both membranes 
together, allowing the assembly o f a pore connection between the opposite membranes, 
which will induce fusion (Mayer, 2001). This model disputes the role of SNAREs in 
triggering bilayer mixing, and rather suggests that these proteins are involved in the 
docking of the opposite membranes.
Homotypic fusion of yeast vacuoles involves the formation of a SNARE complex 
between the v-SNAREs (N yvlp , Ykt6p) and the t-SNAREs (Vam3p, Vam7p, V tilp). It 
was shown that the pairing of these SNAREs is important for vacuole docking, but not 
fusion itself (Ungermann et al., 1998). Indeed, the disassembly of the SNARE complex 
following the addition of excess NSF did not affect content mixing of the vacuoles, 
suggesting that fusion occurred. In addition, antibody inhibition studies indicated that 
SNARE proteins are required only up to the docking stage of fusion (Nichols et al.,
1997). Together, these data demonstrate that SNARE complex formation is not required 
for the fusion step, but rather that the SNARE pairing may induce signals to 
downstream factors, leading to fusion that is controlled by other protein components. 
The pairing of SNAREs may invoke an efflux of calcium from the vacuole lumen,
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which then recruits calmodulin to the membranes, which is part of a protein complex 
involved in triggering membrane fusion of yeast vacuoles (Peters and Mayer, 1998). 
Indeed, calmodulin interacts with the V0 sector of the vacuolar H+-ATPase (V-ATPase) 
on vacuoles, and this interaction was found to occur after trans-SNARE pairing (Peters 
et al., 2001). Moreover, when reconstituted into liposomes, V0 was shown to form 
complexes between opposing membranes in a calcium-dependent manner (Peters et al., 
2001). These complexes form sealed channels, which expand to form aqueous pores 
between opposite membarnes. Additional data showed that vacuole membranes from 
Avphl yeast deficient in one of the V0 subunits- were capable of docking and trans- 
SNARE pairing, but did not fuse, even when only one of the fusion partners was devoid 
of V phlp (Bayer et al., 2003), thus establishing a role for V0 as an important component 
in vacuole fusion downstream of trans-SNARE pairing. These data support a model 
where the V0 sectors on opposing membranes assemble to form a continuous pore 
composed o f multiple subunits and enable membrane fusion.
In conclusion, both the pore and proximity models could be valid, and might 
predominate depending on the type of membrane fusion, homotypic versus heterotypic 
fusion.
Although the function of SNAREs in membrane fusion is incontestably important, 
increasing lines of evidence suggest that other proteins, such as, Rabs, tethering factors, 
SM proteins, Synaptotagmins and others, that also distribute to distinct cellular 
compartments and interact with SNAREs, participate in regulating a single or multiple 
stages of membrane fusion, as well as help to ensure membrane identity, suggesting that 
membrane fusion is a more complex than previously thought.
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1,3 Rab proteins and their effectors
Rab proteins constitute a large family of conserved monomeric small GTPases. 
More than 60 Rab proteins were identified in humans and ~11 Ypt/Sec4 (Rab 
homologues) in yeast. Like SNAREs, Rab proteins are distributed to distinct 
intracellular compartments. Several studies have established that Rab proteins are 
involved in the tethering of vesicles to their target compartments, establishing the 
importance of Rab proteins in membrane fusion. Additionally, Rabs have also been 
implicated in vesicle budding and vesicle transport along the cytoskeleton, elevating 
this family of proteins to key players in different membrane trafficking events (Zerial 
and McBride, 2001).
Rab proteins do not have a transmembrane domain, but are attached to target 
membranes via two C-terminal geranylgeranyl groups. Rab escort proteins (REPs) bind 
newly synthesised Rab proteins, which are then prenylated upon the action of 
geranylgranyltransferase (Andres et al., 1993). REPs deliver the prenylated Rabs to 
their target membrane, where the complex dissociates. On membranes, Rabs can enter 
the GEF-and GAP-mediated GTPase cycle, where Rab proteins oscillate between 
“active” GTP- and “inactive” GDP-bound states. GDP-bound Rabs are cytosolic and are 
found in a complex with GDP dissociation inhibitor (GDI). GDI solubilises Rab-GDP 
proteins by enveloping the geranylgeranyl groups, releasing them into the cytosol. 
Specific guanine-nucleotide exchange factors (GEFs) target GDP-Rab proteins to 
membranes and activate the GDP-Rab proteins by GDP to GTP exchange. Activated 
Rabs can then interact with several effectors that connect the two opposed membranes. 
After fusion, a Rab GTPase-activating protein (GAP) triggers GTP hydrolysis to GDP, 
which results in the dissociation of Rab-effector molecule complexes. The GDP bound
Chapter 1______________________________________________________________ 26
Rab is then recognised by GDI, which removes it from membranes and recycles it to 
another GTPase cycle.
The ability o f Rab proteins to act as GTP-dependent switches allows them to control the 
activity of effector molecules that function as tethering factors (Zerial and McBride, 
2001) (Whyte and Munro, 2002). The function of the tethering factors is to allow close 
positioning of the vesicles with the target compartment, which will facilitate the 
subsequent trans-SNARE pairing followed by fusion. One well-studied example is the 
multimeric complex of proteins involved in the tethering reaction during fusion o f early 
endosomes. On early endosomes, Rab5 was found to bind these membranes and to 
regulate their fusion in vitro (Gorvel et al., 1991). Later, Rab5 was found to interact 
with several down-stream effectors, such as EEA1, on early endosomes, revealing a 
more complex machinery (Christoforidis et al., 1999a). Rab5 was found to interact with 
hVPS34, a phosphatidylinositol-3-OH-kinase (PI(3)K), which preferentially 
phosphorylates phosphatidylinositol (Ptlns) to PtIns(3)P, thus coupling PtIns(3)P 
production to Rab5 localisation (Christoforidis et al., 1999b). The concomitant presence 
of Rab5 and PtIns(3)P on early endosomes allows the recruitment of the tethering factor 
EEA1. EEA1 binds to both PtIns(3)P through its FYVE finger, and to Rab5 through a 
Rab5-binding site located immediately upstream of the FYVE finger (Simonsen et al.,
1998). EEA1 was shown be involved in the tethering of endosomes (Christoforidis et 
al., 1999a). Moreover, EEA1 interacts with the SNARE machinery, and was shown to 
interact with S txl3 , a SNARE protein involved in endosome-endosome fusion 
(McBride et al., 1999). This interaction was suggested to mediate the homotypic fusion 
of early endosomes. The link between tethering molecules and SNARE proteins was 
also found in other membranes, suggesting that this mechanism is conserved. Indeed, 
the Golgi tethering factor, p i 15, was found to interact directly with the Golgi-SNAREs,
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Stx5 and GS28 (Shorter et al., 2002). The discovery that components of the Rab 
machinery interact with the fusion machinery allowed for a link between Rab-dependent 
membrane tethering, docking and finally membrane fusion. In addition, molecular 
interactions o f SNARE proteins within Rab-enriched domains of membranes might 
result in the selective enrichment of SNARE complexes at their site of function. The 
involvement o f large complexes, such as Rabs and their ever-growing list of effectors, 
during different steps of fusion, might contribute in achieving high fidelity during 
membrane fusion.
1.4 SecllMuncl8 (SM) proteins
SM proteins constitute another family of proteins that was found to regulate 
membrane fusion reactions. They are hydrophilic proteins of 60-70 kDa (Jahn and 
Sudhof, 1999). There are four known SM proteins in yeast (Seclp , Sly 1 p, Vps33p and 
Vps45p), and 7 in mammals (M uncl8-1, M uncl8-2, M uncl8-3, VPS33A, VPS33B, 
VPS45 and SLY1). M uncl8-1, M uncl8-2 and M uncl8-3 are functionally homologous 
to yeast S eclp  and function in the regulation of vesicle fusion with the plasma 
membrane. The neuronal-specific Muncl8-1 is the most studied SM protein, and is 
involved in synaptic vesicle fusion. VPS33A and VPS33B are homologous to the yeast 
Vps33p, and are involved the endocytic pathway. VPS45 and SLY 1 correspond to yeast 
Vps45p and Sly 1 p, and are involved in traffic at the Golgi (Gerst, 2003).
Although a role of SM proteins as essential factors in membrane fusion is established, 
their exact mode of function and at which stage they act is still under study. The 
controversy over the precise role of SM proteins in membrane fusion stems mainly from 
the conflicting data obtained from studies using neuronal SM proteins compared to their 
yeast orthologues. All SMs share a common property in that they bind to the Stx family
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of proteins. However, SM proteins interact with the Qa-SNAREs via different 
mechanisms, not all of which involve direct binding. SM proteins, such as the neuron- 
specific M uncl8-1, bind directly to the monomeric Stxl. This binding requires that Stxl 
be in the “closed” conformation, in which the N-terminus, termed the Habc domain, 
folds back onto the SNARE motif (Misura et al., 2000). In contrast to M uncl8, its yeast 
orthologue, Seclp, does not bind directly to the monomeric Qa-SNARE Ssolp , that also 
adopts a closed conformation, but only to the fully assembled SNARE complex 
(Munson et al., 2000). These different modes of binding might be a mechanism to 
prevent binding of SM proteins to non-cognate Stxs, and to provide specificity to 
membrane fusion.
Studies using yeast SM proteins suggest that they positively regulate the formation of 
SNARE complexes. It was demonstrated, for example, that Golgi-SNARE complexes 
do not assemble in the absence Vps45p (Bryant and James, 2001). Furthermore, Sly 1 p, 
an SM protein operating in ER to Golgi fusion, prevents promiscuous SNARE assembly 
in vitro (Peng and Gallwitz, 2002). Together, these results obtained from yeast studies 
suggest a positive role of SM proteins in regulating fusion and, more precisely, in 
promoting the incorporation o f Stxs into cognate SNARE complexes.
In contrast, a different role for SM proteins as negative regulators of fusion has been 
proposed from data demonstrating that Muncl8-1 binding to Stxl blocks SNARE  
complex formation in vitro (Pevsner et al., 1994). Moreover, the crystal structure 
showed that M uncl8 stabilises Stxl in its closed conformation (Misura et al., 2000). 
These observations suggested that Muncl8-1 hinders the SNARE motif of S txl, 
therefore preventing SNARE complex formation.
However, other studies have suggested instead that Muncl8-1 acts positively to regulate 
membrane fusion. For example, mice lacking Muncl8-1 exhibit an inhibition of
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neurotransmitter release (Verhage et al., 2000). Moreover, large dense-core vesicle- 
mediated exocytosis from chromaffin cells was inhibited in the absence of M uncl8-1, 
and stimulated by its overexpression (Voets et al., 2001). These results suggest that 
M uncl8-1, in contrast to previous studies, plays a positive role in the regulation of 
exocytosis. Analysis of cells from Munc 18-1-deficient mice revealed that these proteins 
could function in more than one step during membrane fusion. In chromaffin cells from 
these mice, a reduction in the number of docked dense core granules was observed, 
suggesting a role for SM proteins in the docking of vesicles (Voets et al., 2001). In 
contrast, synaptic vesicle docking in these mice was normal, suggesting that M uncl8-1  
has a role in a post-docking stage o f fusion in neurons (Verhage et al., 2000). A recent 
study showed that Stxl levels are reduced by 70% in Munc 18-1 knock-out mice, which 
is due to a decrease in Stxl stability (Toonen et al., 2005). However, in these cells 
residual Stxl was correctly targeted to synapses, and was capable of forming a SNARE  
complex. Based on the complete lack of neurotransmitter release in Munc 18-1 knock­
out mice, it is possible that SM proteins may also function after SNARE complex 
assembly. This study suggested that binding to Stxl is not the only function of SM
proteins. In fact, it was proposed that SM proteins could also regulate fusion
independently of their interaction with Stxs. In agreement with this, it was shown that 
Munc 18-1 mutants displaying normal binding to Stxl affected both early and late steps 
of exocytosis (Ciufo et al., 2005). These results were attributed to the fact that in 
addition to S tx l, Munc 18-1 binds to a multitude of other proteins involved in 
exocytosis, such as Mints.
In conclusion, SM proteins are an important family of proteins involved in the
regulation of membrane fusion in concert with SNAREs. However, their role in the
Chapter 1______________________________________________________________ 30
regulation o f fusion is not limited to their binding to Stxs, but clearly the role of these 
proteins in fusion is more varied.
1.5 Synaptotagmins
1.5.1 Synaptotagmin I
Synaptotagmins (Syts) belong to the C-terminal-type tandem C2 protein family, 
and are involved in membrane trafficking events. All Syt isoforms share the same 
domain structure. They are characterised by a short N-terminal luminal domain, a single 
transmembrane domain, a variable length spacer domain, and C2A and C2B domains 
(Tucker and Chapman, 2002).
Synaptotagmin I (Syt I) was the first identified and is the best characterised Syt isoform. 
It is a neuronal and neuroendocrine-specific isoform, and is localised on synaptic 
vesicles as well as MSGs called large dense core vesicles (LDCVs) (Matthew et al., 
1981) (Walch-Solimena et al., 1993). The crystal structure of the C2 domain of Syts 
shows that they are compact, rigid eight-stranded P-sandwiches. Flexible loops protrude 
from the ends of these domains, two of which coordinate the binding of three calcium  
ions in C2A (Sutton et al., 1995) (Ubach et al., 1998) and two calcium ions in C2B 
domain (Fernandez et al., 2001) (Figure 4 shows the domain structure of Syt I and the 
crystal structure of Syt I-C2 domains).
Figure 4: Syt I structure. A) Schematic representation of Syt I domain structure. 
Syt I has a short lumenal N-terminal domain, a single transmembrane domain, a 
spacer domain, the C2A (blue), C2B domains (green) and a small C-terminal 
domain. B) Ribbon diagrams of the C2A and C2B domains of Syt I. Each domain 
is formed by eight-stranded-(3-sandwich motif. Calcium-binding loops protrude 
from the top surface of each motif. A total of five calcium ions (red) bind to loops 
1 and 3 of both domains via calcium binding residues (blue) (Top). Five acidic 
residues in both C2A and C2B domains coordinate the binding of three and two 
calcium ions,espectively (Bottom).
(Chapman et al, 2002)
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Initial experiments have addressed the function of Syt I in exocytosis. Microinjection of 
anti-Syt I ab and soluble C2 domains of Syt I inhibit secretion of catecholamines from 
PC12 cells (Elferink et al., 1993). Moreover, injection of peptides corresponding to the 
C2 domain of Syt I into the squid giant synapse inhibits neurotransmitter release 
(Bommert et al., 1993). Genetic studies have also demonstrated that Syt I is important in 
synaptic vesicle release. Mice, Drosophila and C.elegans lacking Syt I show a specific 
disruption of the calcium-triggered synchronous phase of synaptic vesicle fusion 
(Geppert et al., 1994) (DiAntonio et al., 1993) (Nonet et al., 1993). These data suggest 
that Syt I is the calcium-sensor for triggering calcium-dependent exocytosis.
Syt I displays several properties, including binding to phospholipids and to SNARE  
proteins, as well as homo- and hetero-oligomerisation. These properties are thought to 
mediate Syt I function in exocytosis.
Both C2 domains of Syt I interact with lipids. The C2A domain of Syt 1 binds to acidic 
phospholipids in a calcium-dependent manner (Perin et al., 1990) (Davletov and 
Sudhof, 1993). Both calcium-binding loops 1 and 3 within the C2A domain were found 
to penetrate into the lipid bilayer in response to calcium (Bai et al., 2000). A point 
mutation close to one of the calcium-binding sites within the C2A domain decreases by 
two-fold the calcium requirement for the C2A-membrane interaction (Fernandez- 
Chacon et al., 2001). Knock-in mice harbouring this mutation show a similar two-fold 
reduction in exocytosis, suggesting that this property in important for fusion 
(Fernandez-Chacon et al., 2001). The C2B domain of Syt I was also shown to bind 
acidic phospholipids, but only when tethered to the C2A domain, suggesting a 
cooperative function between the two domains (Bai et al., 2002).
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In addition to acidic phospholipids, the C2B domain of Syt I binds phosphatidylinositol 
(4,5)-bisphosphate (PIP2) (Schiavo et al., 1996). Recently, it was shown that the C2B 
domain o f Syt I displays two modes of binding to PIP2. In the absence of calcium, Syt 
I-C2B domain binds to PIP2 weakly. Increases in calcium concentration drive the 
reorientation of C2B and its insertion into the lipid bilayer (Bai et al., 2004a). These 
findings prompted a model in which the Syt I inserts into PIP2-rich domains in the 
plasma membrane to help pull the bilayers together and to accelerate calcium-triggered 
membrane fusion. This ability to bind lipids in a calcium-dependent manner has put the 
function o f Syt I at the last step of fusion (Chapman, 2002).
In addition to binding lipids, Syts, including Syt I, are able to interact with SNARE  
proteins. Syt I was found to interact with Stxl and SNAP-25, and the affinity of this 
interaction increased in the presence of calcium (Chapman et al., 1995) (Gerona et al., 
2000) (Earles et al., 2001). Syt I-SNARE interactions are important for the regulation of 
membrane fusion. Mutations in SNAP-25 that affect interactions with Syt I reduce 
exocytosis (Zhang et al., 2002). Both C2A and C2B domains of Syt I are required for 
binding to t-SNAREs and for fusion, suggesting that they cooperate in the regulation of 
fusion events (Earles et al., 2001) (Bai et al., 2004b). Syt I was shown to stimulate the 
fusion of reconstituted v-and t-SNARE-containing liposomes in the presence of 
calcium. The loss of calcium-dependent SNARE-binding activity correlated with a loss 
of calcium-dependent simulation of liposome fusion, suggesting that Syt I and SNAREs 
are essential components of the fusion machinery (Tucker et al., 2004). It is not known 
whether Syt I-SNAREs interactions occur at one or multiple stages of fusion. One study 
showed that Syt I-SNAP-25 interactions have a role in docking of secretory vesicles in 
AtT-20 cells (Chieregatti et al., 2002). These findings suggested that one role o f Syt I
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during membrane fusion might be to facilitate vesicle docking. In contrast, a different 
study showed that the binding o f Syt I to t-SNAREs is important for a later stage of 
fusion. Indeed, loss o f Syt I-SNARE interaction resulted in the destabilisation o f fusion 
pores, suggesting that this interaction controls fusion pore dynamics (Bai et al., 2004b). 
Although calcium increases the affinity of Syt I to t-SNARES, there is some degree of 
calcium-independent interactions (Zhang et al., 2002) (Rickman and Davletov, 2003), 
with still unclear functional relevance. It is thought that these calcium-independent 
interactions exist to increase the speed of calcium-induced changes in the complex that 
result in high affinity binding. These data place Syt function at multiple stages of 
membrane fusion
Some Syts, including Syt I, display homo- and hetero-oligomerisation properties. Both 
homo-and hetero-oligomerisation can occur in a calcium-dependent and -independent 
manner. A region within the N-terminal domain was shown to mediate the calcium- 
independent oligomerisation o f Syts in vitro (Fukuda et al., 1999) (Fukuda and 
Mikoshiba, 2000b) (Fukuda and Mikoshiba, 2000a). However, the functional relevance 
of the calcium-independent oligomerisation of Syts in vivo is still unknown.
In addition to calcium-independent oligomerisation, some Syt isoforms, such as Syt I, 
were shown to form calcium-dependent homo-and hetero-oligomers (Chapman et al., 
1996) (Sugita et al., 1996) (Osborne et al., 1999) (Fukuda and Mikoshiba, 2000a). The 
calcium-dependent oligomerisation of Syt I was found to depend on the presence of 
lipids, where the C2B domains form ring-like heptameric oligomers (Wu et al., 2003). 
Consistent with an important role for calcium-dependent oligomerisation, a mutation in 
the C2B domain of Syt I that inhibited calcium-triggered oligomerisation resulted in the 
inhibition of secretion, suggesting that this property is important for triggering
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membrane fusion (Desai et al., 2000) (Littleton et al., 2001). How Syt oligomerisation 
regulates fusion is still unclear. It was suggested, however, that the calcium-dependent 
oligomerisation might influence fusion pore kinetics. Indeed, the overexpression of Syt 
I or Syt IV, a calcium- and phospholipid-independent binding isoform, in PC12 cells 
affected the stability and opening time of fusion pores (Wang et al., 2001) (discussed in 
section 1.5.2). In addition, it was shown that Syt isoforms display different sensitivities 
to calcium (Sugita et al., 2002), leading to the suggestion that the association of 
different Syt isoforms might regulate the calcium-dependence of membrane fusion. A 
recent study showed that the upregulation of Syt VII, which possess a higher sensitivity 
to calcium than Syt I and IX, resulted in the targeting of this isoform into MSGs, which 
resulted in an increase in calcium sensitivity for catecholamine release in PC 12 cells 
(Wang et al., 2005). These data suggest that the calcium requirement for exocytosis is 
determined by the precise ratio of different Syt isoforms. However, because endogenous 
Syt VII is not detectable in PC12 cells (Tucker et al., 2003), the localisation and 
function of the overexpressed protein remains controversial (Fukuda et al., 2004) 
(Sugita et al., 2001).
In addition to exocytosis, Syt I was shown to function in endocytosis. Indeed, two 
independent studies showed that in Drosophila and mice lacking Syt I, synaptic vesicles 
recycling from the plasma membrane is affected (Poskanzer et al., 2003) (Nicholson- 
Tomishima and Ryan, 2004). Recently, a role of oligomerisation in endocytosis has also 
been highlighted (Grass et al., 2004). The recognition of the double lysine within the 
C2B domain of Syt I by AP-2 was shown to depend on the multimerisation of Syt I- 
C2B domain. Interestingly, the same double lysine motif within the C2B domain was 
found to mediate both oligomerisation as well as binding to AP-2 (Chapman et al.,
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1998). Thus, whether Syt I adopts a multimeric state to regulate both exocytosis and 
endocytosis remains to be elucidated.
Many different models to explain the possible role of Syt I during exocytosis exist 
(Chapman, 2002). One preferred model is as follows: First, Syt I interacts weakly with 
SNAREs and membranes in preparation for fusion. Following the entry of calcium, the 
calcium-binding loops integrate into PIP2 raft domains in the opposite membrane, and 
the oligomerisation of Syts occur. This helps bring the two membranes in close 
apposition, and stabilises the SNARE complex, followed by complete fusion. This 
model only describes a role for Syt I, PIP2 and SNAREs, and it is very likely that other 
factors are involved (Figure 5).
In conclusion, it is without doubt that Syt I is an important component of the fusion 
machinery. Available data suggest that Syts participate in more than one step during 
membrane fusion. This ability is probably achieved via Syt I interactions with multiple 
effectors during membrane fusion.
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Figure 5: A model for Syt I function during exocytosis. One of the working models describing the function of Syt I dur­
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the target-membrane surface. Syt I interacts weakly with the SNARE proteins and PIP2 before the arrival of calcium. Upon 
calcium entry, Syt I inserts into lipid domains via its C2B domain. This probably help bring the two membranes into close 
apposition and stabilise the SNARE complex. All these steps will drive membrane fusion (Chapman E, 2002).
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1.5.2 Synaptotagmin IV
Synaptotagmin IV (Syt IV) is another isoform of the Syt family of proteins, with 
the same domain structure as the well-characterised Sytl. However, the C2A domain of 
Syt IV contains a conserved mutation in one of the calcium-binding sites, making this 
domain unable to bind calcium (von Poser et al., 1997). On the other hand, the C2B 
domain of Syt IV retains all the calcium-binding sites and it was thought that Syt IV 
bind calcium via this domain. However, the crystal structure of mammalian and 
Drosophila Syt IV showed a species-specific calcium-binding property. Both C2 
domains of fly Syt IV bind calcium and exhibit calcium-dependent phospholipid 
binding, whereas neither C2 domains of rat Syt IV bind calcium or phospholipids 
efficiently (Dai et al., 2004). These data revealed that the orientation and flexibility of 
critical calcium ligands make the rat Syt IV C2B domain unable to form full calcium- 
binding sites. This marked difference in the calcium-binding properties between fly and 
rat Syt IV was suggested to be due to specific features determined by residues that are 
not conserved in their sequences.
Syt IV was first isolated in a screen of inducible neuron-specific immediate-early genes 
(IEGs) in PC 12 cells (Vician et al., 1995). IEGs are genes whose transcription is 
induced in response to cellular stimulation, such as depolarisation and forskolin 
stimulation, in the presence o f a protein synthesis inhibitor, cycloheximide. Forskolin is 
a stimulator of protein kinase A, which plays a role in the activation of the cyclic AMP 
response element-binding protein (CREB) transcription pathway, which in turn is 
involved in the development of learning and memory. Disruption of CREB and the
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CREB activation pathway disrupt long-term memory (Yin et al., 1994). Forskolin was 
found to up-regulate Syt IV expression in PC12 cells (Vician et al., 1995), and 
interestingly, a concensus CREB element has been reported in the promoter o f Syt IV 
(Ferguson et al., 2000).
Syt IV is expressed in the brain, mostly in the hippocampus, and in neuroendocrine 
tissues (Vician et al., 1995). Kainic acid, a glutamate agonist, induces seizures in mice, 
and results in elevated Syt IV message (Vician et al., 1995). Interestingly, Syt IV 
expression is developmentally regulated in brain during periods which correlate with 
synaptic plasticity and remodelling (Ibata et al., 2000). Together these findings made 
Syt IV a good candidate for proteins whose induction might play a role in the 
modulation of synaptic function.
To examine the role of Syt IV in neuronal plasticity in vivo, Syt IV (-/-) mutant mice 
were generated and analysed (Ferguson et al., 2000). Syt IV null mutant mice are 
viable, but they exhibit deficits in motor coordination and hippocampal-related learning 
and memory. Thus, Syt IV may play a role in stabilising memories after they are 
initially established. That is, like kainic acid-induced seizures (Vician et al., 1995), 
learning may trigger changes in Syt IV expression that are critical for memory 
consolidation.
In studies of the molecular mechanisms underlying the possible function of the 
inducible Syt IV in the brain, PC 12 cells are often used as a model system. PC 12 cells 
are derived from a rat pheochromocytoma tumour, and they share some properties of 
neurons in that they contain small synaptic vesicles, called synaptic-like microvesicles 
(SLMVs), and mature secretory granules, also referred to as large-dense core vesicles 
(LDCVs). When PC 12 cells are stimulated by depolarisation, they release their vesicle
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contents in a calcium-dependent fashion. PC 12 cells, like neurons, thus undergo 
calcium-dependent neurotransmitter release from synaptic vesicles.
The subcellular localisation of Syt IV has long been a matter of debate. Initially, Syt IV, 
similarly to Syt I, was characterised as a synaptic vesicle protein, as well as being on 
MSGs (or LDCVs) (Ferguson et al., 1999). Moreover, Syt IV was found to form 
calcium-dependent hetero-oligomers with Syt I (Thomas et al., 1999). Following these 
results, it was suggested that the role of Syt IV, perhaps in concert with Syt I, was to 
modulate synaptic vesicle fusion with the plasma membrane.
In contrast, it was shown using indirect immunofluorescence that Syt IV displays a 
predominantly perinuclear localisation in PC12 cells, and was found in the distal part of  
neurites in NGF-differentiated PC12 cells, and that these signals were distinct from that 
of Syt I (Ibata et al., 2000). Moreover, using subcellular fractionation of rat cerebellar- 
homogenates, it was shown that Syt IV is not found in the synaptic-vesicle enriched 
fractions, suggested that Syt IV and Syt I localise to distinct populations of neuronal 
transport vesicles (Berton et al., 2000). Subcellular fractionation of AtT-20 and PC 12 
cells also demonstrated that Syt IV is localised on ISGs and not MSGs (Eaton et al., 
2000) (Fukuda et al., 2003). Moreover, it was shown in vitro that the calcium-dependent 
and -independent oligomerisation activities of Syt IV are very weak compared to those 
of Syt I, indicating that hetero-oligomerisation of Syt IV and Syt I is very unlikely in 
vivo (Fukuda and Mikoshiba, 2000a) (Osborne et al., 1999) (Fukuda et al., 2004).
These discrepancies in localisation were attributed to the difference in the specificity of 
the abs used in the first studies, where the anti-Syt IV ab recognised a higher molecular 
weight band in addition to that of Syt IV. More importantly, an often overlooked reason 
is that Syt IV localisation was assessed in forskolin-and NGF-treated PC12 cells in the
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studies by Thomas et al. (1999) and Ferguson et al. (1999), whereas Ibata et al. (2000) 
and Fukuda et al. (2003) studied the localisation of the endogenous Syt IV in untreated 
PC 12 cells. In fact, more recent studies showed that the treatment of PC 12 cells with 
NGF and forskolin, as well as the overexpression of Syt IV, induces the sorting of Syt 
IV into MSGs, where it is involved in calcium-regulated exocytosis (Fukuda et al., 
2003) (Fukuda and Yamamoto, 2004) (Wang et al., 2003a).
As with its localisation, the function of the inducible Syt IV remains controversial. 
Functional studies suggest that one role of the inducible Syt IV is to modulate vesicle 
fusion with the plasma membrane, but whether it is a negative or positive regulator of 
exocytosis is under debate. Work from Littleton et al. (1999) showed that the 
overexpression of Syt IV, but not Syt I, in Drosophila inhibited evoked transmission in 
the fly neuromuscular junction (Littleton et al., 1999). Overexpression of Syt IV in AtT- 
20 and PC 12 cells also caused a decrease in ACTH and hGH exocytosis, respectively 
(Eaton et al., 2000) (Machado et al., 2004). Furthermore, electrophysiological 
measurements in PC 12 cells showed that increasing the copy number of Syt IV by 
overexpression shortened the fusion pore opening time, whereas overexpression of Syt I 
prolonged this time (Wang et al., 2001). In contrast, the overexpression of Syt IV in 
pancreatic MIN6-|3 cells allowed full release to occur, suggesting that fusion pores were 
stable and remained open (Tsuboi and Rutter, 2003). These different results could be 
attributed to the use of different cell lines. A more recent electrophysiological study 
showed that overexpression of Syt IV favours “kiss-and-run” fusion, in which fusion 
pores initiate but do not dilate effectively, whereas the overexpression of Syt I favours 
full fusion (Wang et al., 2003a). Syt IV was shown to bind to SNAP-25 and Stxl in a 
calcium-independent manner, suggesting that this interaction might drive the kiss-and-
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run fusion events (Wang et al., 2003a). Moreover, overexpression of a Syt IV-C2B 
domain harbouring a mutation in one of the acidic residue previously thought to mediate 
binding to calcium abolished the ability of C2B to mediate kiss-and-run fusion, leading 
Wang et al. to suggest that Syt IV mediates kiss-and-run events via calcium-binding 
through its C2B domain (Wang et al., 2003a). This calcium-dependent role of Syt IV 
was later put into question after the finding that the C2B domain of Syt IV does not 
bind calcium, although all the calcium-binding residues are conserved (Dai et al., 2004).
It is thought that Syt IV functions similarly in the brain. During seizures, Syt IV is 
upregulated in neurons, and this will allow the slow release of neurotransmitters through 
the small pore size. The continuous slow release will increase the concentration of 
neurotransmitter in the synaptic space, which was suggested to desensitize postsynaptic 
receptors without generating synaptic responses (Klyachko and Jackson, 2002). The 
upregulation of Syt IV could then render the synapse silent to counteract 
hyperexitability during seizures. Thus, the seizure-induced upregulation of Syt IV may 
be a conserved mechanism to down-regulate neuronal activity. This upregulation could 
also be a mechanism for controlling long-term plasticity in the brain, consistent with the 
defects observed in Syt IV null mice.
In contrast, others have suggested that instead of its inhibitory roles, Syt IV may 
promote neurotransmitter release. Expression of Syt IV in a Drosophila Syt I-null 
mutant restored synaptic transmission (Robinson et al., 2002). This discrepancy was 
attributed to the possibility that when synapses have no Syt I, Syt IV may substitute for 
Syt IV and promote vesicle fusion. However, recent crystallography data have shown 
that rat and Drosophila Syt IV, although conserved in their primary sequence, differ in 
their calcium binding properties. Indeed, the Drosophila Syt IV, in contrast to the rat 
Syt IV, is a calcium- and phospholipid- binding protein (Dai et al., 2004). This data,
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although they do not explain the results of Littleton et al., suggests that Drosophila  Syt 
IV, in contrast to the rat isoform, promotes synaptic vesicle fusion.
There are no available data regarding the function of endogenous Syt IV in 
neuroendocrine cells relating to its distribution on ISGs and not MSGs, (Eaton et al.,
2000) (Fukuda et al., 2003). Syt IV displays a similar localisation to Stx6 and VAMP4, 
two SNARE proteins involved in secretory granule maturation in PC 12 cells (Wendler 
et al., 2001) (Hinners et al., 2003). Although a role of Syt IV in granule maturation was 
suggested, it has never been demonstrated.
1.5.3 Controversies in Synaptotagmin function
The Syt family is now the largest o f the C-terminal-type tandem C2 protein families. A 
recent genomic analysis has revealed that sixteen isoforms exist in mammals, five in 
plants, and seven in Drosophila and C. elegans, suggesting that Syts, like SNAREs or 
Rabs, may regulate various trafficking events (Craxton, 2004). It was previously 
thought that Syts do not exist in yeast, but a recent study identified three Syt-like 
proteins containing three C2-domains, called tricalbins (Schulz and Creutz, 2004) 
(Creutz et al., 2004). Although the function of the synaptic vesicle protein Syt I as a 
calcium sensor in neurotransmitter release has been well documented, the localisation 
and function of the other isoforms is still controversial. Several observations suggest 
that most Syt isoforms with different calcium sensitivities, such as Syt VII, IX and X, 
cooperate to regulate the same exocytic process, including that of dense core vesicle 
fusion in PC12 cells (Saegusa et al., 2002) (Tucker et al., 2003). However, since only 
Syt I, IV and IX are found at detectable levels in those cells, this hypothesis is difficult
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to confirm. Another hypothesis is that each Syt isoform may participate in a distinct 
membrane trafficking pathway. Supporting this model, several Syts display different 
localisation than Syt I. In PC12 cells, Syt IV was found to localise in the perinuclear 
area (Ibata et al., 2000). In other cell lines, several Syt isoforms also localised to 
different compartments. For example, in mast cells, Syt III was shown to localise on 
early endosomes as well as secretory granules, and was shown to be involved in the 
delivery of internalised cargo to the perinuclear endocytic recycling compartment, as 
well as having a role in secretory granule maturation (Grimberg et al., 2003). Syt IX, 
however, was localised on the endocytic recycling compartment, and is required for 
trafficking to the plasma membrane (Haberman et al., 2003). Moreover, a recent study 
in Drosophila showed that Syt isoforms localise to non-overlapping subcellular 
compartments, further supporting the idea that Syts function in different membrane 
trafficking steps (Adolfsen et al., 2004).
The availability of specific antibodies and tools to characterise the localisation and 
function of the endogenous synaptotagmins will help answer some of these questions, 
and reveal whether this family o f proteins contributes to the identity o f cellular 
compartments.
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1.6 Biogenesis of secretory granules in neuroendocrine cells.
Eukaryotic cells are capable of secreting components into the extracellular 
space. Two secretion pathways have been described: the constitutive pathway, common 
to all cells, where proteins are transferred in small vesicles from the TGN to the plasma 
membrane and released outside the cell in a spontaneous manner. In contrast to the 
constitutive pathway, the regulated secretory pathway is unique to specialised cells such 
as exocrine, endocrine, neuroendocrine and neuronal cells. In these cells, specialised 
organelles called secretory granules (also termed large dense core vesicles or LDCVs), 
package hormones and bioactive molecules at the TGN, and transport them in highly 
selective events involving active sorting and targeting to the plasma membrane. After a 
series of changes and upon external stimulation, these vesicles fuse with the plasma 
membrane and exocytose their content into the extracellular space. Some cells of the 
haematopoietic lineage or melanocytes contain organelles, called secretory lysosomes, 
that also undergo regulated secretion (Blott and Griffiths, 2002). For example, cytotoxic 
T cells (CTLs) and natural killer cells recognise infected or tumourigenic cells and 
destroy them by secreting cytolytic proteins, which are stored in the secretory 
lysosomes.
1.6.1 Secretory granule formation
Secretory granules initiate their life at the TGN, where the packaging of 
regulated secretory proteins occurs. In neuroendocrine and endocrine cells, the budded 
granule is the intermediate compartment between the TGN and the mature secretory
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granule (MSG), called immature secretory granule (ISG). Morphological data observed 
a “lace-like” coat in the TGN-areas where secretory proteins accumulate prior to 
budding (Ladinsky et al., 1994). The nature of this coat, or whether secretory granule 
budding from the TGN is coat-mediated, is still unknown.
The sorting of secretory proteins into the nascent granule from the TGN was suggested 
to occur via a “sorting for entry” mechanism, where the soluble secretory proteins are 
sorted by binding to specific receptors, or by forming aggregates that would exclude 
proteins not destined for the regulated secretory pathway. One such described receptor 
is carboxypeptidase E (CPE), which was suggested to function as a “sorting receptor” 
for pro-opiomelanocortin (POMC) (Cool et al., 1997). Studies performed on 
Cpefat/Cpefat mice, which express a CPE point mutant that missfolds and fails to be 
exported from the ER, contradicted this suggestion. Indeed, in these mice, pro-insulin is 
not processed to insulin, due to the absence of the pro-peptidase CPE in the secretory 
granules, which results in hyperglycemia and obesity. However, pro-insulin is sorted 
properly into vesicles, suggesting that CPE is not responsible for the sorting of secretory 
proteins (Irminger et al., 1997).
In contrast to receptor-mediated sorting, it was proposed that secretory proteins are 
sorted to the regulated pathway via aggregation. Granins are a family of soluble proteins 
found in secretory granules and expressed in most neuroendocrine and endocrine cells. 
This family of proteins includes Chromogranin A (CgA), CgB, also called 
Secretogranin I (Sgl), Sgll, SgHI and Secretogranin IV (called 7B2). The granins are 
able to aggregate, and this is favoured by a low pH and high calcium concentrations 
(Gerdes et al., 1989). This ability to aggregate was suggested to mediate the sorting of 
secretory granins into the nascent vesicles forming from the TGN (Chanat and Huttner, 
1991), thus excluding proteins not destined for constitutive secretion. It was shown that
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the overexpression of CgB in AtT-20 cells promoted the efficient sorting of POMC into 
secretory granules (Natori and Huttner, 1996). Studies have suggested that an 
amphipathic disulfide loop in the N-terminus of the secretory proteins chromogranin A 
and B, is necessary for their correct sorting. However, it is not known whether this 
sequence exerts its effect on sorting via aggregation or via binding to membranes. Using 
a vaccinia virus expression system in PC 12 cells, the expression of a mutant CgB 
lacking the N-terminal disulfide bond loop, in the absence of endogenous protein 
synthesis, resulted in the missorting of the mutated protein and an inability to enter the 
regulated secretory pathway (Kromer et al., 1998). The mutant CgB was expressed in 
conditions where the endogenous protein synthesis was inhibited to abolish co- 
aggregation with endogenous wild type protein, suggesting that the disulphide loop of  
CgB mediates its sorting via aggregation (Kromer et al., 1998). A different study 
showed that the incubation of PC 12 cells with DTT, which disrupts the disulfide bond 
of CgB, also resulted in its missorting to the constitutive pathway (Chanat et al., 1993). 
However, the DTT treatment did not affect the aggregative property of CgB, suggesting 
that sorting is independent of the aggregation of CgB (Chanat et al., 1994).
Another hypothesis is that the sorting of regulated secretory proteins happens in a later 
compartment. It was suggested that proteins are included in the forming vesicles by 
default. Proteins destined for the regulated pathway are kept in the vesicle, whereas 
other proteins are removed. This hypothesis defines the “sorting by retention” 
mechanism (Arvan and Castle, 1998). In pancreatic P-cells, sorting of insulin from other 
proteins, such the lysosomal hydralases, occurs in the ISG (Kuliawat et al., 1997). 
Moreover, it was shown that in PC 12 cells, proteins such as furin, a secretory granule
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protein, are sorted from the maturing granule (Dittie et al., 1997). The sorting from the 
ISG involves clathrin and its adaptor protein-1 (AP-1) (discussed later).
Although the mechanism of sorting of secretory proteins into the regulated secretory 
pathway is still under debate, it is possible that both mechanisms function, so that 
“sorting for entry” first occurs in the TGN to exclude some proteins, and later a second 
“sorting by retention” step occurs in the ISG to retain the secretory proteins destined for 
the regulated pathway, and remove other proteins not needed for this route. The sorting 
mechanism could also depend on the cell type. In PC 12 cells, the constitutively secreted 
heparan sulphate proteoglycan (hsPG) is not found in ISGs, suggesting that sorting from 
the regulated pathway into constitutive vesicles occurred in the TGN (Tooze and 
Huttner, 1990). A second sorting step, via clathrin, in the ISG removes other proteins 
not found on the MSG (Dittie et al., 1997). In contrast, in pancreatic P-cells, most o f the 
sorting appears to happen in the ISG, where proteins such as the C-peptide are removed 
form the ISG and secreted via a constitutive-like pathway (Kuliawat and Arvan, 1992).
1.7 Maturation of secretory granules
1.7.1 Homotypic fusion of ISGs
After budding from the TGN, ISGs undergo several changes including an 
increase in size upon homotypic fusion, acidification of their lumen, prohormone 
processing and the removal o f unnecessary proteins, to give rise to an MSG, (Figure 6 is 
a working model of secretory granule maturation in PC12 cells), (Tooze et al., 2001). 
Initial observations in mammotroph cells of the anterior pituitary using EM showed the 
presence of an irregular-shaped delimiting membrane containing several dense cores,
Regulated secretory pathway in endocrine cells
MS
|  Maturatnon
ccv EE/LE
t Formation
TGN
Figure 6: Model of regulated secretory pathway in neuroendocrine cells.
Schematic representation of a model for secretory granule biogenesis in PC 12 
cells. Immature secretory granules (ISGs) bud from the TGN and undergo a mat­
uration process, which includes homotypic fusion of ISGs, membrane removal of 
unnecessary proteins via clathrin coated vesicles (CCVs). This maturation pro­
cess give rise to a mature secretory granule (MSG). In response to a stimulus, 
MSGs fuse with the plasma membrane and deliver their contents into the extra­
cellular space.
Figure 7: EM analysis of secretory granules in mammotroph cells. Mammotroph 
cells from the anterior pituitary gland of a lactating rat were used. These cells were 
fixed in 1% 0 s 0 4 inophosphate buffer (pH 7.6) and embedded in Araldite. Sections 
were doubly stained with uranyl acetate and lead citrate. x24,000; inset,x40,000. In the 
cell, the rough-ER (er) close to the cell membrane (cm), as well as the Golgi complex 
(GC) can be observed. Forming granules (aggregating granules are marked (ag)), 
mature granules (sg) and (sg’), with a rounded and uniform in size are also seen. Imma­
ture secretory granules vary in size and shape and are close to the Golgi. The inset 
shows several small cores, or vesicles, delimited by one membrane. This polymor­
phous granule seems to be formed by the fusion of these smaller vesicle, (j), junctional 
elements of the ER; (sv), smooth-ER. (lb), lytic body (Smith and Farquahar, 1966).
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which then become an ovoid-shaped mature granule, that is bigger than an ISG (Smith 
and Farquhar, 1966) (Figure 7 shows an EM picture of secretory granules in 
mammotroph cells, as well as progression through different shapes of secretory 
granules) (The inset in Figure 7 shows several dense cores within one delimiting 
membrane. In PC 12 cells, the measured dense core of the characterised ISG was smaller 
(~80 nm) compared to that of an MSG (~120 nm) (Tooze et al., 1991). These 
observations led to the hypothesis that 3 to 5 ISGs undergo homotypic fusion, followed  
by the removal of excess membranes, to generate an MSG (Tooze et al., 1991). An in 
vitro assay has shown that indeed ISGs undergo homotypic fusion (Urbe et al., 1998). 
ISG-ISG fusion was found to require ATP, GTP, the ATPase NSF and a-SN A P (Urbe 
et al., 1998). Homotypic fusion of ISGs was not inhibited by the addition of botulinum 
neurotoxins, suggesting that plasma membrane SNAREs, although present on ISGs, do 
not participate in this fusion event (Urbe et al., 1998).
So far the only SNARE protein directly shown to be involved in the regulation of ISG- 
ISG fusion is Stx6 (Wendler et al., 2001). Interestingly, Stx6 was found in a SNARE  
complex with SNAP-25, SNAP-29 (GS32) and VAMP4 (Wendler et al., 2001). 
However, as ISG-ISG fusion is resistant to botulinum neurotoxin treatment, it is 
unlikely that a SNAP25-Stx6-containing complex is involved in ISG-ISG fusion. This 
result was surprising, because Stx6 is classified as a Qc-SNARE (Bock et al., 1997), 
and so a canonical Qabc SNARE complex containing SNAP-25 and SNAP-29, both of 
which are considered Qbc-SNAREs, would lack a Qa SNARE. A possible explanation 
is that because Stx6 has an N-terminal domain similar to that of Stxl (Misura et al., 
2002) Stx6 may behave as a Qa-SNARE in a complex containing either SNAP-25 and 
VAMP-4, or SNAP-29 and VAMP-4. Others have found Stx6 in a complex with Stxl6, 
vtila, and VAMP4 (Kreykenbohm et al., 2002) (Mallard et al., 2002), where it would be
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predicted to function as a Qc SNARE. All these SNARE proteins were found in ISG- 
containing fractions from PC 12 cells, making this complex a potential candidate to 
study in ISG homotypic fusion (Wendler et al., 2001) (Wendler, F. Unpublished 
observations).
The search for other proteins involved in regulating the homotypic fusion of ISGs 
continues, and should give us more insight into the molecular mechanisms underlying 
this membrane fusion event.
1.7.2 Membrane remodelling
It was suggested that, following the fusion of ISGs, excess membrane is 
generated, which is then removed via a CCV pathway (Arvan and Castle, 1998) (Tooze 
et al., 2001). Indeed, using EM, clathrin patches were observed on ISGs and not MSGs, 
suggesting that ISG-localised proteins are sorted into the budding vesicles (Orci et al., 
1984) (Orci et al., 1985) (Tooze and Tooze, 1986).
Clathrin coats were found to be associated with ISG membranes through the adaptor 
protein-1 (AP-1), which was demonstrated to bind ISG membranes (Dittie et al., 1996). 
AP-1 coats were suggested to include proteins to be removed form the maturing 
granules, through binding a sorting signals in their cytoplasmic tails. Proteins such as 
CI-MPR and furin were found to be on ISGs and absent from MSGs (Klumperman et 
al., 1998) (Dittie et al., 1997). Moreover, these two proteins were found to bind AP-1, 
and this interaction was enhanced by a casein kinase II (CKII)-mediated 
phosphorylation of their cytoplasmic tails (Dittie et al., 1997). Additional proteins have 
been found on ISGs and not on MSGs, such as VAMP4, Stx6, and Syt IV, suggesting
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that proteins that are not needed on the MSG are being removed (Wendler et al., 2001) 
(Eaton et al., 2000) (Fukuda et al., 2003) (present study, Chapter 3). Recently, VAMP4 
was also found to bind to the p i subunit of AP-1 via a dileucine motif in the 
cytoplasmic tail of VAMP4 (Peden et al., 2001) (Hinners et al., 2003). A CK2-mediated 
phosphorylation within an acidic cluster adjacent to the dileucine motif enhanced this 
interaction (Hinners et al., 2003). Expression of VAMP-4 harbouring mutations in the 
dileucine motif and the phosphorylation site within the acidic cluser, prevented its 
removal from the maturing granule in AtT-20 cells (Hinners et al., 2003). It was 
suggested that the removal of proteins, such as VAMP4 and Syt IV, from MSGs is 
necessary for the granules to acquire their exocytic abilities (Eaton et al., 2000). This is 
an interesting observation, and one can hypothesise that proteins involved in the 
regulation of ISG maturation, such as proteins involved in homotypic fusion, are not 
needed for later stages, and they must be removed in order for the MSG to become a 
mature granule capable of exocytic activity.
1.7.3 Granule acidification and hormone processing
Hormones and granins, generated as large precursors, are subjected to 
endoproteolytic cleavage during granule maturation. Early studies provided the first 
evidence for the conversion of proinsulin into active insulin (Steiner et al., 1967). It was 
later reported that insulin secretory granules contained two endoproteases, which 
converted proinsulin into insulin in a calcium and pH-dependent manner (Davidson et 
al., 1988).
Other endoproteases have been subsequently identified, and now classified as 
Prohormone Convertases (PCs), which include PC1/PC3, PC2, PACE4, PC4, PC5/PC6
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and PC7. The endoproteolytic cleavage of prohormones usually occurs at dibasic amino 
acid sites, although cleavage can also take place at a single basic residue (Seidah and 
Prat, 2002). PCs cleave different precursor hormones and granins into their active form; 
for example, in pituitary cells, PC1/PC3 mediates the initial processing of pro­
opiomelanocortin (POMC) into corticotropin (ACTH) and P-lipotropic hormone (|3- 
LPH), then PC2 converts P-LPH into P-melanocyte-stimulating hormone and |3- 
endorphin (Benjannet et al., 1991). In PC12/PC2 cells, and during the maturation of 
ISGs, Sgll is cleaved by PC2 into a final 18 KDa product (p i8) (Dittie and Tooze, 
1995).
PC2 itself is found as a 75 KDa precursor in the TGN, and is endoproteolytically 
cleaved to the 65 KDa mature form during granule maturation in a pH-dependent 
manner (Urbe et al., 1997) (Lamango et al., 1999). The transport and activation of PC2 
depend on its association with the chaperone, 7p2 (Muller et al., 1997) (Mbikay et al.,
2001). The site where the initiation of processing occurs is controversial. Some suggest 
that it starts in the TGN (Xu and Shields, 1993), whereas others found that processing 
starts in the ISG, and continues during granule maturation (Orci et al., 1987) (Tooze et 
al., 1987).
Early studies have revealed that luminal pH of secretory granules in neuroendocrine and 
endocrine cells is acidic and ranges between pH 5.0 and 5.5 (Johnson and Scarpa, 1976) 
(Carty et al., 1982) (Hutton, 1982). The acidification of many organelles, including 
secretory granules, is carried out by the vacuolar-type proton ATPase (V-ATPase), 
which uses the energy of ATP hydrolysis to transport protons across membranes. The 
V-ATPase belongs to the family of multi-subunit ATP-dependent proton pumps, and 
consists of two major functional sectors, V l5 which contains three catalytic sites for 
ATP hydrolysis, and Vo, responsible for proton translocation across the membranes
Chapter 1_____________________________________________________________ 55
(Sun-Wada et al., 2004). The V-ATPase inhibitor, bafilomycin A l,  inhibited processing 
of POMC, PC2 and SgHI in primary Xenopus intermediate pituitary cells 
(Schoonderwoert et al., 2000). Moreover, inhibition of the V-ATPase by another 
inhibitor, concanamycin A, abolished Sgll processing in isolated PC12-ISGs (Urbe et 
al., 1997), suggesting that the acidification of granules, important for hormone 
processing, is dependent on the activation of the V-ATPase.
It is not well understood how acidification in secretory granules exactly occurs. It was 
demonstrated that acidification o f granules along the secretory pathway is solely 
dependent on the rates of H+ pumping and the rates of H+ leackage, and not membrane 
potential (Wu et al., 2001). It was suggested that the acidification from ISGs to MSGs is 
accomplished by progressively increasing the density of active V-ATPase while 
decreasing the density of H+ leaks (Wu et al., 2001). In contrast, the acidification o f the 
endosomes is regulated by the Na+/K+-ATPase (Cain et al., 1989) (Fuchs et al., 1989). 
This latter produces an interior positive membrane potential in early endosomes, 
preventing maximal acidification by the V-ATPase. In this model, the acidification from 
early to late endosome was suggested to occur by the removal of the Na+/K+-ATPase. 
These results suggest that the mechanism for acidification along the secretory pathway 
differs from that previously proposed for the endocytic pathway.
The different steps described above, including homotypic fusion, membrane 
remodelling, acidification and hormone processing, are highly controlled and regulated. 
The identification of proteins involved in these processes, and the mechanism by which 
they do so, will increase our understanding of how the regulated secretory pathway in 
specialised cells is controlled.
56
1.8 Objective of the thesis
Work from Eaton and colleagues have shown that Syt IV is localised on ISGs 
and not MSGs in AtT-20 cells (Eaton et al., 2000). Two SNARE proteins, VAM P4 and 
Stx6, were similarly shown to localise on ISGs and be removed from granules during 
maturation in AtT-20 cells (Wendler et al., 2001). Moreover, Stx6 was directly shown 
to be involved in the regulation o f ISG-ISG homotypic fusion (Wendler et al., 2001). 
Although a direct involvement of VAMP4 in ISG homotypic fusion was never 
demonstrated, it was found in complex with Stx6 on ISGs, and it was suggested that this 
complex is involved in the regulation of ISG-ISG fusion. A hypothesis emerged that 
proteins involved in the regulation of ISG maturation (i.e. homotypic fusion) are being 
removed from MSGs.
Studies have shown that Syts are involved in the regulation of membrane fusion events. 
Moreover, Syts were shown to interact with the SNARE proteins, making this family of 
proteins important components of the fusion machinery.
The purpose of the thesis was to investigate whether Syt IV is involved in the 
maturation of ISGs in PC 12 cells. After I confirmed that endogenous Syt IV is localised 
on ISGs and not MSGs in PC 12 cells, I asked whether it is involved in the regulation of 
ISG maturation. To investigate this question, I used an in vitro assay that reconstitutes 
ISG-ISG fusion (Urbe et al., 1998), and tested the effect o f soluble Syt IV cytoplasmic 
domain in this membrane fusion event. The inhibition of ISG homotypic fusion 
obtained with the addition of the cytoplasmic domain suggested that Syt IV is involved 
in this process.
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Morover, the Syt IV cytoplasmic domain, and siRNA against Syt IV, affected Sgll 
maturation in PC12 cells, confirming the role of Syt IV in granule maturation in vivo. 
The finding that Syt IV is involved in ISG homotypic fusion led me to ask whether it 
interacts with the SNARE protein Stx6, and further to hypothesise that these two 
proteins are in the same complex that regulates ISG-ISG fusion.
Finally, many proteins removed from the maturing granule, including VAMP4, were 
shown to bind to AP-1, which recruits clathrin to ISG membranes. As mentioned above, 
Syt IV is found on ISGs and not MSGs, suggesting that it is also removed during 
maturation. I hypothesised that the sorting of Syt IV from MSG could occur in the same 
manner. Following this hypothesis, I tested whether Syt IV interacts with AP-1.
In conclusion, the determination of whether or not Syt IV is an additional 
component regulating granule maturation, and in particular homotypic fusion of ISGs, 
will give us more clues about the mechanisms underlying this membrane fusion event, 
and in particular the function of this large family of proteins in membrane trafficking. 
The involvement of Syt IV in the regulation of ISG-ISG fusion provides additional 
evidence to support the notion that Syts, like SNAREs or Rabs, regulate distinct 
membrane fusion events.
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2 Chapter 2: Materials and Methods
2.1 Materials
2.1.1 Chemicals
All chemicals were purchased from the following companies unless otherwise stated: 
Sigma; Bohringer Manheim; Amersham Pharmacia; BDH; Fluka; Roche; Invitrogen; 
Calbiochem or Pierce. 1,2-bis (o-aminophenoxy) ethane-N,N,N’,N’-tetraacetic Acid 
(BAPTA) was purchased from Calbiochem; [3-(2,4-dinitroanilio-3’-amino-N- 
methyldipropylamine] (DAMP) was from Oxford Biomedical Research; [35S]-Sulphate
48.3 mCi/ml was from Amersham Pharmacia; Protein G was either from Amersham 
Pharmacia or Roche. Horse serum and foetal calf serum were from Sigma.
Molecular biology reagents were from Promega; New England Biolabs; Invitrogen or 
Qiagen.
Phosphate buffered saline (PBS), LB-medium for bacterial growth, LB-agar, E4 
(Dulbecco’s modified eagle medium), E4 without antibiotics, E4 without sulphate 
medium for mammalian cell culture, trypsin, versene and glutamine were supplied by 
Cancer Research UK laboratory services.
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2.1.2 Antibodies
P rim ary an tibod ies
Antibody Antigen Species Applications/Dilution Supplier
Anti-Syt IV Syt IV rabbit pab WB, IF (1:1000) M.Fukuda
Japan
Anti-Syt I Syt I mouse mab WB, IF (1:1000) Synaptic
Systems
STO 112 Syntaxin 6 rabbit pab WB (1:500) 
IF (1:200)
S.Tooze 
CRUK
Clone 30 Syntaxin 6 mouse mab IF (1:200) Transduction
laboratories
175 Sgll(C-term) rabbit pab WB (1:1000) Dittie and 
Tooze, 1995
6(31 pi 8 mouse mab IF (1:200) 
IP
Dittie and 
Tooze, 1995
Clone 88 y-adaptin mouse mab WB (1:500) 
IF (1:200)
T ransduction 
laboratories
100/3 y-adaptin mouse
mab
WB (1:200) Sigma
Anti-PC2 PC2 rabbit pab WB, IF (1:1000) B.Eipper 
University of 
Connecticut
Anti-Myc Myc tag rabbit pab IP Abeam
9E10 Myc tag mouse mab WB (1:500) CR-UK
12CA5 HA tag mouse mab WB, IF (1:500), IP CR-UK
Anti-HA HA tag rat mab IF (1:500) Roche
Anti-DNP DAMP mouse mab EM (1:10) Oxford
biomedical
research
S econdary an tibod ies
Antibody Antigen Species Application Supplier
Alexa 488 rabbit,mouse 
and rat IgG
goat,Alexa488-
conjugated
IF (1:1000) Transduction
laboratories
Alexa 555 rabbit,mouse 
and rat IgG
goat,Alexa555- 
conju gated
IF (1:1000) T ransduction 
laboratories
Alexa 633 rabbit,mouse goat,Alexa- 
633conjugated
IF (1:1000) T ransduction 
laboratories
Anti­
mouse Cy3
mouse IgG sheep,Cy3-conjugated IF (1:1000) Jackson
Immunoresearch
Anti­
guinea pig 
Cy3
guinea pig 
IgG
goat, Cy3-conjugated IF (1:500) Abeam
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Anti-goat 
Rhodamine
Goat IgG rabbit, rhodamine- 
conjugated
IF (1:500) Pierce
Anti-rabbit 
Alexa 647
rabbit IgG goat, Alexa 647- 
conjugated
FACS
(1:100)
Transduction
labortories
Anti-
mouse-
HRP
mouse IgG sheep,HRP-conjugated WB
(1:2500)
Amersham
Anti-
rabbit-HRP
rabbit IgG donkey, HRP-conjugated WB
(1:2500)
Amersham
Anti­
guinea pig 
HRP
guinea pig 
IgG
rabbit, HRP-conjugated WB
(1:2500)
Abeam
2.1.3 Oligonucleotides
All oligonucleotides were synthesised and purified by Cancer Research UK
oligonucleotide services.
Prim er’s
name
Oligouncleotide sequence
SytlV-
cytoplasmic
domain
5 ’ T CCCCCGGGT GCCAG AG A AG AT CCGCT A AGT CCA ACA AG 3 ’
3 ’ A AGG AA A A A  A AGCGGCCGCCT A ACC AT C ACAG AGC AT AT G5 ’
SytIV-C2A
domain
5 ’TCCCCCGGGTGCCAG AG A AG AT CCGCT A AGT CCA AC A AG3 ’
3 ’ AAGGAAAAAAAGCGGCCGCTGTGGCACCCAGGACCA ACCG5 ’
Syt IV-C2B 
domain
5 ’TCCCCCGGGT CTT CT GG ACGGGGT G A ACTTCT GGT CTCC3 ’ 
3 ’AAGGAAAAAAAGCGGCCGCTGTGGCACCCAGGACCAACCG5’
HA-Syt IV 
cytoplasmic 
domain
5 ’CCCAAGCTTGCCAGCATGGCATACCCATACGACGTCCCAGAC 
T ACGCT GCT CCT AT C A AC ACC AGCCGGGT G 3 ’
3 ’ CCGG A ATT CCT A ACCAT CA CAG AGC AT AT G5 ’
HA-Syt IV 
C2A 
domain
5 ’ CCCA AGCTT GCC AGCAT GGCAT ACCC AT ACG ACGT CCCAG AC 
T ACGCT A A AC A AG AG A AGCT GGGCACTCT C3 ’
3 ’ CCGG A ATT CCT AAAG AGGAACGAGG ACTT CT CCA ATG AC5 ’
HA-syt IV 5 ’ CCCA AGCTT GCCAGCAT GGCAT ACCCAT ACG ACGT CCCA
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C2B
domain
G ACT ACGCT GCT A AG A AGT CTT CT GG ACGGGGT3 ’ 
3 ’ CCGG A ATT CCT A ACC AT CA C AG AGC AT AT G5 ’
pGEX 5 ’ GGGCT GGCA AGCC ACGTTTGGTG3 ’ 
3 ’ CCCGGG AGCTGCAT GT GT C AG AGG5 ’
T3 5 ’ A ATT A ACCCT CACT A A AGGG3 ’
T7 5 ’ GT A AT ACG ACT C ACT AT AGGGC3 ’
2.1.4 Synaptotagmin IV siRNA sequences
Smart pool consisting of 4  pooled siRNAs duplexes specific for rat Syt IV were
synthesised by Dharmacon. The sequences are as follow:
5 ’ -GAAGAAAGCAUUUGUGG UG-3 ’
5 ’ -GG AG ACA AAUUGCU AAGUG-3 ’
5 ’ -CAACAAG ACUCCUCCAU AC-3 ’
5 ’ -U AAAGGAGUUG AUAUCU AC-3 ’
2.1.5 Constructs
B acteria l expression  vec tors
Name Vector Origin Fusion
protein
GST-Syt IV 
cytoplasmic 
domain
pGEX-4T2 This study soluble
GST-Syt IV 
C2A domain
pGEX-4T2 This study low expression
GST-Syt IV 
C2B domain
pGEX-4T2 This study insoluble
GST-Syt I 
cytoplasmic 
domain
PGEX-KG G. Schiavo 
CRUK
soluble
GST-Vamp4
cytoplasmic
domain
PGEX-KG Ina Hinners 
CRUK
soluble
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M am m alian expression  vectors
Name Vector Origin
HA-Syt IV 
cytoplasmic 
domain
pcDNA 3.1 This study
HA-SytIV  
C2A domain
pcDNA 3.1 This study
HA-SytIV 
C2B domain
pcDNA 3.1 This study
T7-SytIV FL pEF-BOS M.Fukuda
Japan
PC2 pRC-CMV N.Seidah
(Montreal)
Myc-Syntaxin6
FL
pCDNA3.1 F. Wendler 
CRUK
GFP pEGFP Clontech
A den ovira l expression  vec tors
Name Vector Origin
HA-Syt IV cytoplasmic 
domain-VQ
VQAd5CMVK-NpA Viraquest
2.2 Methods
2.2.1 Tissue culture techniques
2.2.1.1 Mammalian cells lines
PC 12 cells are a neuroendocrine cell line derived from a pheochromocytoma o f rat- 
adrenal medulla gland. They are used as a model to study the regulated secretory 
pathway. PC 12 cells, clone 251, were originally from Dr.H.Thoenen (Martnsried, 
Germany) (Heumann et al., 1983). PC12/PC2 cell-line is a PC12 cell line that stably 
expresses the prohormone convertase, PC2 (Dittie and Tooze, 1995). AtT-20 cells
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(AtT20 D16V) were originally obtained from R.Kelly (Gumbiner and Kelly, 1981). 
HEK-293A cells (Human Embryonic Kidney cells) were purchased from Invitrogen.
2.2.1.2 Maintenance of mammalian cells
Solutions: Phosphate-buffered saline (PBS): (137mM NaCl, 3.35 mM KC1, 10 mM 
Na2H P 04, 1.84 mM KH2P 0 4, PH 7.2); trypsin/versene:(0.05% trypsin (w/v), 0.02% 
EDTA (w/v), 1% phenol red in PBS); E4 (Dulbecco’s MEM); glutamine (250 mM 
stock); were provided by Cancer Research UK, Central Cell Services. Horse serum and 
foetal calf serum were from Sigma and were batch tested.
All cells were used between passage 9 and 23 and were grown at 37 °C in humidified 
incubators at 10% C 0 2.
PC12 cells and PC12/PC2 cells were maintained in E4 supplemented with 10% horse 
serum, 5% FCS, 4mM glutamine. HEK cells were maintained in E4 supplemented with 
10% FCS and 4.8 mM glutamine. Cells were grown up to 80 % confluency. For 
passaging, cells were washed once in PBS and incubated for 5 min in trypsin/versene 
until cells detached from the plastic. Cells were collected into a 50 ml polypropylene 
centrifuge tube (Falcon) containing growth media and spun at 1000 rpm for 5 min in a 
swing bucket centrifuge (Heraeus). To obtain a single cell suspension, the pellet was 
resuspended in 1 ml media using a Pasteur pipette that has been flamed to narrow the 
opening. Cells were plated at the desired dilution into flasks, dishes or plates.
2.2.1.3 Storage and recovery of mammalian cells
For storage, the cell pellet was prepared as described above, and resuspended in growth 
medium supplemented with 10% sterile DMSO and 1 ml aliquots were dispensed into 
cryovials (Nunc). Aliquots of these cells were frozen at -  80 °C for one week, before
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long term storage in liquid nitrogen. For recovery, an aliquot was rapidly thawed at 37 
°C and plated into a 70 cm2 tissue culture flask, containing growth medium. The 
medium was replaced the following day, after the cells had attached to the plastic.
2.2.2 Molecular biology techniques
2.2.2.1 Extraction of total RNA from PC 12 cells
Isolation of total RNA from PC 12 cells was performed using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. Briefly a maximum of 107 PC 12 
cells are first lysed and homogenised in the presence of a highly denaturing guanidium 
isothiocyanate (GITC)-containing buffer which immediately inactivates RNAses to 
ensure isolation of intact RNA. Ethanol is added to provide appropriate binding 
conditions and the sample is then applied to an RNeasy mini spin column where the 
total RNA binds to the membrane and contaminants are efficiently washed away. Total 
RNA is then eluted in 30 pi or more, of RNAse-free water. RNA concentration is 
determined at OD260 using a spectrophotometer and finally total RNA was aliquoted and 
stored at -8 0  °C to avoid degradation.
2.2.2.2 cDNA synthesis from total RNA
PC12 cDNA synthesis from isolated total RNA was performed using the thermoscript 
TM RT-PCR system (Life Technologies) following the manufacturer’s instructions. 
Briefly, a mixture of 1 pg of total RNA and oligo (dT)20 primer (50pmol/reaction) was 
denatured by incubating at 65 °C for 5 min. cDNA is then synthesised by adding 
thermoscript RT (15units/pl), lOmM dNTP mix, 0.1 M DTT and lx  cDNA synthesis
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buffer, to the previous total RNA-containing mix at 50°C for 60 min. The cDNA  
synthesis reaction was stored at -2 0  °C or used for PCR immediately.
To amplify specific genes, 2 pi of the cDNA was mixed with gene-specific primers (2 
pM each) and PCR reaction was performed as described in (2.2.2.3).
2.2.2.3 Amplification of DNA by polymerase chain reaction (PCR)
DNA was routinely amplified using the following 50 pi reaction mixture: 1-50 ng of 
template DNA, 2 pM primer (each), 200 pM dNTPs (Promega), 2.5 units Pfu 
polymerase (Stratagene), lx  Pfu buffer. When amplifying cDNA from reverse 
transcription reactions, 2pl cDNA was used. PCR reactions were performed in a thermal 
cycler with the following conditions:
- denaturation: 94 °C, 5 min
- denaturation: 94 °C, 1 min
- annealing: 55-65 °C, 1 min x 30 cycles
- extension: 72 °C, 1 min
- final extention: 72 °C, 12 min
2.2.2.4 Quantitation of DNA and RNA
DNA or RNA was placed in a quartz cuvette with a path length of 1 cm and absorbance 
at wavelength 260 nm was read in a spectrophotometer. An OD260 of 1 corresponds to 
50 pg/ml double stranded DNA, 40 pg/ml RNA and 33 pg/ml single stranded DNA.
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2.2.2.5 Restriction digest of plasmid DNA and DNA fragments
Typically, 0.2-2 pg of DNA was digested using 10 U of the appropriate digestion 
enzyme and lx  enzyme buffer in a 20-50 pi total reaction. Reactions were incubated at 
the enzyme’s working temperature (typically 37 °C) for 1-4 h.
2.2.2.6 DNA agarose gel electrophoresis and extraction
Typically, 1% agarose was disolved in lx  TAE buffer (40 mM Tris, pH 8, 20 mM 
acetic acid, ImM EDTA). Ethidium bromide was then added to a final concentration of 
0.5 pg/ml. DNA samples were resuspended in loading buffer (60% (w/v) sucrose, 0.1% 
bromophenol blue (w/v), 0.1 % xylene cyanol (w/v) in TAE) and run at 5-20V/cm in 
lxTA E buffer.
DNA was routinely purified using QIA quick gel extraction Kit following 
manufacturer’s instructions. Briefly, the gel slice containing the fragment of interest 
was solubilised and applied to the reservoir o f silica-gel membrane column. During 
centrifugation, the DNA attaches to the silica membrane whilst the dissolved agarose 
and other impurities pass through the column. Bound DNA was washed in buffer 
containing ethanol and eluted in 10 mM Tris-HCL, pH 8.5 or in dH20 . All buffers were 
provided in the kit.
2.2.2.7 Ligation of DNA
100-500 ng of digested and gel purified vector DNA were mixed with an excess of 
purified insert DNA (typically 1:3 plasmid to insert ratio); 200 units T4 DNA ligase and 
lx  DNA ligase buffer (New England biolabs) in a total volume of 10 pi. DNA was 
ligated for lh  at room temperature.
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2.2.2.8 Bacterial transformation
100 pi chemically competent bacteria , DH 5-a (Invitrogen) or XL-1 blue (Stratagene), 
were mixed with 10 pi ligation reaction or 10-50 ng of supercoiled plasmid DNA and 
incubated for 40 sec at 42 °C then immediately returned on ice for 2 min. 900 pi of 
SOC medium was added and bacteria were incubated for lh  at 37 °C. Transformed 
bacteria were plated onto LB-agar plates with the appropriate selection antibiotics 
(typically 50-100 pg/ml antibiotic). Plates were incubated O/N at 37 °C.
2.2.2.9 DNA Sequencing
DNA sequencing was carried out using the ABI dye Terminator sequencing kit 
(Applied Biosystems). 20 pi sequencing reactions contained: 100-500 ng template 
DNA, 100 nM primer and 9 pi terminator ready reaction mix. PCR reactions were then 
performed with the following conditions:
- denaturation : 96°C for 30 sec
-annealing : 46-60 C for 15 sec x 25 cycles
- extension : 60 °C for 4  min
Sequencing reactions were purified by centrifugation at 3000 rpm for 3 min in spin 
columns (Qiagen DyeEX 2.0 spin Kit) followed by drying in a vacuum centrifuge. 
Samples were processed by CR-UK Sequencing Services. Briefly, dried DNA was 
resuspended in loading buffer (deionised formamide, 25 mM EDTA (pH 8), 50 pg/ml 
blue dextran), mixed and spun. Samples were heated to 90 °C for 2 min to denature the 
DNA and loaded onto the ABI Prism 377 DNA sequencer (Applied Biosystems). 
Sequence analysis and alignments were done using Sequence Navigator, DNA Strider 
or ClustalX.
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2.2.2.10 Small and large scale preparation of plasmid DNA (Minipreps and 
Maxipreps)
High purity small scale or large scale plasmid DNA was prepared using the QIAprep 
Miniprep Kit or Endo-free Plasmid DNA maxi Kit (Qiagen), respectively following the 
manufacturer’s instructions. Bacteria containing the desired plasmid were grown in 1-5 
ml or 100-300 ml LB media containing the appropriate selection drug for minipreps or 
maxipreps, respectively. Plasmid concentration was measured (as described in 2.2.2.4).
2.2.3 Protein expression and purification
2.2.3.1 Expression of recombinant GST fusion proteins
Expression plasmids were transformed into E.Coli strain BL21 pLys and plated on LB- 
agar plates containing the required antibiotic, which were then incubated at 37 °C O/N. 
For protein expression, a single colony was grown in LB with ampicillin (100 pg/ml) 
overnight at 37 °C, shaking at 150 rpm. The next day, the culture was diluted 1:100 into 
fresh LB and grown at 37 °C until the O D ^  reached 0.6-0.8. Expression of the desired 
protein was induced by the addition of 0.2mM IPTG for Synaptotagmin fusion proteins 
or 1 mM IPTG for other GST fusion proteins. Expression was carried out at 19 °C 
overnight or 30 °C for 4h for Synaptotagmins or for other GST-fusion proteins, 
respectively. 1 ml aliquots of the culture were taken before and after induction, and 
centrifuged at 14,000 rpm for 2 min in a microfuge for analysis. The pellet was 
resuspended in 200 pi SDS-sample buffer, of which 20 pi was analysed by SDS-PAGE  
and visualised with Coomassie blue. The remaining bacteria were pelleted by 
centrifugation at 4000 rpm for 15 min at 4  °C in a JA10 rotor (Beckman centrifuge).
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2.2.3.2 Purification of GST fusion proteins
2.2.3.2.1 Purification of GST-fusion proteins on Glutathione beads and thrombin 
cleavage
Solutions: PBS; lysis buffer (0.1% Triton X-100 + lxcomplete protease inhibitor 
cocktail (Roche) in PBS); high salt wash buffer (500 mM KC1 in PBS); elution buffer 
(50 mM Tris-HCl, pH 8); 5 mM glutathione (Sigma); thrombin (Sigma).
The bacterial pellet was resuspended in lysis buffer (20 ml lysis buffer/1 litre culture 
volume). Lysozyme (1 mg/ml final concentration) was added and cells were lysed by 
sonication on ice for 5x 10 sec. Insoluble material was eliminated by centrifugation at
10,000 rpm in a Beckman JA20 rotor for 15 min at 4  °C. A column (Biorad) was 
packed with glutathione-sepharose 4B column (1ml glutathione-sepharose bed 
volume/500 ml culture volume) and equilibrated with 10 column volumes PBS and 3 
column volumes lysis buffer. The soluble material obtained after centrifugation o f the 
sonicated cells was applied onto the column by gravity flow. The column was then 
washed with 10 column volumes of high salt wash buffer followed by 5 column 
volumes of PBS. Proteins were then eluted with 10 volumes of elution buffer and 1 ml 
fractions were collected and analysed by SDS-PAGE. The protein concentration was 
measured, and the peak fractions were pooled. Glycerol was added to a final 
concentration of 10%. Finally, the purified proteins were stored at -  80 °C in small 
aliquots.
For cleavage of the protein from GST, thrombin was added to the fusion protein bound 
to glutathione sepharose beads. Because the concentration of the protein is not known at 
that time, for each ml of glutathione sepharose bed volume, 50 pi (lU /p l) o f thrombin 
protease in 950 pi PBS was added to the column with the bound protein and incubated 
for 2-4 h at RT. The cleaved protein was collected by gravity flow and analysed by
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SDS-PAGE. After the protein concentration was determined, the aliquoted protein was 
stored at -  80 °C in 10 % glycerol.
2.2.3.22 Purification of Synaptotagmin proteins by gel filtration and cation- 
exchange chromatography
Solutions: Gel filtration buffer (0.2 M Sodium Phosphate, pH 6.3, 0.3M NaCl); elution 
buffer A (20 mM MES, pH 6.3, 10 mM NaCl); elution buffer B (20 mM MES, pH 6.3, 
1M NaCl,); water; 20% ethanol. All buffers were filtered through a Millipore GP 
express membrane, 0.22 pm prior to use.
To eliminate bacterial contaminants (mainly negatively charged), which by binding 
basic regions of Syts copurify with the fusion proteins, a purification method developed 
by Ubach et al was used(Ubach et al., 2001). A Superdex 75 (Pharmacia) gel filtration 
column was connected to an FPLC system (Pharmacia) and pre-washed with water and 
equilibrated with 1 column volume of gel filtration buffer. The sample (5 ml maximum) 
was loaded using a superloop, and proteins were separated at a flow rate of 0.2 ml/min. 
The total column volume was collected in 1 ml fractions and those that contained 
protein, as measured by O D ^ , were analysed by SDS-PAGE and coomassie staining. 
Peak fractions containing the protein were pooled, dialysed in elution buffer A using 
Snakeskin dialysis membrane (1000 Da MW cut-off (Pierce)) and stored on ice for 
further purification.
Next, a cation exchange column (5 ml HiTrap SP, Pharmacia) was connected to the 
Pharmacia FPLC system, washed and equilibrated with at least 5 column volumes 
elution buffer A, 5 column volumes of elution buffer B and finally with 5 column 
volumes of elution buffer A. The pooled Peak fractions obtained from the previous 
purification on the gel filtration column were loaded using a superloop at 0.5 ml/min
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flow rate on the HiTrap SP column. The column was then washed with 5 column 
volumes of buffer A. Proteins were eluted using a linear gradient from 10 mM to 1 M 
NaCl in 20 column volumes. 1 ml fractions were collected and those containing protein 
according to O D ^  were analysed on SDS-PAGE followed by Coomassie staining. Peak 
fractions containing purified Syts were pooled and concentrated using Centricon plus- 
20 (Millipore), followed by a determination of the protein concentration. Finally, the 
purified protein was aliquoted and stored in 10% glycerol at -8 0  °C.
Proteins were dialysed in the appropriate buffer using Slide-A-Lyser cassettes or Slide- 
A-Lyser mini dialysis units (10,000 Da MW cut-off (Pierce)) before use.
This sequential purification procedure effectively removed all A260 absorbing nucleic 
acid contaminants as determined by measuring the A 28O/A 260 ratio.
2.2.4 Protein biochemistry
2.2.4.1 Determination of protein concentration using Bradford assay
The concentration of purified proteins or proteins in total cell lysates was determined 
using Bradford method. Serial dilutions of an IgG standard (Biorad) and protein 
samples were made up in 800 p,l water, mixed with 200 pi of Bio-Rad dye solution and 
incubated for 5-30 min at room temperature. A595 was measured using a 
spectrophotometer and the protein concentration was finally calculated from the IgG 
standard curve.
2.2.4.2 Precipitation of proteins
2.2.4.2.1 TCA precipitation
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Solutions: 100% Trichloroacetic acid (TCA) (w/v); PBS supplemented with 10 pg/ml 
haemoglobin; ethanol:diethyl-ether (1:1, v/v); unbuffered lx  SDS sample buffer (62.5 
mM Tris base (unbuffered), 3% SDS (w/v), 3.3% p-mercaptoethanol (v/v), 10% 
glycerol, 0.015% bromophenol blue (w/v)).
Protein-containing samples were diluted to 900 pi PBS (or 900 pi PBS + haemoglobin 
as carrier in samples with low protein concentration) and 100 pi TCA was added. 
Samples were mixed by vortexing and incubated on ice for 1 hour or overnight at 4 °C. 
The precipitated proteins were pelleted at 13,000 rpm for 30 min at 4°C in a 
microcentrifuge. The supernatants were carefully aspirated, washed with 200 pi 
ethanol:diethy 1-ether and centrifuged for 15 min as described above followed by the 
removal of the supernatant. The pellets were air-dried, resuspended in unbuffered SDS 
sample buffer and vortexed until completely dissolved. Occasionally, samples appeared 
yellow (acidic) after resuspension due to residual TCA. In these cases 3 pi of 
unbuffered 1M Tris base was added.
2.2.4.2.2 Acetone precipitation
Samples were diluted to 1 ml with PBS or PBS + haemoglobin and mixed with 4 ml 
acetone (-20 °C; 80% (v/v) final concentration) in 5.4 ml cryotubes. Proteins were 
precipitated overnight at 4  °C followed by centrifugation at 6000 rpm for 15 min, 4  °C 
in swing bucket centrifuge. Supernatants were aspirated and pellets were air-dried and 
resuspended in SDS sample buffer.
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2.2.4.3 SDS-PAGE electrophoresis
Solutions: 4x lower gel buffer (1.5 M Tris-HCl pH 8.8, 0.4% SDS (w/v)); 4x upper 
buffer (0.5 M Tris-HCl pH 6.8, 0.4% SDS); protogel (National diagnostics) Bis (30% 
acrylamide/0.8% bis-acrylamide (w/v)); TEMED; 10% (w/v) Ammonium persulphate 
(APS); running buffer (190 mM glycine, 25 mM Tris-HCl, 1% SDS (w/v) pH 8.8); lx  
SDS-sample buffer (62.5 mM Tris-HCl pH 6.8, 3.3% P-mercaptoethanol (v/v), 3% SDS 
(w/v), 10% glycerol (w/v), 0.015% bromophenol blue (w/v)); 5x SDS-sample buffer. 
SDS-PAGE was performed on 1.5 mm thick Bio-Rad minigels (Mini-Protean II 
electrophoresis cell) or 20x16 cm Bio-Rad gels (Protean II vertical electrophoresis cell). 
The tables below show the compositions of separating and stacking gels with different 
acrylamide percentages, depending on the size of proteins to be resolved. The volumes 
are sufficient for one mini gel.
Separating gel 7.5% 10% 12% 15%
4xlower buffer 2.25 ml 2.25 ml 2.25 ml 2.25 ml
A A/Bis 2.25 ml 3 ml 3.6 ml 4.5 ml
dH20 4.45 ml 3.7 ml 3.1 ml 2.2 ml
TEMED 4.5 pi 4.5 pi 4.5 pi 4.5 pi
10% APS 45 pi 45 pi 45 pi 45 pi
Stacking gel 4.5%
4x upper buffer 1 ml
AA/Bis 0.6 ml
dH20 2.35 ml
TEMED 4 pi
10% APS 45 pi
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Samples were resuspended in SDS-sample buffer, boiled for 5 min in a water bath, 
centrifuged for 1 min in the microcentrifuge at 14000rpm and finally loaded on the gel. 
Minigels were electrophoresed first at 90 volts for 15 min (stacking) then at 120 volts 
for 1 hr until the sample buffer dye front had reached the bottom of the resolving gel. 
Large gels were electrophoresed overnight at 10 mA per gel.
2.2.4.4 Coomassie blue staining of gels
Solutions: Gel staining buffer (50% methanol (v/v), 10% acetic acid (v/v), 1% 
Coomassie blue R-250 (w/v)); gel destain buffer (20% isopropanol (v/v), 10% acetic 
acid (v/v)).
After electrophoresis, gels were fixed for 10 min in staining buffer then destained until 
the background was completely removed. Gels were then placed between wet Whatman 
3MM paper and cling film and dried on BioRad vacuum dryer at 80 °C for 2-3 hrs. 
Alternatively, gels to be used for autoradiography were washed in water for 5 min after 
destaining, and then incubated for 30 min in 1M sodium salicylate, prior to drying. 
Finally the dried gels are exposed to Kodak XAR film at -7 0  °C for a minimum of 
overnight. Quantitation was performed by densitometry of the autoradiographs using 
Image J analysis software (NIH).
2.2.4.5 Western blotting
Solutions: Transfer buffer (20 mM Tris-HCl, 150 mM glycine, 20% methanol (v/v), pH
8.3); Ponceau S (Sigma) (2% (w/v)) in 3% TCA (w/v); blocking buffer (5% skimmed 
milk (w/v), 0.2% Triton-XlOO in PBS), wash buffer (0.2% Triton-XlOO in PBS).
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Transfer o f  proteins onto nitrocellulose membrane:
After electrophoresis, gels were removed from the glass plate and placed on top of 3 
sheets of wet Whatman 3MM paper, cut to size and layered over a fibre pad. A sheet of 
nitrocellulose membrane (0.2 pM pore size, Schleicher & Schuell), cut to the same size 
as the gel and soaked in water for 5 min, was placed on the top of the gel. This was 
covered with another two pieces of wet whatman 3MM paper and finally a fibre pad. 
Air bubbles were removed using a rubber roller. The cassette in which this gel sandwich 
was assembled was closed and placed, with the nitrocellulose membrane facing the 
anode, into a Bio-Rad Mini Trans-Blot transfer cell that contained an ice cooling unit 
and transfer buffer. The transfer cell unit was placed with a magnetic stirrer and the 
transfer was performed for 1 hr at 100 volts. After transfer, the membrane was stained 
in ponceau S for 2 min then destained in dH20 to check for efficient transfer.
Immunoblotting:
The nitrocellulose membrane was incubated in blocking buffer for 1 hr at room 
temperature or overnight at 4  °C with gentle shaking. The nitrocellulose membrane was 
then incubated in the primary ab diluted in blocking buffer for 1-2 hrs at RT or O/N at 4  
°C. After four washes for 5 min each in blocking buffer, the membrane was incubated 
with the HRP-conjugated secondary ab diluted in blocking buffer for 1 hr at RT. The 
membrane was then washed four times, 5 min each in wash buffer and HRP activity 
was detected by incubating the membrane in ECL-reagent (Amersham) for 1 min. 
Finally, the membrane was exposed to Kodak XAR film for various amounts of time. 
Quantification of the signal was done using Image J anlysis software (NIH).
To reprobe the same membrane, the abs were removed by incubating for 15 min at 50 
°C in stripping buffer (Pierce). The membrane was washed for 15 min in wash buffer,
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incubated in blocking buffer before adding the new antibody. Membranes were stored at 
-2 0  °C.
2.2.4.6 Immunoprecipitation
Direct coupling o f  the monoclonal anti-HA ab to beads bv cross-linking:
Solutions: Protein G-sepharose; 0.2 M sodium borate (pH 9); dimethyl-pimelimidate 
(DMPD) (20mM final concentration, Sigma), 0.2 M Ethanolamine (pH 8); PBS.
Mouse anti-HA ab was cross-linked to beads as follows: a 1:1 mix of protein G- 
sepharose (50% slurry, prewashed in PBS) and ab was incubated at RT for 1 h with 
gentle rocking. Beads were then pelleted at 3000g, 5 min and washed twice with sodium 
borate, pH 9. The cross-linker, DMPD was added to a final concentration of 20 mM and 
the mixture was incubated for 30 min at room temperature. Beads were then pelleted as 
above and the reaction was quenched with Ethanolamine, pH 8 for 2 h. Beads were 
washed twice in PBS and finally stored in PBS+ 0.01% sodium azide.
Before use, beads were washed twice in immunoprecipitation buffer.
Immunoprecipitation
Solutions: TNTE buffer (20mM Tris-HCl pH 7.5, 150 mM NaCl, 0.3% Triton X-100, 5 
mM EDTA); 50% slurry protein G-sepharose (v/v) in TNTE; anti-HA ab cross-linked to 
protein G-sepharose in TNTE (see above); lOOOx CLAPP protease inhibitor cocktail 
stock (chymostatin 50mg/ml, leupeptin 0.5 mg/ml, antipain 50 mg/ml, pepstatin A 
0.5mg/ml, Pefabloc 0.1 mg/ml); Pefabloc 500x stock (250 mg/ml in water); 10 mM 
Tris-HCl pH 7.5); 5x SDS-sample buffer (see 2.2.4.3).
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Cells were scraped in PBS with lxCLAPP and Pefabloc and washed twice in the same 
buffer by centrifugation at 1000 rpm for 5 min. Cells were then lysed at 4°C for 15 min 
in TNTE buffer. To remove nuclei and insoluble material, cells were spun for 10 min at 
maximum speed in a microfuge at 4  °C and the supernatant carefully transferred to a 
fresh Eppendorf tube. The supernatant was split equally between the different 
immunoprecipitation conditions and incubated with the ab for 2 h or overnight at 4°C 
rotating. For abs other than HA, 60 pi of 50% slurry protein G-sepharose in the 
appropriate buffer was added and incubated for a further 1-2 h. Alternatively, anti-HA 
antibody cross-linked to protein G-sepharose (see above) was added directly to the cell 
lysates and incubated for 1-2 h or overnight at 4°C. The immunoprecipitation reactions 
were spun at 1000 rpm for 1 min at 4°C in an Eppendorf centrifuge. The supernatants 
were removed and pellets washed four times with 1 ml in TNTE buffer and once in 1 ml 
Tris-HCl pH 7.5. For each wash, the mixture-containing tubes were inverted, spun at 
1000 rpm for 50 sec in a microfuge and supernatants carefully aspirated with a Pasteur 
pipette with a reduced opening. Bound proteins were eluted from the beads by adding 
10 pi of 5x SDS-sample buffer, vortexed and boiled for 5 min. The bottom of the 
Eppendorf tube was pierced with a 27 g needle, the tube placed in a fresh Eppendorf 
and spun briefly in order to separate eluate from beads. The samples were finally 
subjected to SDS-PAGE and western blotting analysis.
2.2.4.7 GST-pull down assay
Solutions: Binding buffer (25mM Hepes-KOH pH 7.2, 25 mM KC1, 2.5 mM MgOAc, 
0.5% Triton X-100; CLAPP (lOOOx stock); Pefabloc (500x stock); 50% slurry (v/v) 
glutathione sepharose 4B in binding buffer.
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For GST pull down experiments, transfected HEK cells (or a postnuclear supernatant 
from PC12 cells, prepared as described in 2.2.6.1) were lysed in binding buffer for 15 
min at 4°C and spun at 14000 rpm for 10 min to remove insoluble material. 
Alternatively, bovine adrenal medulla cytosol (BAMC) (prepared as described in
2.2.6.3) was diluted in binding buffer and used for GST-pull down.
To separate membranes from cytosol, a PC12-PNS was centrifuged at 45000 rpm (1 hr 
at 4°C) in a TLA 45 rotor. The pellet (membrane fraction) was lysed in binding buffer 
as described above and the cytosol was transferred into a fresh tube and diluted in 
binding buffer. The cytosol or membranes were used separately in a GST-pull down 
experiment.
GST-fusion proteins (35 pg) were incubated with 100 pi glutathione sepharose bead 
and prewashed in binding buffer for lh at 4°C on a rotating wheel in siliconised 
safelock Eppendorf tubes. Samples were spun for 1 min at 1000 rpm (4°C) in a 
microfuge and washed once with binding buffer. The beads were resuspended in HEK 
cell lysates, PC12 PNS, BAMC, membranes or cytosolic fractions from PC12 PNS 
(2mg total protein in each condition) and incubated O/N at 4°C on a wheel. Beads were 
pelleted by centrifugation at 1000 rpm for 1 min in a microfuge and supernatants were 
removed by aspiration. Beads were washed four times in 1 ml binding buffer and bound 
proteins were eluted by adding 10 pi 5x SDS-sample buffer. After boiling for 5 min, 
tubes were pierced with a 27 g needle, placed into a second tube and the eluate was 
collected by brief centrifugation. Samples were subjected to an SDS-PAGE analysis 
followed by western blotting.
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2.2.5 [35S]-sulphate-Iabelling of PC 12 cells
2.2.5.1 Pulse chase [35S]-sulphate-labelling of PC 12 cells
Solutions: Sulphate-free E4 + 4mM glutamine, 0.1% dialysed horse serum and 0.05% 
dialysed foetal calf serum (both dialysed in PBS); complete E4 + 1.6 mM Na2S 0 4; Tris- 
buffered saline (TBS) (5.4 mM KC1, 137 mM NaCl, 0.7 mM Na2H P04, 1.6 mM 
Na2S 0 4, 25 mM Tris-HCl pH 7.4); TBS + PI (TBS, 0.5 mM PMSF, 0.5 mg/ml 
leupeptin).
In PC 12 cells the major sulphated proteins are secretogranin I (Sgl) (also called 
Chromogranin B (CgB)), secretogranin II (Sgll), which are both targeted to secretory 
granules (Rosa et al., 1985), and a heparin sulphate proteoglycan (hsPG), targeted to 
constitutive secretory granules (Tooze and Huttner, 1990). Therefore, we took 
advantage of these markers to follow [35S]-sulphate-labelled Sgll specifically in 
immature secretory granules (ISGs) or mature secretory granules (MSGs), which were 
separated later by subcellular fractionation techniques on sucrose gradients.
To detect ISGs using [35S]-sulphate-labelled Sgll, labelling of PC12 cells was 
performed as follows: a 15 cm dish containing 80% confluent PC 12 cells was incubated 
in sulphate-free E4 for 20 min in a 37 °C, 10% C 0 2 incubator in order to deplete cells of 
endogenous sulphate. The medium was then replaced with 5 ml of sulphate-free 
medium to which lmCi/ml [35S]-sulphate was added and cells incubated for 5 min on a 
rocker in the incubator. In the TGN, modifications such as sulphation of tyrosine 
residues (Baeuerle and Huttner, 1987) and carbohydrates (Kimura et al., 1984) occur. 
The medium was then removed and replaced with complete E4 + 1.6 mM Na2S 0 4 and 
the cells were incubated for a further 15 min to chase the labelled Sgll into ISGs. The 
chase reaction was stopped by placing the dish on ice followed by washing twice with
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ice-cold TBS. Cells were then harvested by scraping in 10 ml TBS + PI and centrifuged 
for 7 min at 800 rpm (4 °C) in a Heraeus centrifuge and further processed to obtain a 
postnuclear supernatant (see 2.2.6.1).
To detect MSGs, endogenous sulphate was depleted as described above and PC 12 cells 
were grown in a 15 cm dish and incubated in 10 ml sulphate-free E4 supplemented with 
0.2 mCi/ml [35S]-sulphate for 6h or overnight without rocking. The medium was later 
replaced with complete E4 + 1.6 mM Na2S 0 4and cells were further incubated for 1 h to 
chase Sgll specifically to MSGs. To stop the chase reaction, the procedure was followed 
exactly as described above.
2.2.5.2 [35S]-sulphate-labelling of PC 12 cells for cell-free ISG-ISG fusion 
assay
3x 500 cm3 dishes containing PC 12 cells were incubated in trypsin for 5 min and the 
detached cells were collected into a 50 ml tube and centrifuged at 800 rpm (Heraeus 
megafuge) for 7 min at 4  °C. The pellet was washed once in sulphate-free E4 by 
centrifugation as described above, resuspended in 10 ml sulphate-free E4 and incubated 
for 20 min in a 37 °C, 10% C 0 2 incubator on a rocker to deplete cells of sulphate. Pellet 
was obtained by centrifugation at the same speed and rotor as described above, 
resuspended in 10 ml sulphate-free E4 supplemented with [35S]-sulphate (lm Ci/m l) and 
labelled for 30 min in a 37 °C, 10% COz incubator on a rocker. Labelled cells were 
pelleted by centrifugation and PNS was prepared as described next (2.2.6.1).
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2.2.6 Subcellular fractionation techniques
2.2.6.1 Preparation of a postnuclear supernatant from PC 12 cells
Solutions: Trypsin; TBS; TBS + PI; homogenisation buffer (HB) (10 mM Hepes-KOH, 
pH 7.2, 250 mM sucrose, 1 mM MgOAc, 1 mM EDTA, 5Dg/ml leupeptin, 0.5 mM 
PMSF); trypan blue solution (Sigma).
PC12 cells were washed twice in TBS, scraped into TBS + PI and pelleted by 
centrifugation at 800 rpm for 7 min in a Heraeus centrifuge. Alternatively, pre-warmed 
trypsin was added to the cells to detach them from the plates. 5 min later, the cells were 
collected with a pipette into a Falcon tube, centrifuged as described earlier and the pellet 
washed in TBS+ PI and re-centrifuged. The cells were resuspended in HB and 
centrifuged at 1800 rpm for 7 min at 4  °C in a Heraeus centrifuge. To make a single cell 
suspension, the pellet was resuspended in 1 ml HB and passed 7 times through a 21 g 
needle. 5 pi of the suspension was mixed with 5 pi of trypan blue solution and analysed 
using a phase contrast microscope. Typically, 90% were single cells and more than 80% 
were not broken indicated by exclusion of trypan blue. The single cell suspension was 
then passed 3-5 times through an ice-cold cell cracker in order to break the cells, which 
was verified with trypan blue as described above. The breakage was considered optimal 
when the suspension contained less than 2% of unbroken cells and a minimum of 
broken nuclei. The cell homogenate was centrifuged at 3200 rpm for 7 min in a Heraeus 
centrifuge to pellet the nuclei and unbroken cells. The supernatant (PNS) was removed 
carefully and transferred to a new tube.
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2.2.6.2 Preparation of ISGs and MSGs
2.2.6.2.1 Continuous velocity gradient
This method, developed by S.A Tooze (Tooze et al., 1991), obtains fractions enriched in 
immature secretory granules (ISGs) or mature secretory granules (MSGs).
First, a linear sucrose gradient ranging from a 0.3 M (5.5 ml) and 1.2 M (6 ml) was 
prepared in a SW40 ultraclear tube (Beckman), placed on a gradient maker (Biocomp), 
and mixed for 10 min at a 50° angle at 36 rpm, and then 1 min at 80° at 12 rpm. 1.5 ml 
of the PC12 PNS obtained as described in 1.2.6.1 was then loaded on top of the gradient 
and centrifugation was carried out for 15 min (time after reaching the set speed) at
25,000 rpm (4 °C) in a SW40 swing-out rotor. 1 ml fractions were collected from top to 
bottom using the auto densi-flow gradient collector (Labconco). Fractions 1-4 were 
enriched in ISGs and constitutive secretory vesicles (CSVs), fractions 5-7 were enriched 
in MSGs whereas fractions 9-11 at the bottom of the gradient contained TGN 
membranes. For analysis of the gradients using autoradiography or western blotting, 
300 pi of each fraction was diluted to 1 ml with PBS + haemoglobin and TCA or 
acetone precipitated as described in (1.2.4.2). For further purification of vesicles, the 
separation was carried out as described in the next section.
2.2.6.2.2 Discontinuous equilibrium gradient
Pooled fractions 1-4 or 5-7 from the velocity gradient were loaded onto a discontinuous 
equilibrium sucrose gradient (top: 0.8 M (1 ml), 1 M (2 ml), 1.2 M (2 ml), 1.4 M (2 ml),
1.6 M (1 ml) bottom) sucrose prepared in ultraclear tubes (Beckman) ISGs or MSGs. If 
necessary, the volume of the pooled fractions was diluted to 4  mis with HB before 
loading onto the equilibrium sucrose gradients. The gradients were centrifuged at
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25,000 rpm in a Beckman SW40 rotor overnight at 4  °C. 1 ml fractions were collected 
from top to bottom using the auto densi-flow gradient collector. Fractions 7-9 from the 
equilibrium gradient, that has been loaded with fractions 1-4 from the velocity gradient, 
contain ISGs and fractions 9-11 from the equilibrium gradient, that has been loaded 
with fractions 5-7 from the velocity gradient, contain MSGs.
For autoradiography or western blotting analysis 1 ml fractions were precipitated (as 
described in 2.2.4.2).
For cell-free assays, ISG-containing fractions 7-9 were pooled, distributed in 1 ml 
aliquots in cryovials and stored in liquid nitrogen for up to 6 months.
2.2.6.3 Preparation of bovine adrenal medulla cytosol (BAMC)
Bovine adrenal medulla cytosol (BAMC) was prepared by S.Tooze as described in 
(Austin et al., 2000). Briefly, BAM was dissected from cortical tissue, roughly chopped 
and homogenised in homogenisation buffer (HB, described in 2.2.6.1) in a Waring 
blender. The lysate was further homogenised with five strokes in a motor-driven 
glass/teflon Dounce homogeniser. The homogenate was centrifuged in aTi70.1 rotor for 
30 min at 30,000g at 4  °C. The supernatant was collected and centrifuged for 90 min at 
100,000g at 4  °C in the Ti70.1 rotor. The supernatant was collected and dialysed against 
binding buffer (described in 2.2.4.7) + 10% sucrose, using Snakeskin dialysis tubing 
(Pierce) with a molecular weight cut off of 3.5 kDa. Typically BAMC concentrations 
were about 20-30 mg/ml.
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2.2.7 Cell-free assays
2.2.7.1 In vitro ISG homotypic fusion assay
Solutions: [35S]-sulphate-labelled PC12-PNS (see 2.2.6.1); purified ISGs from 
PC12/PC2 cells (see 2.2.6.2); lOx fusion buffer (lOx FB) (200 mM Hepes-KOH, pH 
7.2, 500 mM KOAc, 30 mM MgCl2, 10 mM DTT (lOOOx stock stored in -2 0  °C)); 10 
mM Hepes-KOH pH 7.2; MES buffer (50 mM MES pH 5.5, 0.3 M sucrose); ATP- 
regenerating system (Boehringer) (100 mM ATP, pH 7 with NaOH, 800 mM creatine 
phosphate, 3200 U/ml creatine phosphokinase), which were mixed at equal volumes 
(30x stock solution) then used immediately; HB (see 1.2.6.1); 5x lysis buffer (500 mM 
Tris-HCl pH 7.5, 750 mM NaCl, 1.5 % Triton X-100, 25 mM EDTA); Protein G- 
sepharose (50% slurry in lysis buffer (v/v)).
Aliquots of PC2/PC12 cell ISGs were thawed for 2 min at 37 °C, diluted with 2 
volumes of 10 mM Hepes-KOH pH 7.2 and pelleted by centrifugation at 29,000 rpm in 
a SW55 Beckman rotor for 1 h 5 min at 4  °C. The pellets were resuspended in HB at 50 
fold the concentration of the original ISG pool. Each fusion reaction contained: 100 pi 
of [35S]-sulphate-labelled PC12 PNS (containing the substrate, Sgll), 500 pi PC12/PC2 
cell purified ISGs (containing the enzyme, PC2; centrifuged and resuspended in 10 pi) 
lOxFB (final concentration of 20 mM Hepes-KOH pH 7.2, 50 mM KOAc, 3 mM 
MgCl2, 1 mM DTT) and ATP-regenerating system (30-fold dilution) all in a final 
volume of 120 pi to 180 pi. At this point, purified proteins or antibodies were added to 
the fusion reaction to test their effect on ISG-ISG fusion. After vortexing, the reactions 
were incubated at 37 °C for 30 min to allow fusion to occur and then transferred on to 
ice. Samples were diluted with MES buffer, pH 5.5 to a final volume o f 800 pi, 
incubated for a further 30 min on ice to equilibrate the pH (in the ISGs) 5.5 and then
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transferred to 37 °C for 90 min to allow processing of Sgll by PC2 to occur. Reactions 
were then placed on ice and 200 pi of 5x lysis buffer was added to each sample before 
shaking for 10 min at RT. The lysed samples were precleared by centrifugation at
14,000 rpm in a microfuge for 10 min at 4  °C. Supernatants were transferred to new 
tubes to which 90 pi of protein G-sepharose (50 % slurry v/v) and 60 ug of 6p-l 
antibody (recognises the Sgll processing product of 18 kDa (p i8)) was added, and 
immunoprecipitation of p i8 was performed O/N at 4  °C on a rotating wheel. Beads 
were then pelleted by centrifugation for 1 min at 3000 rpm in an Eppendorf centrifuge 
and supernatants removed by aspiration. After 4 washes with lx  lysis buffer followed 
by a final wash in 10 mM Tris-HCl pH 7.5, beads were resuspended in 10 pi 5x sample 
buffer, vortexed and boiled for 5 min. Tubes were pierced with a 27g needle, placed in a 
second Eppendorf tube and the eluates were collected by brief centrifugation in a 
microfuge. Immunoprecipitates were loaded on a 12% SDS-PAGE gel. Gels were 
Coomassie stained, dried (see 2.2.4.4) and exposed to a Kodak X-AR film at -7 0  °C. 
Quantification of p i8 signal was done by densitometry using ImageJ analysis software 
(NIH). The PC2-independent signal (background signal) was subtracted from the signal 
obtained in the presence of PC12/PC2 ISGs.
2.2.8 Sgll processing in PC12/PC2 cells
PC12/PC2 cells grown in 8x32 mm dishes were pulse-labelled with [35S]-sulphate for 5 
min (see 2.2.5.1) and either chased for 0 min, 10 min, 20 min, 30 min, 45 min, 60 min, 
90 min or 180 min. The chase reaction was stopped on ice, washed in TBS + PI, the 
cells lysed in 1 ml TNTE buffer. To make heat-stable fractions, lysed cells were 
collected from the dish into an Eppendorf tube, boiled for 5 min and centrifuged at
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maximum speed in a microfuge for 5 min. After the lysed cells are boiled, the granins 
are in the soluble fraction and are heat stable. After brief centrifugation, the insoluble 
material is pelleted and the soluble fraction (supernatant) is collected. The soluble 
fraction will be enriched in granins and devoid of all the insoluble material that 
aggregated by boiling. The supernatants were transferred into a fresh tube and the heat- 
stable proteins were acetone-precipitated (see 2.2.4.2), resuspended in SDS-sample 
buffer and analysed by 12% SDS-PAGE gel followed by autoradiography.
2.2.9 In vitro ISG binding assay
Solutions: Purified ISGs (see 2.2.6.2); lOx and lx  FB (see 2.2.7.1); ATP-regenerating 
system (Boehringer); HB; lxSDS-sample buffer; trypsin (Sigma); trypsin inhibitor (1 
mg/ml, Sigma).
The method to detect the recruitment of exogenous proteins to ISGs was developed by 
Andrea Dittie (Dittie et al., 1996). Purified proteins or abs were added to 50 pi ISGs 
with fusion buffer and ATP-regenerating system in a final volume of 250 pi. Samples 
were mixed and incubated at 37 °C for 30 min. The samples were then diluted with 
fusion buffer to a total volume of 1 ml and centrifuged at 33,000 rpm in a Ti 50.2 rotor 
for lh at 4  °C. The supernatant was removed and the pellets were resuspended in 25 pi 
lx  SDS-sample buffer. Proteins-bound to ISGs were detected by immunoblotting 
followed by quantification using ImageJ analysis software (NIH).
In some cases, ISGs were pre-treated with various amounts of trypsin (Sigma) and/ or 
1 mg/ml soy bean trypsin inhibitor (STI) (Sigma) for 10 min at 37 °C and returned to 
ice. The amount of protein bound to ISGs membranes was detected as described above.
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2.2.10 Cell biology techniques
2.2.10.1 Transient transfection of mammalian cell
Cells were plated onto 6-well dishes or 10 cm dishes one day prior to transfection. 
Transfection was carried out using Lipofectamine 2000 according to the supplier’s 
instructions (Invitrogen). Briefly, plasmid DNA was mixed with Lipofectamine 2000 in 
serum and antibiotics-free medium (Optimem, Gibco BRL), and incubated for 20 min at 
RT before adding the mixture onto the cells. 5 h after transfection, the medium was 
exchanged for full growth medium. Cells were processed for indirect 
immunofluorescence or lysed 24h post transfection.
2.2.10.2 Synaptotagmin IV siRNA in PC12 cells
PC12 cells were split a day before transfection 1:3 to obtain 80% confluency in 6-well 
dishes or 10 cm plates. For transfection, Syt IV siRNA Smart pool (50 nM final 
concentration) (Dharmacon) (sequence described in 2.2.4) was mixed with Dharmafect 
2 transfection reagent (Dharmacon) in serum and antibiotics-free medium (Optimem), 
and incubated for 20 min at room temperature. The transfection mix was diluted with 
antibiotics-free medium (supplemented with 10% horse serum and 5% FCS) before 
being added onto PC12 cells. The medium was exchanged for full growth medium after 
24 h transfection. Three days post transfection, the cells were processed for indirect 
immunofluorescence or lysed for western blotting.
Chapter 2_____________________________________________________________ 88
To assess Sgll processing in Syt IV-siRNA-treated cells, 2 x 10 cm dishes o f PC12/PC2 
cells were transfected with Syt IV-siRNA as describe above. 48h post-transfection, cells 
were trypsinised, pooled and replated onto 8x35 mm dishes. Finally, Sgll processing 
reaction was assayed (as described in 2.2.8).
To confirm that sorting and budding from the TGN was not disrupted, 2x10 cm dishes 
of PC12 cells were treated with Syt IV-siRNA. 72 h post-transfection cells were pulse- 
chased with [35S]-sulphate (see 2.2.5.1) and PNS prepared from these cells (see 2.2.6.1) 
was subjected to velocity and equilibrium sucrose gradient separation (described in 
2.2 .6).
2.2.10.3 Adenovirus infection of PC 12 cells
PC 12 cells were infected with adenoviruses expressing HA-Syt IV cytoplasmic domain 
(obtained from Viraquest) at 500 pfu/cell. Infection was performed by incubating the 
adenoviruses with PC12 cells overnight in a 37 °C in a 10% C 0 2 incubator in full 
growth medium. Next day, cells were washed twice with medium and processed either 
for indirect immunofluorescence or electron microscopy.
To check for the presence of acidic compartements in cells infected with HA-Syt IV 
cytoplasmic domain, infected or non-infected cells were incubated with 30 pM of the 
acidic granule marker DAMP (Oxford Biomedical Research) for 30 min in the 37 °C 
incubator. Following a wash with PBS, cells were processed for immuno-EM with 
monoclonal anti-DNP (1:10) and polyclonal anti-HA abs (1:100) followed by gold 
conjugated anti-mouse and anti-rabbit secondary abs.
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2.2.10.4 Indirect immunofluorescence
Solutions: Poly-D lysine (Sigma) (1 mg/ml in dH20); 3% paraformaldehyde (PFA) 
(methanol-free, TAAB, 16% stock diluted in PBS, stored at -  20 °C); PBS; 50 mM 
NH4C1; permeabilisation solution (0.2 % Triton X-100 in PBS); blocking solution (0.2% 
gelatin in PBS); Moviol prepared as follows: (2.4 g Moviol 4-88 (Calbiochem) were 
mixed with 6g glycerol and 6 ml o f dHzO for 2h at RT. 12 ml o f 200 mM Tris-HCl pH 
8.5 was added and the mixture incubated at 53 °C with occasional vortexing until the 
Moviol was dissolved. The solution was clarified by spinning at 5000g for 15 min in a 
Heraeus centrifuge, aliquoted and stored at -  20 °C).
Glass coverslips were coated with poly-D-lysine for 10 min at RT and washed twice 
with dH20 . Cells were then plated onto the coated coverslips in 35 mm dishes and left 
to grow O/N. The next day, cells were washed twice with PBS and fixed with 3% PFA 
for 20 min followed by quenching of the fixative with 50 mM NH4C1 in PBS for 10 min 
at RT. After washing twice with PBS, cells were permeabilised for 3-5 min with 0.2% 
Triton X-100 in PBS followed by washing twice with PBS, then twice again with 
blocking solution in which cells were incubated for 30 min. The cells were incubated in 
the primary ab, diluted in blocking solution, for 30 min. Excess antibody was washed 
away with the blocking solution and cells were incubated again with the secondary ab, 
diluted as above, for the same duration. Cells were washed twice with blocking solution 
then twice again with PBS. Finally cover slips were washed in dH20  and mounted in 
Moviol on glass slides. Images were acquired by confocal microscopy (Zeiss plan- 
Apochromat 63x/1.40 NA oil objective lense) using LSM 510 software and processed 
with Photoshop 7.0.
Alternatively, cells were fixed and permeabilised in cold methanol for 10 min at -2 0  C°, 
washed twice with PBS then incubated for 30 min in blocking solution. Cells were
Chapter 2_____________________________________________________________ 90
incubated with the primary, then secondary antibodies and processed as described 
above.
2.2.10.5 FACS-sorting of PC12 cells
Transfected PC 12 cells were trypsinised, collected in a Falcon tube and centrifuged for 
5 min at 1000 rpm in Heraeus centrifuge. Cells were washed twice in PBS, transferred 
to an Eppendorf tube, fixed and stained as described previously with slight 
modifications. The whole procedure was performed in an Eppendorf tube and washings 
were done by centrifugation at 1000 rpm for 3 min in a microfuge. The ab dilutions 
were lOx more concentrated than the dilutions used for indirect immunofluorescence. 
At the end of the procedure, the labelled cells were resuspended in PBS and sorting was 
performed using the Mo-flo cell sorter (DAKO-cytomation) by the staff of the FACS 
core laboratory (Cancer Research UK). Sorted cells were pelleted by centrifugation at 
1000 rpm for 5 min in a Heraeus centrifuge and the pellet was resuspended in lx  SDS- 
sample buffer. Samples were loaded on SDS-PAGE gel followed by western blotting 
analysis.
2.2.10.6 Immunogold-labelling for electron microscopy
Cryo-fixation of cells, specimen preparation and immunogold labelling were performed 
by Rose Watson in the electron microscopy unit at CR-UK according to standard 
techniques. Briefly, cells were incubated in DAMP (described in 2.2.10.3) before being 
processed for immunogold labelling. For immuno-labelling, pelleted cells were fixed in 
2% paraformaldehyde/0.2% glutaraldehyde in Sorensens buffer for 2h at RT. After 
washing, cells were resuspended in 10% gelatine, pelleted and stored in 2.3% sucrose to 
cryprotect the specimen. After 3h, the specimen was rapidly frozen in liquid nitrogen
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followed by the cutting of ultrathin sections. Sections were transferred to a 
carbon/formvar-coated grids and stored on 2% gelatine at 4  °C.
Prior to labelling, the gelatine on which the grids were placed was heated for 20 min at 
37 °C. Samples were then incubated in 0.1% glycine for 3 min followed by 0.1% BSA 
for 2 min and primary abs diluted in 1% BSA for 30 min. After washing, samples were 
incubated with protein A gold (5 and 10 mm) diluted 1:50 in 1% BSA. Samples were 
then washed and post-fixed in 1% glutaraldehyde for 5 min. Negative staining of the 
sample was done with saturated 2% uranyl acetate for 5 min, followed by washing in 
water and incubation in 4% methyl cellulose, 0.4% uranyl acetate at 4  °C for 5 min. 
Finally, sections were embedded in 4% methyl cellulose, 0.4% uranyl acetate and 
examined. Pictures were taken with JEOL 1010 electron microscope (Japanese Electron 
Optical Limited).
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3 Chapter 3: Synaptotagmin IV is localised on the immature 
secretory granules and absent from the mature secretory 
granules in PC 12 cells
3.1 Aim
In this chapter, I will present a study aimed at investigating the localisation o f Syt 
IV in the neuroendocrine cell line PC 12. The localisation o f Syt IV on ISGs, and 
whether or not it is present on MSGs, is still controversial. It was demonstrated that Syt 
IV is localised on MSGs in PC12 cells (Ferguson et al., 1999) (Thomas et al., 1999). 
Later, other studies showed that Syt IV is localised on ISGs and absent from MSGs in 
the neuroendocrine cell line ATt-20 (Eaton et al., 2000). However, both studies did not 
examine endogenous Syt IV. A different study looking at the localisation of endogenous 
Syt IV in PC 12 cells using electron microscopy revealed that this isoform is on ISGs 
and not on MSGs (Fukuda et al., 2003). To confirm these last results, I undertook 
subcellular fractionation on sucrose gradients, combined with the use of a specific anti- 
Syt IV ab. This method allows for the efficient separation of ISGs from MSGs, and 
therefore a potentially more accurate means of determining the localisation o f the 
endogenous Syt IV.
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3.2 Generation o f antibodies against Synaptotagmin IV
In order to study the localisation of Syt IV in PC 12 cells, I generated polyclonal 
abs against Syt IV. The peptide sequence, KAGSSSDLENVT, corresponding to the 
amino acids 112 to 121 in the spacer domain of rat Syt IV, was synthesised by the 
peptide synthesis laboratory, Cancer Research UK. The different isoforms of the Syt 
family show a high degree of homology, especially within their C2 domains. However, 
the spacer domain, where the peptide sequence was chosen, is less conserved among 
members of this family of protein (Figure 3.2.1). This was done to minimise the risk of 
cross-reactivity of the generated anti-Syt IV ab with other isoforms o f the same family. 
The peptide was crosslinked to limulus polyphemus haemocyanin (LPH) and injected 
into two guinea pigs (MS3 and MS4) by Biogenes (Germany), according to standard 
procedure. Guinea pig serum MS3 had no detectable titre in an ELISA assay performed 
by Biogenes, nor did it show any specific signal by indirect immunofluorescence (data 
not shown). This anti-serum was thus not reactive with Syt IV. The anti-serum MS4 
was tested by western blotting of cell lysates from PC 12 cells or HEK cells 
overexpressing the full-length rat T7-Syt IV (Figure 3.2.2). A specific anti-Syt IV ab, 
provided by Dr Mitsunori Fukuda (Riken Institute, Japan) that recognises both native 
and overexpressed forms of Syt IV was used as positive control (Ibata et al., 2000).
Syt IV
Syt XI 
Sytll 
Syt I 
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Syt IX 
Syt VIII 
Syt VII 
Syt VI 
Syt X 
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Figure 32.1: Anti-Syt IV antibody (MS4) peptide sequence alignment.
A) A schematic representation of Syt IV domain organisation. N is the lumenal N-terminal domain, TM is the transmembrane domain and 
C is the C-terminal end of the cytoplasmic domain of Syt IV. The red line represents where the MS4 antibody sequence is within the 
spacer domain . B) The alignement of the MS4 sequence region within the spacer domain of rat Syt IV with rat Syt I-XIII (red box) using 
ClustalX alignment software.
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Figure 3.2.2: MS4 antibody Screening by western blotting.
Serum (MS4) against Syt IV from guinea pigs was screened by western 
blotting of cell lysates from untransfected HEK cells (Untr) (10 pg), HEK 
cells overexpressing T7-Syt IV (10 pg) and PC 12 cells (50 pg). As posi­
tive control, a specific anti-Syt IV ab was used (left hand panel). MS4 
recognised the overexpressed T7-Syt IV (*) but did not react with the 
endogenous Syt IV in PC 12 cells recognised by the specific anti-Syt IV ab 
(closed arrow).
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In HEK cells, where there is no expression of the endogenous Syt IV, both the MS4 and 
the control anti-Syt IV ab recognised a ~50 KDa band corresponding to the 
overexpressed T7-Syt IV. This band was not present in untransfected HEK cell lysates. 
However, in contrast to the control anti-Syt IV antibody, MS4 did not react with the 
endogenous Syt IV in PC 12 cell lysates. The band was not seen even after longer 
exposure of the blot (data not shown). Other bands were observed, suggesting that this 
ab cross-reacts with other proteins in the cell lysates tested. The MS4 is therefore able 
to detect the overexpressed, but not the endogenous Syt IV by western blotting.
Next, the MS4 antiserum was tested using indirect immunofluorescence. When PC 12 
cells were fixed using PFA, the MS4 antiserum did not give any specific staining, and 
the staining was similar to that obtained with the preimmune (PI) serum (Figure 3.2.3 
A). However, when methanol fixation was used, the MS4 displayed a perinuclear 
staining characteristic o f Syt IV distribution (Ibata et al., 2000) (Figure 3.2.3 B). The 
MS4 staining colocalised with the Golgi marker GM130 and with Stx6 in the 
perinuclear area (Figure 3.2.4 A,B). Most importantly, the MS4 staining colocalised 
with the specific anti-Syt IV ab provided by Dr M.Fukuda (Figure 3.2.4 C). However, 
this colocalisation was mostly in the perinuclear area. The granular structures 
recognised by the specific anti-Syt IV ab in the periphery of the cells were not 
colabelled with the MS4. To investigate further whether the MS4 staining was specific, 
PC 12 cells overexpressing T7-Syt IV were fixed and labelled with mouse anti-T7 ab 
and MS4, or with the specific anti-Syt IV ab and MS4. Surprisingly, the MS4 antiserum 
did not display the same staining as the anti-T7 (Figure 3.2.5 A) or the control anti-Syt 
IV antibodies (Figure 3.2.5 B), but rather had the same perinuclear staining as seen in 
untransfected PC12 cells.
A) PFA fixation B) Methanol Fixation
Figure 3 2 3 :  MS4 antibody screening by indirect immunofluorescence in 
PC12 cells. PC12 cells were fixed with A) 3% PFA or B) 100% cold methanol 
then labelled with A 3 ) MS4 pre-immune (PI) or MS4 bleed-out (BO) at 1:100 
dilution. The MS4 was detected with anti-guinea pig-Cy3. Images were acquired 
with a confocal microscope using LSM 510 software, Zeiss plan-Apochromat 
63*/l .40 oil objective lense.
A)
B)
C)
Figure 3 2 4 : MS4 serum partially colocalises with Golgi markers by indirect 
immunofluorescence. PC 12 cells were fixed with methanol and labelled with A) 
MS4 and GM130, B) MS4 and Stx6, C) MS4 and anti-Syt IV ab (provided by 
M Fukuda). MS4 was detected with anti-guinea pig -Cy3, monoclonal anti GM130 
and anti-Stx 6 ab with anti-mouse Alexa-488 and finally polyclonal anti-Syt IV 
was detected with anti-rabbit Alexa-488. Images were taken as described above.
B)
K 1
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Figure 3.2.5: MS4 serum does not react with the overexpressed T7-Syt IV in 
PC 12 cells. PC 12 cells were transfected with T7-Syt IV, fixed with methanol and 
colabelled with A) MS4 and anti-T7 or B) MS4 and anti-Syt IV (M.Fukuda). MS4 
was detected with anti-guinea pig-Cy3, T7 or Syt IV with anti-mouse or anti-rabbit 
Alexa-488 secondary antibodies, respectively. Images were aquired as described 
previously.
Mock-treated cells
Syt IV-siRNA treated cells
Figure 3.2.6: Indirect immunofluorescence of Syt I siRNA-treated PC12 cells using 
MS4. PC 12 cells were mock treated (top) or treated with Syt IV-siRNA (bottom) as 
described in Chapter 2. The cells were then fixed with methanol and labelled with MS4 
and anti-Syt IV ab (M.Fukuda). MS4 and anti-Syt IV ab were detected with the second­
ary anti-guinea pig-Cy3 and anti-rabbit Alexa-488 antibodies, respectively. Confocal 
images were acquired as described previously.
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There are two likely explanations for why the MS4 antiserum does not recognise T7-Syt 
IV. First, the epitope recognised by the MS4 antiserum is masked due to the folding of 
the overexpressed T7-Syt IV. Second, the MS4 antiserum reacts non-specifically with 
another Golgi-localised protein. To answer this question, PC 12 cells were treated with 
siRNA against Syt IV, fixed and labelled with the specific anti-rabbit Syt IV antibody 
and anti-guinea-pig MS4. In cells where the Syt IV was knocked-down by siRNA 
treatment, shown by the decreased staining of Syt IV by the specific ab, MS4 signal did 
not disappear but instead still displayed a perinuclear staining (Figure 3.2.6).
Together these results suggest that the MS4 does not recognise Syt IV but 
instead is labelling a different Golgi-localised protein. Therefore, I concluded that The 
MS4 antibody was not suitable for use in this study.
3.3 Synaptotagmin TV is localised on ISGs and absent from MSGs in 
PC 12 cells
To study the localisation of endogenous Syt IV in PC 12 cells, the specific anti-Syt 
IV ab provided by Dr M.Fukuda was used. This ab has been tested against all Syt 
isoforms and was found to recognise only Syt IV (Ibata et al., 2000).
First, I looked at the localisation of Syt IV with different sub-cellular markers by 
indirect immunofluorescence.
To specifically label MSGs, I used PC12/PC2 cells, a PC12 cell line stably expressing 
the pro-hormone convertase, PC2 (Dittie and Tooze, 1995). In PC12/PC2 cells, PC2
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cleaves Sgll at dibasic amino acid cleavage sites and produces a fragment called p i8, 
which accumulates in MSGs. p i8 can then be detected using a specific antibody that 
recognises only p l8 , and not full length or partially processed Sgll (Figure 3.3.1). 
PC12/PC2 cells were fixed with PFA, permeabilised and double-labelled with anti-Syt 
IV ab, with anti-Stx6 ab as perinuclear marker, and anti-Syt I (Perin et al., 1991) and 
anti-pl8 abs as MSG markers. Syt IV showed a strong colocalisation with Stx6 in the 
perinuclear area (Figure 3.3.2 A). No colocalisation of Syt IV with the MSG markers 
p i8 or Syt I was observed (Figure 3.3.2 B, C).
To see if the endogenous Syt IV is distributed on ISGs, and whether is present or absent 
from MSGs, I undertook a subcellular fractionation approach. This approach separates 
ISGs from MSGs on a continuous velocity 0.3M-1.2M sucrose gradient followed by a 
discontinuous equilibrium 0.8M-1.6M sucrose gradient as described in chapter 3 (Dittie 
et al., 19%). In PC12 cells, there are three major sulphated proteins, the constitutively 
secreted heparin sulphated proteoglycan (hsPG) (Gowda et al., 1989) and two secretory 
granule proteins, secretogranin II (Sgll) and chromogranin B (CgB), that follow the 
regulated secretory pathway (Rosa et al., 1985). After a 5 min labelling with [35S]- 
sulphate, these three proteins are sulphated in the TGN on tyrosine residues. A 15 min 
chase will allow the detection of Sgll and CgB in ISGs and the hsPG in CSVs. An O/N 
chase will allow the detection of Sgll and CgB in MSGs. PC 12 cells were [35S]-sulphate 
labelled for short periods (5 minutes pulse and chased for 15 minutes), or overnight (1 
hour pulse and chased overnight) to label ISGs or MSGs, respectively (Dittie et al., 
1996).
KRKR
p86
£18
Anti-pl8
Figure 33.1: Schematic representation of Sgll and pl8. Full length Sgll (p86) and 
its degradation product p i8 are represented, the black arrows are dibasic processing 
sites (Lys-Arg) used by PC2. Many degradation products of Sgll are generated by PC2 
and the final endoproduct is pl8, which accumulates in MSGs. Both Sgll and pl8 are 
sulphated on a tyrosine residue (S 04). Monoclonal anti-pl8 ab is directed against the 
C-terminal end of p i8 and is specific for p i8.
A)
B)
C)
Figure 3.3.2: Localisation of Syt IV in PC12/PC2 cells using indirect immunofluo­
rescence. PC12/PC2 cells were fixed with 3% PFA, permeabilised with 0.2% TX-100 
and double labelled with abs against A) Syt IV and Stx 6, B) Syt IV and p i8 and C) 
Syt IV and Syt I. Polyclonal anti-Syt IV abs were detected with secondary anti-rabbit- 
Alexa 488 and monoclonals anti-Stx 6, anti-pl8 and anti-Syt I abs were detected with 
anti-mouse-Cy3. Images were aquired by confocal microscopy using LSM 510 soft­
ware, Zeiss plan-Apochromat 63*/1.40 oil objective lense (Bars, 5pm).
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The post nuclear supernatant (PNS) from these labelled cells was subjected to a 
continuous velocity sucrose gradient fractionation. This first gradient will allow the 
separation of ISGs or MSGs from the TGN. After centrifugation, fractions were 
collected and then analysed by SDS-PAGE.
Syt IV was found mainly in the light ISG-containing fractions, as well as Golgi- 
containing fractions at the bottom of the gradients, characteristic of the perinuclear 
localisation observed by indirect immunofluorescence (Ibata et al., 2000) (Figure 3.3.3
A, top panel). In contrast, Syt I, shown to localise mainly on MSGs and synaptic 
vesicles (Perin et al., 1991), showed a peak distribution in the slightly heavier MSG- 
containing fractions (Figure 3.3.3 A, bottom panel).
The light fractions (1-4) and the slightly heavier fractions (5-7) were then loaded on two 
separate discontinuous equilibrium sucrose gradients. This step will permit further 
separation of ISGs from CSVs and MSGs. Fractions from both gradients were collected 
and analysed by autoradiography and SDS-PAGE. Syt IV distributed mainly in the ISG 
containing fractions (7-9), which contain the [35S]-sulphate-labelled Sgll (Figure 3.3.3
B, top panels). In addition, Syt IV displayed the same distribution as Stx6, which was 
previously found in ISG fractions (Wendler et al., 2001) (Figure 3.3.3 B, bottom 
panels). In contrast, Syt IV was not found in the MSG fractions (9-11), identified by the 
[35S]-sulphate-labelled Sgll in heavier fractions (Figure 3.3.3 C, top panels), whereas 
the isoform Syt I distributed in the MSG fractions (Figure 3.3.3 C, bottom panel).
In conclusion, this study confirms that Syt IV is localised on ISGs and is absent 
from MSGs.
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Figure 3.3.3: Distribution of Synaptotagmin IV in PC 12 cells by subcellular 
fractionation. A) PNS from PC 12 cells was loaded onto a 0.3 M -1.2 M continuous 
sucrose gradient, centrifuged and fractions collected. Western blotting was per­
formed using both anti-Syt IV (top panel) and anti-Syt I (bottom panel) abs. Alter­
natively, PC 12 cells were labelled with [35S]-sulphate for B) 5 min and chased for 
15 min to label ISGs or C) labelled for 1 h and chased O/N to label MSGs. PNS 
from these cells was loaded on a continuous velocity sucrose gradient and centri­
fuged. Fractions B) 1-4 or C) 4-6 from the velocity gradients were further separated 
on a 0.8-1.6 M discontinuous equilibrium sucrose gradient. Fractions from both 
gradients were collected and analysed on an SDS-PAGE. Top panels B,C): Autora­
diogram showing [35S]-sulphate-labelled CgB and Sgll. Bottom panels: western 
blot analysis using B) anti-Syt IV and anti-Stx 6 abs or C) anti-Syt IV and anti-Syt I 
abs. The diffuse band between 120 and 90 KDa in a hsPG.
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3.4 Discussion
In this chapter, I attempted to generate abs against Syt IV. The anti-Syt IV ab 
(MS4) was obtained by the injection of a synthetic peptide corresponding to a sequence 
in the spacer domain of the protein. By indirect immunofluorescence, the MS4 staining 
displayed a perinuclear localisation similar to that obtained with the specific anti-Syt IV 
ab provided by Dr M.Fukuda. Surprisingly, the MS4 antiserum did not recognise the 
overexpressed protein, suggesting that the staining observed was non-specific. This was 
confirmed when the MS4 staining did not disappear in cells treated with Syt IV siRNA. 
From these data, I concluded that the protein recognised by the MS4 antiserum is not 
Syt IV, but rather the MS4 antiserum cross reacts with a Golgi-localised protein. This 
protein could be another isoform of the Syt family of proteins. Although the sequence of 
the immunogen was obtained from the spacer domain, where there is less sequence 
conservation, this region still retains some similarity between the different isoforms of 
this family of proteins. One candidate could be Syt XI, which is the closest homologue 
to Syt IV. However, blotting PC 12 cell lysates with anti-Syt XI ab did not allow the 
detection of the protein, suggesting it is not expressed or expressed at very low levels 
(Tucker et al., 2003). The overexpression of all isoforms and labelling with the MS4 
antiserum would reveal whether this ab is cross-reacting with another Syt isoform or a 
protein that belongs to a different family.
In conclusion, the MS4 antiserum was unsuitable for the purposes of this study. 
Therefore, for future studies where an ab against Syt IV is required, I used the anti-Syt 
IV ab provided by M.Fukuda.
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An additional aim was to study the localisation of endogenous Syt IV in PC 12 cells. At 
the start of my study, Syt IV localisation was still inconclusive due to the conflicting 
data from different studies (Ferguson et al., 1999) (Eaton et al., 2000) (Fukuda et al., 
2003) (Wang et al., 2001). Initial reports had shown that Syt IV localised to MSGs and 
colocalised with Syt I in PC12 cells (Ferguson et al., 1999) (Thomas et al., 1999). 
Because endogenous Syt IV was undetectable in their PC12 cell line, this study was 
conducted on PC12 cells treated with forskolin, which was known to be one of the 
stimulants that increases Syt IV expression (Vician et al., 1995). Later, using indirect 
immunofluorescence, another study demonstrated that Syt IV and Syt I had distinct 
distributions in PC12 cells (Ibata et al., 2000). Moreover, using electron microscopy, 
Syt IV was shown to localise on ISGs and not MSGs in wild type PC 12 cells (Fukuda et 
al., 2003). These discrepancies were attributed to the lack of specificity of the anti-Syt 
IV ab used in the first study. A different analysis conducted in ATt20 cells expressing 
low levels of Flag-Syt IV showed that the overexpressed protein is on ISGs and not on 
MSGs (Eaton et al., 2000). However, in AtT20 cells expressing higher levels of Flag- 
Syt IV, the protein was found on both ISGs and MSGs. Part of the answer to these 
contradictions came from data that demonstrated that forskolin treatment or 
overexpression induces the sorting of Syt IV to MSGs (Fukuda and Yamamoto, 2004) 
(Wang et al., 2003a). Therefore, these earlier data did not identify the true subcellular 
localisation of the endogenous Syt IV.
In this study, by using the specific anti-Syt IV ab (Ibata et al., 2000) and a subcellular 
fractionation approach, I found that endogenous Syt IV distributed in the ISG- 
containing fractions. In contrast to Syt I, Syt IV was not found in MSGs. This was also 
seen by indirect immunofluorescence, where Syt IV had a distinct staining from that of 
Syt I and p i8.
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In the equilibrium sucrose gradients, where ISGs are found in fractions 7-9, Syt IV, as 
well as Stx 6, were also detected in fraction 6. This fraction contains membranes such as 
early endosomes and CCVs (Dittie et al., 1999) (Dittie et al., 1996). However, Syt IV 
did not colocalise with transferrin receptor (Ibata et al., 2000) and EEA1 (data not 
shown) by immunofluorescence, suggesting it is unlikely that Syt is on early 
endosomes. The Syt IV found in fraction 6 however could be on clathrin coated vesicles 
(CCVs). Immuno-EM staining of Stx6 and VAMP4, two proteins removed during ISG 
maturation (Wendler et al., 2001), revealed that they are localised to CCVs in the 
proximity of the Golgi (Bock et al., 1997; Steegmaier et al., 1999). Like Stx6 and 
VAMP4, Syt IV could be removed from the maturing granule via CCVs. It will be 
interesting to investigate this question. Immuno-EM labelling of Syt IV and Adaptor 
protein-1 (AP-1) as well as blotting purified CCVs with anti-Syt IV ab will reveal 
whether this protein is localised on CCVs. Previous studies have shown that VAM P4 is 
sorted from ISGs via binding to AP-1 (Hinners et al., 2003). It will be of great interest 
to investigate whther Syt IV displays binding to AP-1, which may suggest a common 
sorting pathway between proteins removed during granule maturation (The sorting of 
Syt IV will be further discussed in chapter 7).
In the equilibrium gradient, where MSGs distribute into fractions 9-11, Syt IV was 
found in fractions 6-8. These fractions contain membranes such as late endosomes and 
lysosomes (Dittie et al., 1999). To address the question of whether Syt IV localises on 
late endocytic compartments, a preliminary staining with LAMP-1 was performed (data 
not shown). Lack of colocalisation with this marker suggests that Syt IV is not on these 
compartments. However, to further characterise Syt IV localisation, a more thorough 
analysis should be performed including: costaining with the late endosomal markers,
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such as lysobiphosphatidic acid (LPBA) as well as late endosomes subfractionation and 
subsequent immunoblotting against Syt IV.
An additional explanation to take into consideration is that a small proportion of Sgll is 
also observable in the lighter fractions 6-8, in the MSG gradient, suggesting that a slight 
contamination of ISG membranes, where Syt IV distributes, is found in this gradient.
In conclusion, I confirm and extend previous findings that Syt IV is found on 
ISGs, and is removed from these granules during maturation in PC 12 cells.
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4 Chapter 4: The cytoplasmic domain of Synaptotagmin IV 
inhibits ISG-ISG homotypic fusion
4.1 Aim
Endocrine, neuroendocrine and exocrine cells are specialised cells that undergo 
regulated secretion (Arvan and Castle, 1998) (Tooze et al., 2001). In these cells, 
hormones and peptides to be secreted are packaged into ISGs, which bud from the 
TGN. After formation, ISGs undergo several changes, which include homotypic fusion 
(Urbe et al., 1998), membrane remodelling via CCVs (Klumperman et al., 1998) 
(Kuliawat et al., 1997), and hormone processing subsequent to the acidification of the 
granule’s content (Moore et al., 2002) (Orci et al., 1987). These maturation steps lead to 
the formation of MSGs, which undergo calcium-dependent exocytosis with the plasma 
membrane following an external stimuli.
To study one aspect of the maturation of ISGs, an in vitro assay that reconstitutes ISG- 
ISG fusion was developed by S.Urbe (Urbe et al., 1998). This assay revealed an 
involvement of proteins such NSF and a-SNAP in the regulation of ISG-ISG fusion. 
Localisation studies demonstrated that Syt IV, like the SNARE protein Stx6, was 
present on ISGs and absent from MSGs (Wendler et al., 2001). Moreover, the latter 
protein was found to be important for ISG homotypic fusion (Wendler et al., 2001).
In Chapter 3, I confirmed that endogenous Syt IV is localised on ISGs and is absent 
from MSGs in PC12 cells. It is now established, in particular from studies on Syt I, that
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the Syt family of proteins are involved in regulating membrane fusion events (Bai and 
Chapman, 2004).
The similarity in the distribution of Syt IV and Stx6, and the data suggesting that Syts 
are part of the fusion machinery, have led us to hypothesise that Syt IV might play a 
role in granule maturation prior to its removal from the maturing granules.
4.2 Purification o f  the recombinant Synaptotagmin TV cytoplasmic 
domain
One approach to study the function of Syt IV in granule maturation is to add the 
purified recombinant Syt IV cytoplasmic domain into the in vitro fusion assay, and to 
ask whether this fragment has an effect on ISG-ISG fusion.
To do this, I generated a GST-Syt IV cytoplasmic domain fusion protein and expressed 
it in bacteria as described in Chapter 2. This fusion protein was initially purified by 
affinity chromatography using glutathione-sepahrose beads. The band at ~  70 kDa 
represents the purified GST-Syt IV cytoplasmic domain (Figure 4.2.1 A). Two major 
contaminants appeared to co-purify with the fusion protein. The band at 35 kDa 
represents a degradation product of the GST-Syt IV cytoplasmic domain. This was 
demonstrated by blotting with the anti-Syt IV antibody, which reacted with both the 
GST-Syt IV cytoplasmic domain and the degradation product (data not shown). This 
degradation product was also reported after bacterial expression o f cytoplasmic domains 
of other Syt isoforms (Tucker et al., 2003).
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Figure 4.2.1: Purification of the Syt IV cytoplasmic domain.
A) Syt IV cytoplasmic domain was expressed as a GST fusion proteins in E.coli and 
purified by affinity chromatography using glutathione sepahrose beads. Lysates 
from uninduced or induced bacteria and the proteins eluted with Glutathione (El- 
E6) from the column were loaded on an SDS-gel followed by coomassie staining. 
The arrow shows the position of GST-Syt IV cytoplasmic domain. B) GST-Syt IV 
cytoplasmic domain (open arrow) was cleaved using thrombin and the Syt IV cyto­
plasmic domain (closed arrow) was eluted from the column. GST-Syt IV cytoplas­
mic domain, and Syt IV cytoplasmic domain, was run on an SDS-PAGE and 
analysed by coomassie blue staining.
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The addition o f a cocktail of proteases inhibitors did not prevent proteolysis of the Syt 
IV cytoplasmic domain. The band above the GST-Syt IV cytoplasmic domain is 
presumably a bacterial protein contaminant. This protein was removed during later 
purification steps.
In order to obtain a Syt IV cytoplasmic domain free from the GST moiety, thrombin 
was added to glutathione-sepharose column containing the bound GST-Syt IV 
cytoplasmic domain, and cleavage was allowed to occur for 3h at RT. The cleaved ~45 
kDa Syt IV cytoplasmic domain was collected from the column by gravity flow, and 
analysed by SDS-PAGE (Figure 4.2.1 B). Previous studies revealed that negatively- 
charged contaminants, mostly RNA (Wu et al., 2003), co-purifiy with the recombinant 
Syt I cytoplasmic domain, due to the presence of polybasic regions especially in the 
C2B domain. These contaminants were shown to enhance non-specific interactions with 
other proteins (Ubach et al., 2001). To obtain a Syt IV cytoplasmic domain free of 
these contaminants, I used the purification method developed by Ubach et al, which 
consisted in further purifying the protein by gel filtration followed by cation exchange 
purification columns (Ubach et al., 2001).
The cleaved Syt IV cytoplasmic domain obtained after elution from the glutathione- 
sepharose affinity column, as described above, was loaded on a Superdex-75 gel 
filtration column (Pharmacia) for separation according to protein size. The eluted peak 
fractions, as identified by absorbance at 280nm (Figure 4.2.2 A), were analysed by 
SDS-PAGE. The major peak was found in fractions 51-54, which contained mostly Syt 
IV cytoplasmic domain (Figure 4.2.2 B). Other fractions contained contaminating 
proteins, for example the high MW protein, which eluted before the Syt IV cytoplasmic 
domain.
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Figure 4.2.2: Syt IV cytoplasmic domain purification by gel filtra­
tion. The cleaved Syt IV cytoplasmic domain purified on glutathione 
beads (shown in figure 4.2.1) was further separated by gel filtration on 
superdex-75 column. A) Is a chromatogram of the OD280 profile from
the cleaved Syt IV cytoplasmic domain pool loaded on a superdex 75 
size exclusion column. B) Fractions containing peak absorbance were 
collected and loaded on SDS-gel for analysis. Fractions 51-54 contain 
Syt IV cytoplasmic domain.
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Fractions from the gel filtration column containing the Syt IV cytoplasmic domain were 
pooled and further purified by cation exchange in the appropriate buffer, which releases 
the protein from the negatively-charged bacterial contaminants. Proteins with a positive 
charge will bind to the column, whereas negatively-charged proteins will be removed 
during the washes. Bound proteins were eluted with a gradient from 10 mM NaCl (0% 
buffer B) to 1 M NaCl (100% buffer B). The highest elution peak was in fractions 50-60 
corresponding to a concentration of ~ 45% buffer B (0.45 M NaCl) (Figure 4.2.3 A). 
These fractions were analysed on SDS-PAGE, which confirmed that they contained the 
purified Syt IV cytoplasmic domain (Figure 4.2.3 B).
The purified Syt IV cytoplasmic domain was stored at - 80°C in small aliquots before 
use in the in vitro fusion assay. All Syt fragments used in this study were purified as 
described for the Syt IV cytoplasmic domain.
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Figure 4.2.3: Syt IV cytoplasmic domain purification on cation 
exchange column. Peak fractions containing Syt IV cytoplasmic 
domain separated on the gel purification column (shown in figure 4.2.2) 
were pooled and further purified on a cation exchange, Hi-Trap SP col­
umn. Syt IV cytoplasmic domain elution with a NaCl gradient from 10 
mM (0%  buffer B) to 1M (100% buffer B) from the cation exchange 
column. A) is a chromatogram of the OD280 profile and the % of buffer 
B. B) Peack fractions were collected and loaded on an SDS-PAGE gel 
for analysis. The purified Syt IV cytoplasmic domain is eluted mostly in 
fractions 54-59 at ~ 45% of buffer B.
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4.3 The cytoplasmic domain of Synaptotagmin TV, hut not that of 
Synaptotagmin I, inhibits ISG-ISG fusion
To test the hypothesis that Syt IV is involved in the regulation of granule 
maturation, I added the purified Syt IV cytoplasmic domain to the in vitro fusion assay 
that reconstitutes ISG-ISG fusion (Urbe et al., 1998), and asked whether this fragment 
has an effect on this membrane fusion event.
The in vitro ISG homotypic fusion assay was performed as described in Chapter 2. 
Briefly, a [35S]-sulphate labelled PNS from wild type PC12 cells (containing the 
substrate Sgll and not the pro-hormone convertase PC2) and purified ISGs from 
PC12/PC2 cells (stably expressing the enzyme PC2) are mixed together with ATP, ATP 
regenerating system and fusion buffer. The reaction is then incubated for 30 min at 37 
°C for fusion, followed by the processing of Sgll into an 18 kDa (p i8) degradation 
product by the proenzyme PC2 at 37 °C for 90 min at pH 5.5. The Sgll degradation 
product, p i8, is then immunoprecipitated with a specific anti-pl8 antibody. The 
immunoprecipitates are finally solubilised in SDS-sample buffer, and the proteins are 
separated on a SDS-PAGE gel followed by autoradiography and quantification of the 
p i8 signal (see figure 4.3.1 for illustration).
To test the effect of Syt IV on ISG fusion, I added an increasing amount of the purified 
recombinant Syt IV cytoplasmic domain into the complete fusion reaction mixture. This 
resulted in a dose-dependent inhibition of ISG homotypic fusion to a maximum of ~ 
40% (Figure 4.3.2 circle). In contrast, the addition of the denatured Syt IV cytoplasmic 
domain into the complete reaction did not have any effect on the ISG-ISG fusion
Labeling of PC 12 cells 
with l^^S]-sulphate
PNS
Isolation of I 
PC12/PC2 c
1 .
[ PC2
SGs from 
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|  ISGs
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Fusion reaction
(30 min, 37 °C) 
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( pl*v . . . .  pi 8* ■ 1PC2
V. .PC2 . pl«* . .)
\ -
Processing reaction
(90 min, 37 °C)
- pH 5.5
lyse and immunoprecipitate with anti-p!8 ab
SDS-PAGE and autoradiography
Figure 4.3.1: ISG-ISG in vitro assay scheme.
[35S]-sulphate labelled PNS (containing the substrate, Sgll) are mixed with Purified 
ISGs from PC12/PC2 cells (containing the enzyme PC2) in the presence of ATP, ATP 
regenerating system and fusion buffer. The complete reaction is incubated at 37 °C for 
30 min for fusion to occur. The processing of Sgll by PC2 into the 18 kDa degradation 
product, p l8 , is then done at 37 °C for 90 min at pH 5.5. The p l8  is then 
immunoprecipitated using the specific anti-pl8 ab. Immunoprecipitates are solubilised 
and subjected to SDS-PAGE gel analysis followed by autoradiography. Quantification 
of p i8 signals is done using ImageJ analysis software.
Syt I-CD 
Syt IV-CD 
B  Denatured Syt IV-CD
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oVh
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Figure 4.3.2: The cytoplasmic domain of Syt IV, but not Syt I inhibits 
ISG homotypic fusion. An ISG homotypic fusion was performed as 
described in (Urbe et al., 1998) and measures fusion by the production of 
p i8 from [35S]-sulphate- labelled Sgll. The complete fusion reaction con­
tains PC2 ISGs, PC12 [35S]-sulphate-labelled PNS and ATP. Syt IV 
(circle), denatured Syt IV (square) or Syt I (triangle) cytoplasmic domains 
were added at the indicated concentrations on ice, and fusion assay was 
performed. After subtraction of the background from PC2-ISG minus 
reactions, the fusion was assayed by quantifying the amount of p i8 pro­
duced using ImageJ software and is presented as a percent of the complete 
fusion reaction (n=3 experiments in duplicates, error is SEM). The addi­
tion of more Syt IV cytoplasmic domain did not increase the inhibition 
further than 50% (data not shown).
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(Figure 4.3.2 square). In PC12 cells, Syt I, IV and IX are the most abundant Syt 
isoforms, while Syt IV is expressed at lower levels compared to Syt I and IX (Zhang et 
al., 2002). I asked whether ISG homotypic fusion could be regulated by another Syt 
isoform. The addition of the purified Syt I cytoplasmic domain, previously shown to 
inhibit exocytosis (Earles et al., 2001), into the complete fusion reaction, had no effect 
on ISG-ISG fusion (Figure 4.3.2 triangle). This suggests that the inhibition of ISG 
homotypic fusion is specific to the Syt IV cytoplasmic domain, and does not involve 
Syt I.
In conclusion, the ISG-localised Syt IV is a component important for ISG homotypic 
fusion.
4.4 The Syt TV cytoplasmic domain and anti-Stx6 ab have an additive 
inhibitory effect on ISG homotypic fusion
Previous data showed that the ISG-localised SNARE protein Stx6 is also 
involved in ISG homotypic fusion (Wendler et al., 2001). This effect was shown by the 
addition of anti-Stx6 ab to the in vitro fusion assay, resulting in the inhibition of ISG 
homotypic fusion.
Because both Syt IV and Stx6 are involved in the regulation of ISG fusion, I asked what 
effect the combined inhibitory reagents would have. The addition of Syt IV cytoplasmic 
domain or anti-Stx6 ab separately into the fusion reaction resulted in inhibition of ISG- 
ISG fusion to a maximum of ~ 40% (Figure 4.4.1 A), confirming the previous data that 
both proteins are involved in ISG homotypic fusion. Surprisingly, the addition of Syt IV 
cytoplasmic domain together with anti-Stx6 ab into the fusion assay resulted in an
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additive inhibitory effect on ISG homotypic fusion (Figure 4.4.1 A). To ensure that this 
effect is specific, the Syt IV cytoplasmic domain was combined with the anti-Stxl ab, 
shown previously to have no effect on ISG fusion (Wendler et al., 2001), and the anti- 
Stx6 ab was combined with Syt I cytoplasmic domain, which did also not have an 
inhibitory effect on ISG homotypic fusion. The combined reagents were added in the 
complete fusion reaction (Figure 4.4. IB). In contrast to the combination of anti-Stx 6 ab 
with Syt IV cytoplasmic domain, anti-Stxl ab with Syt IV cytoplasmic domain or anti- 
Stx6 ab with Syt I cytoplasmic domain combinations did not increase the inhibition of 
ISG-ISG fusion (Figure 4.4.1 B). This demonstrates that the additive inhibitory effect is 
specific to the combination of Syt IV and Stx 6.
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Figure 4.4.1: Syt IV cytoplasmic domain and anti-Stx6 antibody have an 
additive inhibitory effect on ISG-ISG fusion.
A) A complete fusion reaction was incubated with 9 M Syt IV-CD, 10 g 
anti-Stx6 ab, or Syt IV-CD combined with anti-Stx6 ab (n=3 in duplicates, 
error is SEM). B) As control, complete fusion reaction was incubated with 9 
M Syt IV-CD, 10 g anti-Stx6 ab, 9 M Syt I-CD, 10 g anti-Stxl ab, 9 M 
Syt IV-CD combined with 10 g anti-Stxl or anti-Stx6 ab and 10 g anti-Stx 
6 combined with 9 M Syt I-CD. A and B) Fusion reactions were performed 
at 37 °C for 30 min followed by substrate processing for 90 min as described 
in Chapter 2. p i8 was immunoprecipitated and the signal quantified using 
ImageJ analysis software. The background signal measured in the absence of 
PC2 signal was subtracted.
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4.5 BAPTA inhibits ISG homotypic fusion
Many membrane fusion events, such as yeast homotypic vacuole fusion (Peters 
and Mayer, 1998), early endosome-early endosome fusion (Mills et al., 1999), and 
fusion of granules with the plasma membrane (Heinemann et al., 1994), are known to be 
calcium-dependent.
Syt family of proteins are characterised by the presence of the C2A and C2B domains in 
their cytoplasmic tail. Some, but not all Syts, are able to bind calcium ions. For 
example, Syt I binds a total of five calcium ions via its C2 domain, and functions as the 
calcium sensor for exocytosis. It is established that Syt IV is not able to bind calcium 
via its C2A domain due to an amino acid substitution in one of the calcium-binding 
sites (von Poser et al., 1997). However, it was assumed that rat Syt IV could bind 
calcium via its C2B domain because it retains all the calcium binding sites found in Syt 
I (Wang et al., 2003a). A recent crystal structure of rat Syt IV revealed that changes in 
the orientation of the calcium ligands within the C2B region render this domain unable 
to form full calcium-binding sites (Dai et al., 2004), making Syt IV a non-calcium 
binding isoform.
The finding that Syt IV is involved in ISG homotypic fusion, and the recent data 
showing that rat Syt IV does not bind calcium raised the question of whether this fusion 
event is dependent on calcium. To investigate whether or not ISG-ISG fusion is 
dependent on calcium, an increasing amount of BAPTA was added to the complete 
fusion reaction. This resulted in a dose-dependent inhibition of ISG homotypic fusion of 
up to ~  90% (Figure 4.5.1 A). Addition of BAPTA after the fusion reaction had no 
effect on ISG-ISG fusion. Preliminary results showed that the addition of the same
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concentrations of EGTA into the fusion assay did not have an inhibitory effect on ISG 
fusion (Figure 4.5.1 B). A slight stimulation o f ISG-ISG fusion is observed upon 
addition of EGTA. However, this stimulation was not significantly higher with 
increasing concentrations of EGTA compared to that of control (no EGTA). Although 
this result needs to be verified, I think that this effect is not significant.
Yeast vacuole fusion and early endosome homotypic fusion events were also found to 
be inhibited by BAPTA and not EGTA (Peters and Mayer, 1998) (Mills et al., 1999). 
This is presumably due to the fact that calcium is released at the final step of fusion 
(Peters and Mayer, 1998). Therefore a fast calcium-chelator, such as BAPTA, is 
required to abolish the calcium effect. It was not possible to determine whether the 
calcium involved in ISG homotypic fusion is released from the lumen of ISGs, as is the 
case for yeast vacuole fusion (Peters and Mayer, 1998), since in our in vitro fusion 
assay the substrate donor compartment is obtained from a postnuclear supernatant.
ISGs + + + + +
BAPTA
(mM) - 0.5 1 5 5*
B)
ISGs + + + +
EGTA (mM) - 0.5 1 5
Figure 4.5.1: BAPTA, but not EGTA inhibits ISG homotypic fusion.
A) Complete fusion reactions containing [35S]-sulphate-labelled PNS from PC12 
cells, PC2-ISGs, ATP and fusion buffer, were pre-incubated with or without 
increasing amounts of BAPTA or 5mM BAPTA* added after the fusion incubation, 
(n=3 in duplicates, error is SEM). B) Complete fusion reactions were pre-incubated 
with increasing amounts of EGTA. The fusion assay and the quantification of p i8 
signal was carried as described in Chapter 2.
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4.6 Discussion
Svt IV  is involved in ISG-ISG fusion
I have confirmed that endogenous Syt IV is localised on ISGs and not MSGs in 
PC 12 cells (Chapter 3). This protein was of particular interest because of its similar 
localisation to Stx6 and VAMP4, two SNARE proteins involved in ISG maturation 
(Wendler et al., 2001) (Hinners et al., 2003). Moreover, Syts represent a large family of 
proteins with a role as regulators of membrane fusion (Bai and Chapman, 2004).
In this study, I used the in vitro ISG-ISG fusion assay to test the hypothesis o f whether 
Syt IV is involved in ISG-ISG fusion. I showed that the addition of increasing amounts 
of purified recombinant Syt IV cytoplasmic domain into the complete fusion assay 
inhibited ISG homotypic fusion in a dose-dependent manner. These findings revealed a 
novel role for the endogenous Syt IV in the regulation of granule maturation in PC 12 
cells.
Most studies looking at the function of Syt IV were conducted with the overexpressed 
protein, where it is sorted to MSGs (Wang et al., 2003a). The overexpressed Syt IV is 
involved in exocytosis and, in particular, kiss-and-run fusion (Wang et al., 2003a). It is 
unlikely that endogenous Syt IV participates in kiss-and-run fusion events of ISGs 
because upon fusion ISGs increase in size, suggesting that they undergo full fusion 
(Tooze et al., 1991).
The removal of endogenous Syt IV during granule maturation (Eaton et al., 2000) 
(Fukuda et al., 2003) suggests that it is not involved in exocytosis, in contrast to the 
overexpressed protein. In confirmation, several studies have investigated whether the
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endogenous Syt IV is involved in vesicle fusion with the plasma membrane. Firstly, in 
an N-terminal antibody-uptake experiment, abs against the luminal domain of Syt IV 
were added to the extracellular medium of K+-depolarised PC 12 cells. If the MSGs 
undergoing exocytosis contain Syt IV, the N-terminus of Syt IV would be accessible on 
the outer surface of the cell membrane, and therefore it should be recognised by anti-Syt 
IV ab in the culture medium. In these conditions, there was no uptake of the N-terminal 
anti-Syt IV abs by the wild type PC12 cells, suggesting that endogenous Syt IV is not 
present on MSGs undergoing exocytosis (Fukuda et al., 2003). A second study showed 
that catecholamine release from “cracked” PC 12 cells was not affected by the addition 
of recombinant Syt IV cytoplasmic domain, whereas an inhibition of release was 
observed when recombinant Syt I was added (Tucker et al., 2003). Together, these 
studies demonstrate that endogenous Syt IV is not a regulator of exocytosis in 
neuroendocrine cells.
In PC12 cells, Syt I, IX and IV are the most highly expressed Syt isoforms (Zhang et al., 
2002). Syt I and IX are both found on MSGs and are involved in exocytosis (Fukuda et 
al., 2002) (Tucker et al., 2003). Because it was found that the addition of recombinant 
cytoplasmic domains of both Syt I and Syt IX inhibits secretion from PC 12 cells, 
possibly through hetero-oligomerisation of both isoforms (Tucker et al., 2003), I tested 
whether an isoform other than Syt IV was involved in ISG homotypic fusion. 
Consequently, I added the purified recombinant Syt I cytoplasmic domain into the in 
vitro fusion assay. In contrast to Syt IV, Syt I cytoplasmic domain did not inhibit ISG 
homotypic fusion, suggesting that Syt I is not involved in this membrane fusion event. It 
was suggested previously that endogenous Syt I and IV have different functions in 
PC 12 cells. First, Syt IV and I display different distributions (Ibata et al., 2000), and
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second, the two isoforms do not have the ability to hetero-oligomerise (Fukuda and 
Mikoshiba, 2000a) (Osborne et al., 1999).
It is also unlikely that Syt IX is involved in ISG homotypic fusion. Syt IX also displays 
a different distribution than Syt IV (Fukuda, 2004), and both isoforms do not 
oligomerise (Fukuda and Mikoshiba, 2000a). Moreover, Syt IX, like Syt I, regulates 
exocytosis from PC12 cells (Tucker et al., 2003). Although it needs to be verified, I 
think a role of Syt IX in ISG homotypic fusion is unlikely because these data suggest 
that Syt IX possesses a more similar role to Syt I, which does not inhibit ISG-ISG 
fusion.
Svt IV c\toplasmic domain and Stx6 ab have an additive inhibitory effect on 
ISG homotypic fusion.
Both Stx6 and Syt IV are involved in ISG homotypic fusion. In an attempt to 
increase our understanding of how these two proteins regulate this membrane fusion 
event, I asked what effect the addition of inhibitory reagents for both proteins would 
affect ISG homotypic fusion.
The combined addition of the anti-Stx6 ab and Syt IV cytoplasmic domain resulted in 
an unexpected additive inhibitory effect on ISG-ISG fusion. This result suggested that 
the binding on ISGs, as well as the function of an individual reagent, was not affected 
by their combined addition. Indeed, I verified and confirmed that the binding of both 
Syt IV cytoplasmic domain and anti-Stx6 ab on ISG membranes was not affected by the 
addition of the other reagent (Chapter 5, Figure 5.4.2).
The additive effect on ISG homotypic fusion obtained by the combination of anti-Stx6 
ab and Syt IV cytoplamsic domain is difficult to interpret. One reason is that we do not
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have a substantial understanding of how ISG homotypic fusion occurs. In addition, we 
do not know how these inhibitory reagents act on their effectors.
However, I speculate that there are two possible explanations:
First, the additive inhibitory effect is due to the fact that Stx6 and Syt IV act in parallel 
pathways, meaning that there are some vesicles that lack Stx6 and/or Syt IV. This 
scenario requires that ISGs be of a heterogeneous nature. I think that this is unlikely, 
because we have no indication that ISGs have different SNAREs or Syt components. In 
fact, immunoisolation experiments using the anti-Stx6 ab showed that close to 100% of 
the ISG-localised Sgll was recovered (Wendler et al., 2001), suggesting that all ISGs 
have Stx6.
Second, and the likeliest explanation, is that the additive effect could be attributable to 
the Syt IV cytoplasmic domain and anti-Stx6 ab inhibiting different stages during ISG 
homotypic fusion. Because when isolated ISGs at different stages of fusion (Urbe et al., 
1998), it is therefore possible that ISGs are susceptible to specific inhibition by either 
anti-Stx6 ab or by the Syt IV cytoplasmic domain.
In conclusion, although the experiments presented in Figure 4.4.1 confirmed that both 
Syt IV and Stx6 are indeed needed for ISG homotypic fusion, they did not reveal at 
which specific stage of fusion Syt IV and Stx6 are involved.
It will be interesting to understand how these two reagents inhibit ISG fusion. An 
important question to answer is at what stage of fusion, whether tethering, docking or 
fusion, do Syt IV and Stx6 act. Adding individual reagents during the time course of 
fusion, and observing whether the susceptibility to the inhibitory reagent is lost at the 
beginning or end of fusion, will help answer this question.
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Calcium is required for ISG-ISG fusion
It is established that calcium is required for many membrane fusion events. For 
example, exocytosis, yeast vacuole-vacuole fusion, early endosome homotypic fusion, 
and endosome-lysosome fusion were all shown to depend on the presence of calcium 
(Burgoyne and Clague, 2003). In addition, calcium is required at the last step of 
membrane fusion, and subsequent to SNARE assembly, as was shown for yeast vacuole 
homotypic fusion (Peters and Mayer, 1998).
Some proteins, such as Syts, which possess the ability to sense calcium and to bind to 
the fusion machinery, were shown to be involved in membrane fusion. Indeed, Syt I is 
able to bind calcium through its C2 domain. In the presence of calcium, Syt I displays 
high-affinity interactions with phospholipids as well as with the SNARE machinery 
involved in exocytosis (Bai and Chapman, 2004).
Syt IV differs from Syt I in that it is not able to bind calcium (Dai et al., 2004). This led 
to the question of whether calcium sensing is accomplished by another protein, or 
whether ISG fusion is calcium independent and possibly requires a non-calcium binding 
Syt isoform. The addition of BAPTA to the in vitro fusion assay inhibited ISG-ISG 
fusion, demonstrating that ISG homotypic fusion is in fact calcium-dependent. This 
suggested that a calcium-binding protein, as yet to be identified, is required for ISG 
fusion. Two hypotheses emanate from these observations:
The first hypothesis is that a second Syt isoform, which localises on ISGs, could play a 
role in sensing calcium during ISG membrane fusion. This role could be either 
dependent or independent of Syt IV function in ISG homotypic fusion. Indeed, the 
putative calcium sensing Syt isoform will act at a different stage of fusion than that Syt
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IV. In support of this, studies on Syt I showed that it is involved in multiple stages of 
fusion, docking (Chieregatti et al., 2002), fusion pore opening (Wang et al., 2001) and 
membrane recycling (Nicholson-Tomishima and Ryan, 2004). It would then be likely 
that Syt IV acts at a stage prior to the one involving the calcium sensing Syt isoform. 
However, the putative calcium sensor protein activity could be dependent on hetero­
oligomer formation with Syt IV. Indeed, many Syts were shown to form hetero­
oligomers in vitro in a calcium-dependent manner (Fukuda and Mikoshiba, 2000a) 
(Osborne et al., 1999). The hetero-oligomerisation of different isoforms with different 
calcium affinities is thought to modulate calcium sensitivity of membrane fusion.
In both cases, this isoform has to be identified and the hypothesis verified. Because I did 
not find an involvement of Syt I in ISG homotypic fusion, it is unlikely that it is the 
calcium sensor involved in this fusion event. At present there are no other identified Syt 
isoform that display the same localisation as Syt IV in PC12 cells, i.e. present on ISGs 
and not MSGs. Moreover, Syt IV did not show any calcium-dependent hetero­
oligomerisation activity in vitro with Syt I (Fukuda and Mikoshiba, 2000a).
The identification of other Syt isoforms which bind calcium, and display an ISG 
localisation, and testing their effect on ISG fusion, will be a first step towards 
addressing this hypothesis.
The second hypothesis is that another calcium-binding protein, such as calmodulin, 
could be involved in ISG homotypic fusion. Calmodulin is an EF-hand calcium-binding 
protein, and was identified as a calcium sensor for many membrane fusion events. 
Indeed, in yeast, calmodulin antagonists such as W7, as well as anti-calmodulin abs, 
inhibit vacuole homotypic fusion (Peters and Mayer, 1998). Moreover, the requirement 
for calcium/calmodulin was found to be downstream of the completed docking reaction, 
suggesting they act at the final step of fusion (Peters and Mayer, 1998). Calmodulin was
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suggested to act in the final stage of vacuole fusion by interacting with the VO sector of 
the V-ATPase, which through an association on opposite membranes forms the fusion 
pore (Bayer et al., 2003).
Other intracellular membrane fusion events, such as early endosome homotypic fusion, 
are regulated by calmodulin in a calcium-dependent manner (Colombo et al., 1997). 
Interestingly, calmodulin was found to interact with Stxl3 and EEA1, two proteins 
shown to be involved in early endosome homotypic fusion (Mills et al., 2001). This data 
suggested that EEA1 and Stxl3 could serve to localise calmodulin to the site of fusion. 
To address this second hypothesis, addition of calmodulin antagonists into the in vitro 
assay might reveal whether calmodulin is involved in the regulation of ISG homotypic 
fusion.
In conclusion, I showed in this chapter that the ISG-localised Syt IV is involved 
in ISG homotypic fusion. This fusion event was specific to Syt IV, as the MSG- 
localised Syt I, shown to be involved in exocytosis, had no effect. The calcium- 
dependence of ISG-ISG fusion, and the fact that Syt IV does not bind calcium, raises 
the possibility that another protein, possibly another calcium sensor as yet to be 
discovered, could be involved in regulating the calcium-dependence step of ISG 
homotypic fusion.
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5 Chapter 5: Syt IV cytoplasmic domain is recruited to ISG 
membranes and binds to the SNARE protein Stx6
5.1 Aim
The findings I presented in chapter 4  showed that Syt IV cytoplasmic domain 
inhibited ISG-ISG fusion, suggesting that this isoform is an important component in the 
regulation of granule maturation. Because the cytoplasmic domain of Syt IV was able to 
inhibit ISG homotypic fusion, I asked whether the target of this domain resides on these 
membranes, and specifically if its recruitment was via protein components on ISG 
membranes. Syts, via their C2 domains, can bind SNARE proteins, and this binding is 
thought to be an important requirement in the regulation of membrane fusion events 
(Bai and Chapman, 2004). I therefore tested whether Syt IV interacts with the SNARE 
protein, Stx6, which resides on ISG membranes and, like Syt IV, is involved in the 
regulation of ISG homotypic fusion.
5.2 Synaptotagmin TV cytoplasmic domain is recruited to ISG 
membranes
In an attempt to answer the question of whether the Syt IV cytoplasmic domain is 
recruited to ISG membranes, I used an in vitro ISG binding assay, which reconstitutes
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binding of exogenous proteins to purified ISG membranes. This assay was previously 
used to demonstrate ARF-1 (Austin et al., 2000) and AP-1 binding to ISGs (Dittie et al., 
1996).
Increasing amounts of the purified Syt IV cytoplasmic domain were incubated with a 
constant amount (50 pi) of purified PC12 ISGs in fusion buffer and ATP at 37 °C for 30 
min. Membranes were subsequently collected by centrifugation and the bound Syt IV 
cytoplasmic domain was detected using anti-Syt IV ab (Figure 5.2.1 A).
The Syt IV cytoplasmic domain was recruited to ISG membranes in a dose-dependent 
manner. This demonstrates that ISGs contain saturable binding sites for Syt IV, and 
further suggests that the inhibitory effect of the Syt IV cytoplasmic domain on ISG 
homotypic fusion is on these membranes. No recombinant protein was detected in the 
pellet in the absence of ISGs (Figure 5 .2 .IB), demonstrating that the binding is not a 
result of non-specific aggregation of the protein.
Having shown that Syt IV cytoplasmic domain is recruited to ISG membranes, I asked 
whether this recruitment is via protein or lipid components in the ISGs. Using liposome- 
binding assays, it was demonstrated that Syts such as Syt I and IX are able to bind 
phospholipids via their C2 domains in a calcium-dependent manner (Hui et al., 2005). 
In contrast, there are several reports that Syt IV does not bind phospholipids (Bai et al., 
2002) (Dai et al., 2004) (Hui et al., 2005), except one study, which showed that Syt IV 
was in fact able to bind liposomes containing only negatively-charged phospholipids
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Figure 5.2.1: The cytoplasmic domain of Syt IV is recruited to ISG membranes.
A) Increasing amounts of Syt IV cytoplasmic domain were incubated with purified 
PC12-ISGs (50 pi) in fusion buffer and ATP for 30 min at 37°C followed by centrif­
ugation to pellet the membranes. The amount of Syt IV bound to ISG membranes 
was determined by immunoblotting with anti-Syt IV ab and quantified using ImageJ 
software (n=3 in duplicates, error is SEM). B) 20 nM of Syt IV cytoplasmic domain 
were incubated without or with PC12-ISGs (50 pi) as described above and bound 
Syt IV was detected with anti-Syt IV ab.
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(Fukuda et al., 1996). Although the lipid composition of ISG membranes is not known, 
it is unlikely that they are composed solely of negatively-charged phospholipids.
To investigate if the component(s) responsible for Syt IV cytoplasmic domain 
recruitment are of a protein or lipid nature, I repeated the in vitro ISG binding assay in 
the presence of trypsin to degrade protein components. ISGs were pre-treated with 
increasing amounts of trypsin for 10 min at 37 °C, followed by the addition of trypsin 
inhibitor. After centrifugation, the amount of bound Syt IV was determined using an 
anti-Syt IV ab. Pre-treatment with trypsin reduces the binding of Syt IV cytoplasmic 
domain to ISG membranes in a dose-dependent manner (Figure 5.2.2 Top panel), 
suggesting that this recruitment is via proteinaceous ISG-components. When trypsin 
inhibitor was added to ISGs before trypsin, the latter did not affect Syt IV cytoplasmic 
domain binding, demonstrating that the trypsin inhibitor activity was efficient. 
Similarly, preincubation of ISGs without the addition of trypsin or trypsin inhibitor did 
not affect Syt IV cytoplasmic domain recruitment.
The same blot, used previously to determine Syt IV binding upon trypsin treatment, was 
re-probed with an anti-Sgll ab. The luminal protein Sgll was not degraded, 
demonstrating that the granules stayed intact during the assay (Figure 5.2.2 bottom 
panel). While it cannot be excluded that phospholipases could be activated by trypsin, 
which could alter the lipid composition of membranes, these results are in agreement 
with several reports demonstrating that Syt IV is unable to bind phospholipids (Dai et 
al., 2004) (Hui et al., 2005).
In conclusion, these data suggest that protein components on ISG membranes are 
necessary for the recruitment of the Syt IV cytoplasmic domain.
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Figure 5.2.2: The Syt IV cytoplasmic domain recruitment to ISG 
membranes is sensitive to trypsin-treatment. ISGs (50/d) were pre- 
incubated with increasing amounts of trypsin for 10 min at 37 °C. Trypsin 
inhibitor (STI) was added before (*) or after the pre-incubation. Binding 
reactions including 10 nM Syt IV cytoplasmic domain were performed as 
described previously. Syt IV bound to ISGs was detected with anti-Syt IV 
ab. The same blot was stripped and reprobed with anti-Sgll ab, Sgll is not 
degraded, suggesting that the vesicles were intact during the assay 
(bottom panel).
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5.3 Synaptotagmin TV interacts with The SNARE protein, Syntaxin 6
It is now established that Syts are part of the machinery that regulate membrane 
fusion events (Tucker and Chapman, 2002). Syt I, for example, was found to bind the t- 
SNAREs Stxl (Chapman et al., 1995) and SNAP-25 (Schiavo et al., 1997), and this 
binding is a necessary step in the regulation of exocytosis (Earles et al., 2001).
The previous results showed that the cytoplasmic domain of Syt IV was able to bind 
ISG membranes. Moreover, this binding was mainly via protein components. These 
data suggest that protein(s) on ISG membranes are responsible for the recruitment of the 
Syt IV cytoplasmic domain, and perhaps that the inhibition of ISG homotypic fusion 
observed after the addition of this domain is accomplished via this interaction.
Because Stx6 is the only ISG SNARE protein found so far to regulate ISG-ISG fusion 
(Wendler et al., 2001), I hypothesised that Syt IV may be part of a complex that 
includes Stx6.1 therefore looked for interaction between Stx6 and Syt IV.
To address this question, I first performed a GST pull-down assay with GST-Syt IV 
cytoplasmic domain. This was obtained with the same purification method used for the 
cleaved Syt IV cytoplasmic domain, as described in Chapter 4 (data not shown). This 
method eliminates the possibility that bacterial contaminants might interfere with the 
binding properties of Syt IV, which was a problem for recombinant Syt I (Ubach et al., 
2001). Purified GST-Syt IV cytoplasmic domain as well as GST bound to glutathione- 
sepharose beads were incubated with Triton -X  100-extracted lysates from HEK cells 
over-expressing myc-full length Stx6. The bound proteins were subjected to SDS- 
PAGE, followed by immunoblotting with anti-myc ab. GST-Syt IV interacted with
Chapter 5______________________________________________________  139
myc-stx6 in a dose-dependent manner (Figure 5.3.1). No binding of myc-Stx6 to GST 
alone was detected, indicating that the Syt IV-Stx6 interaction is specific.
Next, to reinforce the GST-pull down data, I tested whether Syt IV interacted with Stx6 
using co-immunoprecipitation. HA-Syt IV cytoplasmic domain and myc-Stx6 were co­
transfected into HEK cells. Cells were then lysed in Triton X-100-containing buffer, 
and lysates subjected to immunoprecipitation with either anti-HA or anti-myc ab bound 
to protein G beads, or beads alone. Myc-Stx6 was immunoprecipitated with anti-HA ab 
(Figure 5.3.2 A), as was HA-Syt IV cytoplasmic domain when using anti-myc ab for 
immunoprecipitation (Figure 5.3.2 B). No proteins were immunoprecipitated with beads 
alone, suggesting that Syt IV interaction with Stx6 is specific. The unavailability of a 
suitable anti-Syt IV ab for immunoprecipitation did not allow me look for interactions 
with the endogenous proteins.
These data demonstrate that Syt IV and Stx6 interact, and further imply that both 
proteins are part of the same protein complex.
GST GST-Syt IV CD
10% total 20 50 20 50
---------
Bg
myc-Stx6
Figure 5.3.1: Syt IV interacts with Stx6 in GST pulldown assays. 
GST-Syt IV cytoplasmic domain, or GST alone were bound to glutathione 
beads then incubated with Triton X-100 lysates from HEK cells 
overexpressing myc-Stx6. Bound proteins as well as 10% of the total used 
for each sample were subjected to SDS-PAGE followed by western blot­
ting with anti-myc ab.
A)
Untransfected HA-Syt IV CD/myc-Stx6
+ 10% total - +
—
IP: anti-HA-Syt IV 
IB: anti-myc-Stx6
B)
Untransfected HA-Syt IV CD/myc-Stx6
10% total 10% total - +
ITT *  j:
IP: anti-myc-Stx6 
IB: anti-HA-Syt IV
Figure 5.3.2: HA-Syt IV cytoplasmic domain interacts with myc-Stx6.
HEK cells were cotransfected with HA-Syt IV cytoplasmic domain and myc-Stx6. 
Triton X-100 lysates from A) untransfected and A,B) transfected cells were used 
for immunoprecipitation with anti- A) HA (+) or beads alone (-) and B) with anti- 
myc antibody (+) or beads alone (-). Immunoprecipitates as well as 10% of total 
input were subjected to SDS-PAGE and analysed with A) anti-myc or B) anti-HA 
antibodies.
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5.4 Both Syt TV-C2A and C2B domains display binding to Stx6
To investigate which Syt IV domain is required for binding to Stx6,1 performed 
a co-immunoprecipitation experiment with Triton X-100 lysates prepared from HEK 
cells co-expressing myc-Stx6 and either the HA-Syt IV-C2A or HA-Syt IV-C2B 
domains. When using an anti-HA ab, myc-Stx6 was immunoprecipitated from both cell 
lysates expressing HA-Syt IV-C2A or HA-Syt IV-C2B domains (Figure 5.4.1 A). 
Similarly, when using anti-myc antibody, both HA-Syt IV-C2A and HA-Syt IV-C2B 
domains were co-immunoprecipitated (Figure 5.4.1 B). This demonstrates that both 
domains are involved in the binding of Syt IV to Stx6. These results were similar to 
those obtained with Syt I, where both C2A and C2B domains were found to mediate the 
binding to the plasma membrane t-SNAREs Stxl and SNAP-25 (Gerona et al., 2000). 
The efficiency of binding of the individual domains of Syt IV to myc-Stx6 was lower 
than that obtained with the complete Syt IV cytoplasmic domain (compare Figure 
5.3.2A and 5.4.IB). This observation suggests that the C2A and C2B domains of Syt IV 
can cooperate to mediate binding to Stx6, as is the case for Syt I binding to plasma 
membrane SNAREs (Earles et al., 2001) (Bai et al., 2004b).
Next, I attempted to look at which region of Stx6 binds Syt IV. Although Stx6 is 
classified as a Qc-SNARE, it harbours a great similarity to the Qa-SNAREs, such as 
Stxl, due to the presence of the Habc domain at the N-terminus of the protein (Bock et 
al., 2001) (Misura et al., 2002), lacking in the Qc SNAREs. Previous results in the lab 
have shown that, in contrast to the anti-Stx6 ab, the recombinant Stx6 cytoplasmic 
domain does not inhibit ISG homotypic fusion and is unable to bind SNARE proteins,
A)
IP: anti-myc-Stx6 
IB: anti-HA-Syt IV
B)
IP: anti-HA-Syt IV 
IB: anti-myc-Stx6
HA-C2A/myc-Stx6 HA-C2B/myc-Stx6
10% total - + 10% total - +
— *
HA-C2A/myc-Stx6 HA-C2B/myc-Stx6
10% total - + 10% total - +
Figure 5.4.1: HA-Syt IV binds to myc-Stx6 via both C2A and C2B domains.
HEK cells were cotransfected with myc-Stx6 and HA-C2A domain or myc-Stx6 and 
HA-C2B dom ain. Triton X-100 lysates from  HEK cells were subjected  to 
immunoprecipitation with A) anti-myc (+) or beads alone (-) and B) anti-HA (+) or 
beads alone (-). 10% of the input for each sample and the immunoprecipitates were 
analysed with A) anti-HA and B) anti-myc abs.
A)
Syt IV CD (20 nM) 
Anti-Stx6 ab (10 ng)
B)
Syt IV CD (20 nM) 
Anti-Stx6 ab (10 ng)
Heavy chain -►
Light chain
ISGs
only
Anti-
Stx6
ab MW (kDa) 
-56
-38
-29
Figure 5.4.2: Syt IV cytoplasmic domain and anti-stx6 ab bind to a differ­
ent region within Stx6. Complete in vitro  ISG binding reactions containing 50 
pi ISGs, ATP and A) 20 nM Syt IV cytoplasmic domain, with or without 10 ng 
anti-Stx6 ab or B) 10 ng anti-Stx6 ab with or without 20 nM Syt IV cytoplasmic 
domain were incubated for 30 min at 37 °C. Bound A) Syt IV cytoplasmic 
domain was detected using anti-Syt IV ab and B) anti-stx6 ab using anti-mouse 
secondary ab-HRP conjugated.
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such as VAMP4, suggesting that the bacterially-expressed Stx6 cytoplasmic domain is 
inactive (Wendler et al., 2001) (Wendler F, unpublished observations). Therefore, I 
performed an in vitro ISG binding assay with both the anti-Stx6 ab, which binds to Stx6 
Habc domain (Otto G and Wendler F, unpublished observation), and the Syt IV 
cytoplasmic domain. If Syt IV cytoplasmic domain and anti-Stx6 ab bind to the same 
region in Stx6, there should be a decrease in binding of Syt IV because of competition 
for binding to the same site. After incubation of the complete binding reaction at 37 °C 
for 30 min, the bound Syt IV cytoplasmic domain or anti-Stx6 ab are detected with anti- 
Syt IV ab or HRP-conjugated secondary ab, respectively. The binding of Syt IV 
cytoplasmic domain to ISG membranes was similar with or without anti-Stx6 ab (Figure 
5.4.2 A). Similarly, the binding of anti-Stx6 ab was the same with or without Syt IV 
cytoplasmic domain (Figure 5.4.2 B). This result suggests that the Syt IV cytoplamsic 
domain and the anti-Stx6 ab bind to a different region within Stx6.
5.5 Discussion
Possible mode of inhibition of ISG homotypic fusion bx the cytoplasmic domain of 
Svt IV.
The cytoplasmic domain of Syt IV was able to inhibit ISG-ISG fusion, and could 
be recruited to ISG membranes. This result suggests that the target of Syt IV 
cytoplasmic domain inhibition resides on these membranes. This binding is mediated 
strictly by protein components, as the recruitment of Syt IV cytoplasmic domain was 
reduced after the pre-treatment of ISG membranes with trypsin. This confirms reports
Chapter 5____________________________________________________________146
showing that Syt IV, in contrast to Syt I, is not a phospholipid-binding isoform (Dai et 
al., 2004).
The Syt family of proteins are components of the fusion machinery, and were found to 
bind to SNARE proteins. Syt I, for example, forms a complex with Stxl and SNAP-25 
(Chapman et al., 1995; Gerona et al., 2000). Although the mechanism of Syt function in 
regulating membrane fusion events is not fully understood, the ability of the 
cytoplasmic domain of Syts to inhibit secretion is clearly based on their ability to 
disrupt endogenous Syt-effector interactions that are critical for membrane fusion to 
occur (Bai and Chapman, 2004).
A scenario has been proposed by which the Syt I cytoplasmic domain could inhibit 
exocytosis through binding to the endogenous SNAP-25 and Stxl, therefore inhibiting 
the formation of the functional complex formed by endogenous Syt I-SNAP-25-Stxl. 
Indeed, mutations in SNAP-25 that affect interactions with Syt I reduce exocytosis 
(Zhang et al., 2002). In addition, selective disruption of the ability of Syt I to engage 
SNAP-25 and Stxl, by lengthening the linker that connects the C2A and C2B domains, 
inhibited exocytosis (Bai et al., 2004b). These studies suggest that the Syt-SNARE 
interaction is an essential step in regulating membrane fusion.
Based on these data, the finding that Syt IV interacts with the ISG-SNARE Stx6 could 
suggest that Syt IV is part of a protein complex which includes Stx6 that regulates ISG- 
ISG fusion. It is therefore conceivable that, in the same way observed for Syt I 
cytoplasmic domain, the exogenous Syt IV cytoplasmic domain might bind to an ISG 
SNARE(s), possibly Stx6, thereby inhibiting the formation of a functional endogenous 
Syt IV-ISG-SNARE complex, and leading to inhibition of ISG homotypic fusion.
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Previous studies have shown that Syt IV is also able to bind Stxl and SNAP-25, and 
that this binding is thought to regulate exocytosis, a function of the overexpressed Syt 
IV, which localises to MSGs (Wang et al., 2003a). It is therefore possible that Syt IV 
forms a complex with SNAP-25 and Stxl on ISG membranes. SNAP-25 and Stxl are 
not thought to function on ISGs, but rather that the presence of these two proteins on 
these membranes is a result of their transport to the plasma membrane. It is unlikely that 
the formation of a Syt IV-Stxl-SNAP-25 complex is functional in ISG homotypic 
fusion. Indeed, the addition of botulinum neurotoxin A and C, which cleave SNAP-25 
and Stxl, as well as anti-SNAP 25 and anti-Stxl abs into the in vitro reaction did not 
inhibit ISG-ISG fusion (Wendler et al., 2001), suggesting that the complex including 
SNAP-25 and Stxl at least is not functional during ISG-ISG fusion (Wendler et al., 
2001).
At present, we do not know the nature of the full ISG-SNARE complex involved in 
homotypic fusion. Stx6 has been found in two different SNARE complexes, one 
containing SNAP-25, SNAP-29 and VAMP4 (Wendler et al., 2001) and another 
containing Stxl6, V tila  and VAMP4 (Kreykenbohm et al., 2002) (Mallard et al., 2002). 
Also, an involvement of these other SNAREs in ISG homotypic fusion has not been 
determined. It will be interesting to investigate whether Syt IV interacts with any of 
these proteins.
The identification of the full SNARE complex involved in ISG-ISG fusion will help 
resolve this issue. This could be done by proteomic analysis of the ISG protein 
components. Inhibitory reagents for likely candidates from this analysis could be added 
to the in vitro fusion reaction to determine an involvement of specific proteins in the 
regulation of ISG homotypic fusion. Alternatively, immunoprecipitation of solubilised 
ISG membranes using anti-Stx6 or a suitable anti-Syt IV ab, followed by mass-
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spectroscopy analysis, would reveal unknown binding partners of Stx6, to which 
reagents could be developed and tested in the fusion assay. The lack of an anti-Syt IV 
ab to use in immunoprecipitation experiments did not allow me to look for interaction 
with endogenous Stx6.
It is unlikely that the Stx6 and Syt IV complex are on early endosomes. The 
immunostaining of PC 12 cells with an anti-Stx6 and anti-Syt IV ab showed they 
colocalise mainly in the perinuclear area (Chapter 3, Figure 3.3.1), where ISGs localise. 
In addition, unlike Stx6 (Bock et al., 1997) (Simonsen et al., 1999), Syt IV is not found 
on endosomes (Ibata et al., 2000). However, it is still possible that the Stx6-Syt IV 
complex is also on other membranes.
Mode of interaction of Sxt IV with Stx6
Binding studies with the Syt IV-C2A or Syt IV-C2B domains revealed that both 
domains are involved in the interaction with Stx6. The binding of the full Syt IV 
cytoplasmic domain to Stx6 was, however, greater than that obtained with the 
individual domains, suggesting that both domains cooperate to mediate binding to Stx6. 
In studies performed with Syt I, it was also found that binding affinity to SNAP-25 and 
Stxl was higher with the full Syt I cytoplasmic domain than with the individual C2A or 
C2B domains (Gerona et al., 2000) (Rickman and Davletov, 2003) (Zhang et al., 2002). 
Moreover, both Syt I domains were found to cooperate to regulate exocytosis (Earles et 
al., 2001) (Wang et al., 2003b). The binding of both Syt IV-C2A and C2B domains to 
Stx6 suggests that, like Syt I binding to t-SNAREs, both Syt IV domains are required 
for high-affinity binding to Stx6, and that this binding is required for ISG homotypic 
fusion.
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It would be interesting to investigate whether either or both domains of Syt IV are 
required for ISG homotypic fusion. Unfortunately, due to the insolubility of the GST- 
C2A and GST-C2B domains, I could not investigate this question using recombinant 
proteins.
Next, I attempted to identify the Stx6 domain responsible for Syt IV binding. Previous 
studies mapped the Syt I binding domain to the SNARE motif of both Stxl or SNAP-25 
(Kee and Scheller, 1996) (Gerona et al., 2000). I therefore asked whether Syt IV 
interacts with the SNARE domain of Stx6. To do this, I performed a GST-pull down 
experiment using GST-Stx6-Habc domain and GST-Stx6 cytoplasmic domain. After 
several attempts, using Triton X-100 extracts of PC12 or HEK-cells overexpressing 
HA-Syt IV cytoplasmic domain as a starting material, I could not detect binding of Syt 
IV to either the GST-Stx6-Habc or cytoplasmic domain (data not shown). Work in the 
lab has identified specific binding partners, other than SNAREs, of the Stx6-Habc 
domain (G. Otto, unpublished observations), suggesting that the recombinant Habc 
domain is folded properly and is functional. However, several attempts to co- 
immunoprecipitate other SNARE proteins, such as VAMP4, using the Stx6 cytoplasmic 
domain were never successful (F. Wendler, unpublished observation), whereas co- 
immunoprecipitation of VAMP4 with full length Stx6 was possible (Wendler et al., 
2001). This indicates that the cytoplasmic portion of Stx6 is not folded properly, and is 
not fully functional when expressed without the transmembrane domain. This could be 
due to the fact that the SNARE motif, close to the C-terminal membrane spanning of the 
protein, requires the trans-membrane domain for its proper folding and/or interactions 
with its SNARE partners. Therefore, I could not investigate which domain of Stx6 
mediates the binding with Syt IV.
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As an alternative strategy, and to have an indication of the Stx6 domain responsible for 
Syt IV binding, I combined both anti-Stx6 ab and Syt IV cytoplasmic domain in the 
binding assay. This combination did not affect the binding of either reagent, suggesting 
that the Stx6 ab and the Syt IV cytoplasmic domain interact with separate sites in Stx6. 
The anti-stx6 ab binding site was mapped to the Habc domain of Stx6 (G. Otto, 
unpublished observations), suggesting that the Syt IV cytoplasmic domain binds to Stx6 
somewhere other than the Habc domain.
In conclusion, in this chapter I found that the Syt IV cytoplasmic domain inhibited ISG 
homotypic fusion and that it is recruited to ISG membranes strictly via protein 
components on these membranes. The finding that Syt IV interacts with Stx6 via both 
C2A and C2B domains suggests that these proteins are part of the same complex 
involved in ISG homotypic fusion.
Chapter 6 151
6 Chapter 6: Syt IV cytoplasmic domain and siRNA- 
mediated knockdown of Syt IV inhibit granule maturation
in vivo
6.1 Aim
In neuroendocrine and endocrine cells, granins and prohormones are processed by 
prohormone convertases (PCs) during granule maturation. This processing is dependent 
on the acidification of the granule lumen, which is required for PC activation, and 
therefore function.
In Chapter 4 , 1 presented data showing that the Syt IV cytoplasmic domain inhibits ISG- 
ISG fusion in vitro. In this chapter, I will study the effect of this domain, as well as 
siRNA specific for Syt IV, on granule maturation in vivo. I will specifically look at 
whether these reagents have an effect on Secretogranin II (Sgll) processing, which 
occurs during ISG maturation and can be used as a measure of granule maturation.
6.2 Syt TV cytoplasmic domain inhibits Sgll processing
In PC12/PC2 cells, Sgll processing by PC2 starts in the TGN and continues in the 
MSG (Urbe et al., 1997). The final degradation product, which accumulates in MSGs is 
an 18 kDa peptide (p i8) detectable with a specific anti-pl8 ab, which does not
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recognise full length Sgll. I investigated the effect of the Syt IV cytoplasmic domain on 
ISG maturation in vivo, by specifically using Sgll processing as a read-out for 
maturation. A key point for my studies is the use of wild type PC12 cells transiently 
transfected with PC2 rather than the PC12/PC2 cell line, which are PC12 cells stably 
expressing PC2 (Dittie and Tooze, 1995). Use of this double transfection protocol was 
necessary because of the background signal of p i 8 in PC12/PC2 cells where a storage 
pool in MSGs existed before the addition of Syt IV cytoplasmic domain. Therefore, 
wild type PC12 cells will be transfected with the Syt IV cytoplasmic domain, together 
with PC2, in order to investigate whether the appearance and accumulation of p i8 is 
affected. Wild type PC 12 cells were transfected with HA-Syt IV cytoplasmic domain 
and PC2, GFP and PC2 or PC2 alone. Cells were fixed, permeabilised and labelled with 
rat-anti-HA, rabbit-anti-PC2 and mouse-anti-pl8 abs (Figure 6.2.1 A). Transfection of 
HA-Syt IV cytoplasmic domain together with PC2 resulted in an inhibition of p i8 
accumulation, whereas transfection of GFP with PC2 or PC2 alone, did not have any 
effect on p i8 appearance and accumulation. In addition, transfection of HA-avidin with 
PC2 also had no effect, showing that the HA tag does not interfere with Sgll processing 
(data not shown). Quantification of the intensity of the p i8 signal in an equivalent 
number of cells co-transfected with HA-Syt IV cytoplasmic domain and PC2 revealed a 
three-fold decrease compared to the intensity of p i8 in cells expressing GFP and PC2 or 
PC2 alone (Figure 6.2.1 B).
■ ■ GFP
w m HA-Syt IV CD
PC2
■ ■ p l8
Figure 6.2.1: HA-Syt IV cytoplasmic domain inhibits Sgll processing.
A) PC 12 cells were cotransfected with HA-Syt IV cytoplasmic domain and PC2, GFP 
and PC2, or PC2 alone. The cells were fixed and labelled with rat anti-HA (green), rab­
bit anti-PC2 (blue) and mouse anti-pl8 abs (red). Images were taken with identical 
acquisition parameters using a Zeiss LSM 510 confocal microscope (bar, 5 pM). B) 
Transfected cells were individually selected and the mean of intensity of each channel 
was measured using Photoshop 7.0 software. Columns represent the average of the mean 
of intensity of each channel, error is the SEM, where n=44 cells for all conditions.
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Together, these results showed that the dominant negative Syt IV cytoplasmic domain 
inhibits the processing of Sgll into its degradation product p i8. This confirms the data 
obtained in Chapter 4 that Syt IV is involved in the maturation of ISGs.
6.3 Syt IV cytoplasmic domain inhibits PC2 maturation
The previous data showed that the cytoplasmic domain of Syt IV inhibited Sgll 
processing in vivo. As previously mentioned, the processing o f Sgll during granule 
maturation is accomplished by the protease activity of PC2. PC2 is found as a 75 kDa 
precursor in the TGN, which is then autoproteolytically cleaved to a 65 kDa active 
mature form in a pH-dependent manner (Zhou et al., 1999).
To gain further understanding into the inhibition of p i8 accumulation upon transfection 
of HA-Syt IV cytoplasmic domain, I asked if the inhibition of Sgll processing is a result 
of failure to activate PC2. To answer this question, I co-transfected wild type PC12 cells 
with HA-Syt IV cytoplasmic domain and PC2. Transfected PC12 cells or PC12/PC2 
cells were fixed and FACS-sorted using anti-HA and anti-PC2 abs or anti-PC2 ab alone, 
respectively. FACS-sorted cells were lysed in sample buffer and subjected to SDS- 
PAGE followed by blotting with the anti-PC2 ab, which is capable of detecting the 
precursor 75 kDa and the mature/processed 65 kDa form of PC2 (Figure 6.3.1 A). In the 
cells transfected with the dominant negative HA-Syt IV cytoplasmic domain, there was 
a higher ratio of pro-PC2 to PC2 than in PC12/PC2 cells. As a positive control for PC2 
activity, I used stably transfected PC12/PC2 cells, because of the low transfection
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Figure 6.3.1: PC2 is found mainly in the proform in ceils expressing the HA-Syt IV 
cytoplasmic domain. PC 12 cells were cotransfected with HA-Syt IV cytoplasmic 
domain and PC2. A) Cells positive for both HA-Syt IV and PC2 were FACS sorted by 
labelling with anti-HA (Alexa 488) and anti-PC2 (Alexa 647) abs. As control PC12/PC2 
cells labelled with anti-PC2 ab were FACS sorted using identical conditions. 150,000
HA-Syt IV+/PC2+ cells and 300,000 PC12/PC2 cells were loaded on an SDS-PAGE gel 
and blotted with the anti-PC2 ab. 5 pg of a PC 12 cells lysate was used as a negative con­
trol for the PC2 ab. B) HA-Syt IV cytoplasmic domain and PC2 cotransfected PC 12 cells 
were fixed and labelled with anti-HA (white) anti-PC2 (green) and CgB abs (red). Imag­
es were taken using confocal microscopy and LSM 510 software (bar 10 pM).
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efficiency obtained with transient transfection combined with the extended FACS 
sorting required.
During granule maturation, pro-PC2 is packaged at the TGN into ISGs, where it 
remains as they mature into MSGs. To eliminate the possibility that the processing 
defect of pro-PC2 is a result of its failure to enter granules, PC 12 cells were co­
transfected with HA-Syt IV cytoplasmic domain and PC2. Transfected cells were triple­
labelled with anti-HA, anti-PC2 and the MSG marker anti-chromogranin B (CgB). In 
these cells, PC2 co-localised with the MSG marker CgB (Figure 6.3.1 B), suggesting 
that the transfected PC2 is properly packaged into granules. PC2 colocalises with CgB 
only in the newly formed MSGs.
Together, these results suggest that the Syt IV cytoplasmic domain affects one or more 
of the steps leading to secretory granule maturation in vivo, as reflected by the inhibition 
of PC2-dependent Sgll processing and pro- PC2 maturation.
6.4 Syt IV siRNA reduces Sgll processing in PC 12/PC2 cells
To test the effect of depletion of endogenous Syt IV on granule maturation in 
vivo, and to confirm my previous results obtained with the Syt IV cytoplasmic domain, I 
treated PC12/PC2 cells with siRNA directed against Syt IV, and asked whether this 
affects Sgll processing.
PC12/PC2 cells were transfected with a smart pool of 4  siRNA duplexes directed 
against rat Syt IV (Dharmacon), or mock-transfected using Dharmacon transfection 
reagents (described in Chapter 2). Three days post-transfection cells were fixed, 
permeabilised and labelled with anti-Syt IV and anti-Syt I abs for immunofluorescence.
Mock Syt IV-siRNA
Figure 6.4.1: Syt IV-siRNA in PC 12 cells. PC 12 cells were treated with 50 nM Syt 
IV-siRNA or mock treated using Dharmacon transfection reagents. A) 72 h post 
treatement, cells were fixed, permeabilised and labelled with anti-Syt IV (green) and 
anti-Syt I abs (Blue). Images were acquired using confocal microscopy and LSM 510 
software (bar, 20 pM). B) Alternatively, cells were lysed in sample buffer and subject­
ed to an SDS-PAGE followed by western blotting with anti-Syt IV and anti-Syt I abs.
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Alternatively, cells were lysed and subjected to SDS-PAGE, followed by blotting with 
anti-Syt IV and anti-Syt I abs (Figure 6.4.1). Depending on the experiment, a reduction 
of between 45% and 80% in Syt IV levels in siRNA-treated PC12/PC2 cells was 
detected by both immunofluoresence (Figure 6.4.1 A) and immunoblotting (Figure 
6 .4 .l.B), whereas the level of Syt I was not affected by Syt IV siRNA (Figure 6.4.1 A,
B).
I used a pulse-chase protocol to follow the newly-synthesised Sgll in PC12/PC2 cells. 
Cells were pulsed for 5 min with [35S]-sulphate to label the TGN pool, followed by a 
chase with excess sulphate. In the TGN, the newly sulphate-labelled Sgll is detected as 
an 86 kDa precursor. After its exit from the TGN, and during the chase, when Sgll is 
found in ISGs then MSGs, it is processed at several dibasic sites by PC2 to generate a 
38 kDa, 28 kDa and, finally an 18 kDa (p i8) degradation product (Dittie and Tooze, 
1995) (For illustration, Figure 6.4.2). Using this approach, I asked whether PC2 
processing of Sgll is affected by the reduction of the endogenous Syt IV level in 
PC12/PC2 cells. Two 15 cm dishes of PC12/PC2 cells were treated with Syt IV siRNA 
or mock-treated. Two days post-treatment, cells were harvested, pooled, replated into 
7x32 mm dishes, to ensure the same level of reduction in Syt IV expression in all 
samples, and incubated for a further 24h. All dishes were then pulse-labelled with [35S]- 
sulphate for 5 min then chased for 0, 10,20,30,60,90 and 180 min to follow Sgll 
processing. The chase reaction was stopped by transferring the dishes onto ice, followed 
by cell lysis in a Triton X-100-containing buffer. Heat-stable fractions, which allow an 
enrichment of granins, were prepared, and the heat-stable proteins were precipitated and 
subjected to SDS-PAGE and autoradiography (Figure 6.4.3). In cells treated with Syt 
IV siRNA, the processing of full length Sgll to the degradation products p38, p28 and 
finally p i8 was lower compared to that in mock-treated cells (Figure 6.4.3 A).
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Figure 6.4.2: Schematic representation of Sgll and its processing products.
p86 is the full length Sgll (MW=86 kDa). p 38, p28, p i8 are the Sgll-degradation prod­
ucts (MW=38, 24, 18 kDa, respectively). Arrows represent dibasic cleavage sites (Lys- 
Arg) utilised by PC2. Sgll and its degradation products are sulphated on Tyr 126 (SO4).
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Figure 6.4.3: Syt IV-siRNA reduces Sgll processing in PC12/PC2 cells.
A) PC12/PC2 cells were treated with Syt IV-siRNA or mock treated with transfection 
reagents alone as described previously. 72 h post-treatment, cells were pulse labelled 
with [35S]-sulphate for 5 min and chased for the indicated length of time. Cells were 
lysed in TNTE buffer, a heat-stable fraction was prepared, and analysed by SDS-PAGE 
gel and autoradiography. Arrows indicate the position of the Sgll-processing products 
p38 and p i8. B) Quantification of the ratio of p38/p86 using ImageJ software. Three 
separate experiments were analysed and the average is shown. Error is SEM, P= 0.0159, 
paired t-test.
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The extent of this inhibition was determined from the ratio of p38 to p86 in cells treated 
with Syt IV siRNA or mock-treated. This confirmed that there was a slower processing 
in siRNA-treated compared to the mock-treated cells (figure 6.4.3 B). Maximum 
inhibition of processing occurs after 45 min of chase, when in the mock-treated cells the 
rate of processing is maximal.
To eliminate the possibility that the lower levels of p i8 observed following treatment 
with Syt IV-siRNA is not due to inhibition of granule biogenesis from the TGN, or to 
fragmentation of the Golgi, a pulse-chase assay was performed. PCI2 cells were treated 
with Syt IV-siRNA or mock-treated as above. Three days post-treatment, cells were 
pulsed with [35S]-sulphate for 5 min to label Sgll in the TGN (Tooze and Huttner, 
1990). A PNS from these cells was loaded on a velocity sucrose gradient. Fractions 
were later collected, proteins precipitated and subjected to SDS-PAGE gel followed by 
autoradiography. In cells treated with Syt IV-siRNA and similarly to in mock-treated 
cells, Sgll distributed in fractions 9-11 characteristic of the TGN, suggesting that the 
TGN is intact in siRNA-treated cells (Figure 6.4.4 A,B).
To check whether the biogenesis of the granules is normal in cells treated with Syt IV- 
siRNA, PC12 cells were subjected to 5 min pulse with [35S]-sulphate followed with 15 
min chase, to chase labelled Sgll into ISGs. PNS from these cells was subjected to 
velocity gradient centrifugation (Tooze and Huttner, 1990). Fractions were collected, 
proteins precipitated, lysed in sample buffer and finally subjected to SDS-PAGE 
followed by autoradiography. Similarly to mock-treated cells, in Syt IV-siRNA cells 
Sgll distributed in fractions 1-4 in the velocity gradient (Figure 6.4.5 A,B), the 
distribution characteristic of ISGs. This demonstrates that secretory granule formation 
occurred normally in the absence of Syt IV.
A) Mock-treated cells
hSpG
^ S g ll
hSpG
♦ S g l l
Figure 6.4.4: The Golgi is not fragmented in cells treated with Syt IV-siRNA.
PC 12 cells were mock treated (A) or treated with Syt IV-siRNA (B) as described 
previously. 72 h post-treatement, cells were pulse labelled with [35S]-sulphate for 
5 min. A PNS from these cells was prepared and separated by velocity gradient 
centrifugation. Fractions were collected and analysed by SDS-PAGE and autora­
diography.
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Figure 6.4.5: Secretory granule biogenesis is normal in Syt IV-siRNA treated 
cells. PC 12 cells were mock treated (A) or treated with Syt IV-siRNA (B). Cells 
were then labelled with [35S]-sulphate for 5 min followed by 15 min chase to label 
ISGs. PNS from these cells was prepared and subjected to velocity gradient cen­
trifugation. Fractions were later collected and precipitated proteins were separated 
on an SDS-PAGE gel followed by autoradiography.
B) Syt IV-siRNA-treated cells
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Together, these results demonstrate that reducing the levels of endogenous Syt IV 
affects Sgll processing, further confirming that this protein is important for granule 
maturation.
6.5 Discussion
In this chapter, I demonstrated a role of Syt IV in granule maturation in vivo. 
First, the co-transfection of the dominant negative HA-Syt IV cytoplasmic domain and 
PC2 into PC12 cells resulted in an inhibition o f p l8 appearance and accumulation, 
suggesting that Sgll processing was inhibited. Similarly, the treatment of PC12/PC2 
cells with Syt IV-siRNA resulted in a reduction of Sgll processing. The maximum 
reduction of processing in knockdown cells occurred when the processing rate was 
maximal in control cells, at 45 min. This correlates well with the t1/2 of 45 min for 
maturation of ISGs in PC12 cells (Tooze et al., 1991). Together, these data confirmed 
that Syt IV is required for granule maturation. Recently, and although the effect was 
modest, it was shown that expression of a soluble form of Stx6 in INS-1 p cells slowed 
proinsulin processing (Kuliawat et al., 2004). This is an interesting observation, because 
Stx6, like Syt IV, is involved in ISG maturation in PC12 cells (Wendler et al., 2001).
I speculate that the inhibition of Sgll processing is probably a result of an inability to 
activate PC2 during ISG maturation. Indeed, in cells transfected with the dominant 
negative Syt IV cytoplasmic domain, PC2 was found mainly in the unprocessed form, 
whereas in PC12/PC2 cells, PC2 was mainly in mature/processed form. We have been 
unable to test for PC2 activation after siRNA treatment because of the lower than usual
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transfection efficiency after siRNA treatment, which precludes expressing PC2 in the 
Syt IV-deficient wild-type PCI2 cells.
PC2 autocatalytic activation was found to be dependent on the acidification of granules 
(Lamango et al., 1999), which occurs during the maturation from ISGs to MSGs. 
Indeed, the pH of ISGs was found to be 6.3, which acidifies to 5.5 in the MSGs, where 
the catalytic activity of PC2 is at its maximum (Urbe et al., 1997). The findings that 
PC2 is mainly in the unprocessed form in transfected HA-Syt IV cells, and that PC2 
activation is pH-dependent (Urbe et al., 1997), led me to speculate that the reduction in 
pro-PC2 processing was due to a failure of ISG acidification. Although the mechanism 
of secretory granule acidification is not known, it has been proposed to occur following 
an increase in the membrane density of the vacuolar H+-ATPase, as well as a decrease 
in H+-permeability (Wu et al., 2001). Interestingly, perturbation of the vacuolar H+- 
ATPase has also been shown to reduce processing in Xenopus intermediate pituitary 
cells (Schoonderwoert et al., 2000).
The inhibitory effect on Sgll processing observed with the dominant negative Syt IV 
cytoplasmic domain or Syt IV-siRNA could be explained by the following hypothesis: 
Addition of these inhibitory reagents could lead to the inhibition of homotypic fusion of 
ISGs, which would also limit membrane remodelling. This will lead to the retention of 
normally removed proteins, such as other ATPases, for example the Na+/K+ ATPAse, 
that may compete with the V-ATPase for ATP. Additionally, removal of H+ channels 
responsible for H+ leaks into ISGs, as well as an increase in density of the V-ATPase, 
might also be inhibited. This would lead to the subsequent inhibition of granule 
acidification, which is necessary for the activity of PC2 and therefore Sgll processing.
I attempted to investigate whether the granule pH in cells transfected with the dominant 
negative Syt IV cytoplasmic domain was perturbed. I chose to use DAMP (3-(2,4
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dinitroanilino)-3’-amino-N-methyldipropylamine) as a tool to visualise acidic granules. 
DAMP accumulates in acidic organelles, where it can be visualised using electron 
microscopy (EM), after fixation and labelling with anti-DNP abs (Anderson et al., 1984) 
(Anderson and Orci, 1988). DAMP has previously been used to label the maturing 
granules in endocrine and neuro-endocrine cells (Orci, 1986) (Tooze and Tooze, 1986). 
To do this, I infected PC 12 cells with an adenovirus expressing the HA-Syt IV 
cytoplasmic domain. To facilitate the detection of transfected cells during EM analysis, 
viral infection was used to obtain a maximal transfection efficiency (Figure 6.5.1), as 
transfection of PC12 cells using Lipofectamine 2000 (Invitrogen) usually gives only 5% 
transfection efficiency. Infected and non-infected PC12 cells were incubated with 
DAMP, followed by immunolabelling with anti-HA and anti-DNP abs using electron- 
microscopy (EM) techniques. From the analysis so far, no major differences in the 
staining of DAMP were observed (Figure 6.5.2). Furthermore, ~ 70% of the 220 
granules counted in cells infected with adenovirus-HA-Syt IV cytoplasmic domain, 
with similar results obtained in uninfected cells, were DAMP-positive. Therefore, these 
results were inconclusive. The difficulty in such an analysis comes from the fact that 
these cells contain many “old” granules, making it impossible to distinguish the “new” 
granules from the “old”. Another drawback is that determining the pH from the DAMP 
accumulation is not a very sensitive technique.
The development of more sensitive techniques is required for an accurate analysis of 
pH, such as using the pH-sensitive GFP protein, ratiometric pHluorin, fused to the 
granule marker, phogrin (Yuste et al., 2000). This will allow for the specific detection 
of newly made granules, and has the advantage of accurate quantification of the pH 
changes during the maturation of ISGs. A small difference in the pH of MSGs, between 
cells overexpressing the dominant negative HA-Syt IV cytoplasmic domain or Syt IV-
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siRNA, and normal cells, will be detectable by a change in the measured fluorescence 
of the ratiometric pHluorin-phogrin.
In conclusion, I demonstrated in this chapter that the transfection of Syt IV 
cytoplasmic domain and reduction of expression levels of endogenous Syt IV using 
siRNA, affected granule maturation in vivo, measured by Sgll processing.
0 pfu/cell
100 pfu/cell
50 pfu/cell
500 pfu/cell
Figure 6.5.1: Optimisation of the adenovirus expressing HA-Syt 
IV cytoplasmic domain in PC 12 cells. PC 12 cells were infected 
with adenovirus expressing HA-Syt IV cytoplasmic domain at 50, 
100 or 500 pfu/cell. Infection was performed by incubating the ade­
novirus with PC 12 cells O/N at 37 °C in full growth medium. 
Infected cells were washed, fixed, permeabilised and labelled with 
anti-HA ab. Images were acquired using confocal microscopy and 
LSM 510 software.
Figure 6.5.2: Identification of pH changes in cells expressing HA-Syt IV cytoplasmic 
domain. PC 12 cells were infected with HA-Syt IV cytoplasmic domain. 24 h later, 
infected or non-infected PC 12 cells were incubated with DAMP for 30 min at 37 °C. 
Later cells were prepared and sectioned for immunogold labelling. A) Ultra-thin sections 
of infected PC 12 cells were labelled with rabbit anti-HA and mouse anti-DNP abs fol­
lowed by 10 nM anti-rabbit-protein A-gold and 5nM anti-mouse protein A-gold. B) Non­
infected cells were labelled with mouse anti-DNP ab followed by 5 nM protein A-gold. 
Black arrows show dense core granules, where DAMP accumulated characterised with 
anti-DNP ab labelling and white arrows show granules that did not have any DAMP 
accumulation (bar 0.2 pM).
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7 Chapter 7: Synaptotagmin IV interacts with the adaptor 
protein-1 (AP-1)
7.1 Aim
In Chapter 3, I presented data showing that Syt IV is localised on ISGs and is 
absent from MSGs. This result suggested that Syt IV is removed from secretory 
granules during their maturation. Previous work in the lab has demonstrated that 
removal of proteins, such as M6PR (Dittie et al., 1999), Furin (Dittie et al., 1997) and 
VAMP-4 (Hinners et al., 2003), from ISGs was via AP-1-containing clathrin-coated 
vesicles (CCVs). Based on these studies, I hypothesised that the removal of Syt IV from 
the maturing granules could occur in the same way; therefore, I looked for interaction of 
Syt IV with AP-1 using a GST pull-down assay.
Next, because of our limited knowledge of the mechanisms that regulate ISG-ISG 
fusion and, more specifically, protein complexes involved in this process, Syt IV and 
Stx6 being the only ones identified so far, I attempted to identify unknown binding 
partners for Syt IV. Moreover, the identification of Syt IV binding partners will direct 
us further in understanding the mechanism by which this protein regulates granule 
maturation. In an attempt to identify unknown Syt IV binding partners, I undertook a 
tandem affinity purification (TAP) approach (Puig et al., 2001).
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7.2 Syt IV interacts with AP-1 in a GST-pull-down assays
The maturation of secretory granules includes removal of proteins, which are 
thought not to be needed for later steps, via CCVs in an AP-1-dependent pathway. It 
was demonstrated that the cytosolic domains of components on ISGs, such as VAMP4, 
M6PR and furin, are able to recruit AP-1, and that their sorting from the maturing 
granules depends on this interaction (Dittie et al., 1999) (Dittie et al., 1997) (Hinners et 
al., 2003). As Syt IV is not found on MSGs, I asked whether the sorting of this protein 
during granule maturation was via an AP-1 dependent pathway.
First, I used immunofluorescence to look at whether Syt IV colocalises with AP-1. 
PC 12 cells were fixed, permeabilised and double-labelled with polyclonal anti-Syt IV 
and monoclonal anti-y-adaptin (AP-1) ab. Syt IV displayed a good colocalisation with 
AP-1 near the Golgi area (Figure 7.2.1). Next, in order to determine whether Syt IV and 
AP-1 interact, I performed a GST pull-down assay. Recombinant GST-Syt IV or GST- 
VAMP-4 cytoplasmic domains, or GST alone, were bound to glutathione-sepharose 
beads for 2h at 4  °C. GST fusion proteins bound to beads were then incubated with total 
PNS prepared from PC 12 cells (described in Chapter 2) O/N at 4  °C. After several 
washes, proteins bound to beads, as well as 10% of total input for each sample, were 
subjected to SDS-PAGE followed by immunoblotting with anti- y-adaptin ab (Figure 
7.2.2). Syt IV interacted with AP-1 in a dose-dependent manner. Similarly, VAMP-4 
interacted with AP-1, as shown previously (Peden et al., 2001) (Hinners et al., 2003). 
No binding to GST alone was detected, demonstrating that this binding was not a result 
of a non-specific interaction with the GST moiety.
Figure 7.2.1: Syt IV colocalises with AP-1 in the perinuclear region of PC12 
cells. PC 12 cells were fixed with 3% PFA, permeabilised and double labelled 
with anti-Syt IV and AP-1 abs. Polyclonal anti-Syt IV and monoclonal anti-AP- 
1 abs were detected with secondary anti-rabbit Alexa-488 and anti-mouse-Cy3 
abs, respectively. Images were acquired by confocal microscopy using LSM 510 
software, Zeiss plan-Apochromat 63*/1.40 oil objective lense (bar 5 pM).
10% GST GST-Syt IV GST-VAMF4
total 20 50 20 50 20 50■ ------- — — ftgAP-1
Figure 7.2.2: Syt IV interacts with AP-1 in a GST pull 
down assay. GST-Syt IV, GST-VAMP4 cytoplasm ic 
domains and GST (20, 50 pg)-bound to glutathione beads 
were incubated with total PC 12 PNS. After washing, bound 
proteins were lysed in sample buffer and subjected to an 
SDS-PAGE followed by western blotting with anti-y-adaptin 
ab (AP-1).
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73 Synaptotagmin TV displays a preferential binding to membrane- 
bound AP-1
Previous work in the lab has demonstrated binding of VAM P-4 to cytosolic AP-1 
using bovine adrenal medulla cytosol (BAMC) (Hinners et al., 2003). Similarly to the 
previous experiment, GST-Syt IV or GST-VAMP-4 cytoplasmic domains, as well as 
GST alone, were bound to glutathione beads. Proteins bound to beads were further 
incubated with BAMC, washed and bound proteins were subjected to SDS-PAGE 
analysis, followed by blotting with anti-Ap-1 ab. Surprisingly, GST-Syt IV did not bind 
AP-1 very efficiently in these conditions, whereas VAMP-4 binding was robust (Figure 
7.3.1). In the previous experiment (Figure 7.2.2), a total PNS containing both cytosolic 
and membrane-bound AP-1 was used. To confirm differential binding of Syt IV to AP- 
1 ,1 prepared cytosolic or membranes fraction from total PNS derived from PC12 cells 
by centrifugation. GST-Syt IV cytoplasmic domain, GST-V AMP-4 cytoplasmic domain 
and GST bound to glutathione beads were incubated separately with the cytosolic 
fraction or solubilised membranes. After washing, bound proteins were subjected to 
SDS-PAGE and immunoblotting with anti-y-ab. Interestingly, AP-1 from the membrane 
fraction bound strongly to Syt IV (Figure 7.3.2 A). In contrast, a lower binding of 
cytosolic AP-1 to Syt IV was observed (Figure 7.3.2 B). VAMP-4 displayed the same 
degree of binding regardless of the source of AP-1 used. Together, these results 
demonstrate that Syt IV, in contrast to VAMP-4, binds more efficiently to the
API (y-subunit)
Figure 7.3.1: Syt IV does not bind efficiently to AP-1 
from bovine adrenal medulla cytosol (BAMC). GST, 
GST-Syt IV and GST-Vamp4 cytoplasmic domains (30 pg) 
bound to glutathione beads were incubated with BAMC. 
bound proteins were lysed in sample buffer and subjected to 
SDS-PAGE and blotting with anti-y-adaptin ab.
A) Membranes
B) Cytosol
Figure 7.3.2: Syt IV binds preferentially to the mem­
brane-bound AP-1. Total PNS from PC 12 cells was sub­
jected to ultracentrifugation to separate cytosol from mem­
brane fractions. The solubilised membranes (A) and 
cytosolic fractions (B) were later incubated with GST, GST- 
Syt IV and GST-Vamp4 cytoplasmic domains (30 pg). After 
washing, bound proteins were lysed in sample buffer and 
subjected to an SDS-PAGE and blotting with anti-y-adaptin 
ab.
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membrane-bound than to the cytosolic AP-1. These findings further suggest that Syt IV 
possesses a different AP-l-binding mechanism than that of VAMP-4.
While I have not determined how this binding occurs, the possibilities as to why Syt IV 
displays this preferential binding towards AP-1 on membranes will be discussed below.
7.4 Identification of unknown Syt TV binding partners using the TAP 
purification method.
To identify unknown Syt IV binding partners, I used the TAP purification approach 
(Puig et al., 2001). This method offers the advantage of isolating whole protein 
complexes in a physiological setting. The target protein is fused to the TAP tag, which 
contains a calmodulin-binding domain (CBD), the TEV protease cleavage site, and the 
protein A domain. To purify protein complexes bound to the target TAP-tagged protein, 
lysates from cells overexpressing the fusion protein are first passed over an IgG column. 
The tagged protein and its interactors will bind to the IgG beads via the protein A 
domain. After several washes, the fusion protein is subjected to cleavage with the 
tobacco etch virus (TEV) protease, which will release the tagged protein and interactors 
from the IgG column. This eluate is then subjected to a second purification step on a 
calmodulin column (CBD), where the tagged protein will bind via the CBD domain in a 
calcium-containing buffer. The tagged protein and its binding partners are finally 
released from the CBD column with an EGTA-containing buffer. Protein in the eluate is 
precipitated and subjected to SDS-PAGE, followed by analysis using mass- 
spectrometry to identify the unknown binding proteins (For illustration, Figure 7.4.1).
Associated 
proteins
Contaminants
Calmodulin binding peptide 
ProtA
Target ™  pro^ jn cleavage site
Binding
TEV protease 
cleavage
©VT
First affinity 
column
IgG beads
Second affinity 
column (Ca?*)
Calmodulin
beads
Native elution 
EGTA
Figure 7.4.1: Tap tag purification method. Cells overexpressing the Tap tag fused to 
the target protein are lysed and subjected to the first purification step through an IgG- 
beads column. The fusion protein and its interactors will bind to the column via the 
protein A domain. After several washes the fusion protein is cleaved with the TEV 
protease and the protein is then released from the column. The released protein is then 
subjected to a second purification step through a calmodulin-beads column. Finally, 
after several washes, the protein and its binding partners are eluted with EGTA. The 
eluates are precipitated and lysed in sample buffer. Samples are loaded on SDS-PAGE 
and analysed by mass-spectrometry (Puig A et al 2001).
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To apply this method for the identification of unknown binding partners to Syt IV, the 
TAP tag was fused to the full-length rat-Syt IV at the C-terminus of the protein (Figure 
7.4.2 A). To check for expression, the Syt IV-TAP construct was transfected into PC 12 
cells, and cells were labelled with secondary IgG ab, which will recognise the protein A 
in the TAP tag. In transfected cells, Syt IV-TAP displayed a dispersed cytosolic 
staining, which I confirmed by western blotting was due to the degradation o f the 
expressed fusion protein (data not shown). Another neuroendocrine cell line, AtT-20, 
was used. In these cells, transfected Syt IV-TAP displayed mostly a perinuclear 
staining, whereas the TAP alone control was cytosolic (Figure 7.4.2 B). In addition, 
western blotting of cell lysates expressing Syt IV-TAP showed a band at the expected 
molecular weight of ~  72 kDa, demonstrating that it was not degraded (Figure 7.4.2 C). 
The lack of degradation of the Syt IV-TAP protein in AtT-20 cells is presumably due to 
the absence of specific proteases which are present in PC12 cells and are responsible for 
the degradation of the fusion protein. Unfortunately, the use of this technique for the 
identification of binding partners was not possible due to the low transfection efficiency 
obtained in AtT-20 cells. Scaling-up the number of cells did not yield enough material 
to be detected by mass-spectroscopy. Another drawback observed when using this 
technique is the high loss of the fusion protein and bound proteins, due to two 
successive purifications and several washes. This purification method is certainly very 
useful, but depends very much on the availability of large amounts of starting material, 
which are only obtainable from cells where a high transfection efficiency can be 
obtained.
A)
TEVCBD Protein ASyt IV
Syt IV-TAP TAP tag
60 kDa—I
Figure 7.4.2: Expression of Syt IV-TAP and TAP tag in AtT-20 cells.
A) Full length Syt IV was fused to the TAP tag containing the calmodulin binding 
domain (CBD), the TEV cleavage site (Tabbaco Etch Virus site) and protein A (two 
IgG domains repeats). B) Syt IV-TAP and TAP tag (right) were transfected into AtT- 
20 cells using Lipofectamine 2000. Cells were then fixed with 3% PFA, permeabilised 
and labelled with the secondary anti-goat-Rhodamine-conjugated ab. Images were 
acquired using confocal microscopy and LSM 510 software. C)AtT-20 cells were 
Transfected with Syt IV-TAP or mock transfecd with transfection reagent alone. Cells 
were then lysed in Triton X-100-containing buffer and and loaded on an SDS-PAGE 
gel followed by blotting using HRP-labeled-secondary ab.
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7.5 Discussion:
The hypothesis that Syt IV could interact with AP-1 came from data showing 
that Syt IV is on ISGs and absent from MSGs, suggesting that Syt IV is removed during 
maturation (Eaton et al., 2000) (Fukuda et al., 2003) (Chapter 3). AP-1 is part of the 
sorting machinery involved in a removal of ISG proteins, such as VAMP-4, during 
granule maturation (Hinners et al., 2003). GST-pull-down experiments performed with 
cytosol or membranes as sources of AP-1 revealed that Syt IV displays a preferential 
binding to the membrane-bound form. This was unexpected, as proteins, such as 
VAMP4 (Hinners et al., 2003), bind to cytosolic AP-1.
Two possibilities may explain this differential binding: First, Syt IV displays a low 
affinity binding to AP-1, which increases upon adding membranes that contains 
protein(s), such as VAMP-4, which would mediate a stronger interaction of Syt IV with 
membrane-bound AP-1. In support of this, it was demonstrated that peptides with a 
tyrosine-based endocytic motif, present in other cargo proteins, stimulated binding of 
AP-2 to Syt I, and enhanced AP-2 recruitment to the plasma membrane (Haucke and De 
Camilli, 1999). This suggested a mechanism by which the interaction of AP-2 with Syt I 
is enhanced by the presence of additional cargo proteins to be loaded in the nascent 
endocytic vesicle, making Syt I part of a docking complex for AP-2.
Proteins bind to AP-1 via tyrosine or di-leucine-based sorting motifs present in their 
cytoplasmic tails (Bonifacino and Traub, 2003). It is therefore possible that cargo 
proteins containing these motifs, which are loaded in CCVs forming from ISGs, could 
in the same way inhance the affinity of Syt IV with AP-1. This hypothesis can be tested 
by incubating the GST-Syt IV cytoplasmic domain with BAMC or PNS from PC12
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cells in the presence of peptides containing either tyrosine or di-leucine motifs, and 
asking whether the binding of Syt IV to AP-1 can be stimulated in these conditions.
The second hypothesis arising from the finding that Syt IV displays stronger binding to 
membrane-bound compared to the cytosolic AP-1, is that Syt IV may bind specifically 
to the phosphorylated form of AP-1. It was demonstrated that AP-1, upon membrane 
binding, becomes phosphorylated on the p i subunit, and dephosphorylated on the p i 
subunit (Ghosh and Kornfeld, 2003). The phosphorylation of the p i subunit of AP-1 
enhances binding to the tyrosine sorting signal in the cytoplasmic tails of MPR cargo 
molecules, which was suggested to facilitate their capture and retention in the forming 
CCVs (Ghosh and Kornfeld, 2003). It will be interesting to investigate whether the 
same applies for Syt IV. Extracting AP-1 from purified CCVs with Protein phosphatase 
2A (PP2A) and Hsc-70, which induce dephosphorylation of AP-1 and its subsequent 
release (Ghosh and Kornfeld, 2003), and testing whether it will decrease the binding to 
Syt IV, will help answer this question.
In addition, to determine whether the binding to AP-1 mediates the sorting of Syt IV 
from ISGs, it will be interesting to identify the motif within the Syt IV cytoplasmic 
domain responsible for this interaction. Proteins have been shown to mediate binding to 
p i subunit of AP-1 via both a tyrosine-based motif, such as that in CD-MPR (Ghosh 
and Kornfeld, 2004) and via a di-leucine-based motif, such as that in VAMP4 (Peden et 
al., 2001). Interestingly, the Syt IV-C2B domain contains a tyrosine-based motif 
(297^ QST300) that could mediate the binding to AP-1. However, it is also possible that 
Syt IV could interact with AP-1 via an unusual unidentified motif present in its 
cytoplasmic domain. Indeed, the binding of Syt I to AP-2 is mediated via a double 
lysine motif (Chapman et al., 1998), which is also found in the SytIV cytoplasmic
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domain. Mutation of the tyrosine and the double lysine motifs in Syt IV will reveal their 
requirement for AP-1 binding.
Addressing these questions will help further our understanding of how Syt IV is sorted 
from ISGs, and more importantly, how the differential binding to AP-1 contributes to 
the removal of proteins during granule maturation.
Chapter 8 183
8 Chapter 8: Concluding remarks
The similar distribution of Syt IV to the SNAREs Stx6 and VAMP4 on ISGs, and 
not MSGs, in neuroendocrine cells (Eaton et al., 2000) (Wendler et al., 2001) (Chapter 
3), prompted me to investigate whether Syt IV is part of a protein machinery involved 
in secretory granule maturation.
I showed using in vitro and in vivo approaches that the Syt IV cytoplasmic domain, as 
well as siRNA against Syt IV, inhibited ISG-ISG fusion as well as Sgll processing, 
demonstrating that Syt IV is required for secretory granule maturation.
The interaction of Syt IV with Stx6 further suggested that they might be part of the 
same complex regulating ISG homotypic fusion, an essential step during granule 
maturation in PC 12 cells. This study has identified a novel component of the putative 
complex involved in ISG-ISG fusion. It would be interesting to use Syt IV as a “bait” in 
interaction studies to characterise the full protein complex involved in ISG homotypic 
fusion. Identification of the complete complex will advance our understanding o f this 
membrane fusion event in particular, and the regulation of ISG maturation in general. 
Furthermore, the continued dissection of Syt IV function in ISG fusion, such as the 
fusion step it regulates or the mode of its binding to Stx6, will be additional questions to 
answer. Doing so will give further clues on the way this family of proteins regulate 
membrane fusion events. Moreover, comparing the mode of function between Syt IV 
and the calcium-dependent phospholipid-binding protein Syt I, will reveal similarities as 
well as differences in the way they regulate fusion.
It would also be of great interest to analyse Syt IV-knock-out mice. In particular, 
investigating whether the granule size or content is affected in the endocrine or
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neuroendocrine cells of these mice will give additional proof that Syt IV is important 
for secretory granule maturation under physiological conditions.
Finally, this study has revealed a novel role for Syt IV in an intracellular 
membrane fusion event, and reinforces the notion that this family of proteins participate 
in distinct membrane trafficking events.
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